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1   SUMMARY 
1.1   Abstract 
Aberrant expression of several PRMTs is linked to the pathogenesis of human cancer. 
PRMTs catalyse the arginine methylation of many substrates, which are implicated in 
cancer development, progression and aggressiveness. In this context, only few studies 
investigated PRMT6 so far and its possible role in tumourigenesis and the control of 
cellular processes, which could also be deregulated in human cancer by PRMT6. Hence, 
the present study analysed the expression of PRMT6 in murine lung cancer, tried to 
reveal the role of PRMT6 in cell proliferation and senescence and continued the 
validation of putative interaction partners of PRMT6. 
In the first part of this thesis, immunohistochemical (IHC) stainings demonstrated that 
Prmt6 protein levels are predominantly increased in lung tumour cells compared to 
healthy tissue using the LLC1 and Kras
LA2
 mouse models. The second part of this thesis 
showed that PRMT6 negatively regulates the transcriptional expression of the tumour 
suppressor genes CDKN1A and p16-INK4A. Both are direct target genes of PRMT6, 
whereby the corresponding histone mark H3R2me2a is exclusively enriched at the 
CDKN1A gene. Knockdown of PRMT6 results in proliferation defects of several 
transformed cell lines and induces a senescent phenotype in non-transformed human 
diploid fibroblasts. Furthermore, PRMT6 was found to inhibit the onset of oncogene-
induced senescence (OIS), in which CDKN1A is an activator of the senescent 
phenotype. In the third part of this thesis, PRMT6 was shown to interact with PCNA, 
DDB1 and DDB2. These interactors are subunits of the CUL4A-RING ubiquitin E3-ligase 
complex (CRL4) and hint to possible novel cellular functions of PRMT6 in the 
ubiquitylation processes either after DNA damage or during replication and transcription. 
In summary, the present study reveals that PRMT6 is overexpressed in murine lung 
cancer. It uncovers novel functional aspects of PRMT6 being a positive regulator of 
proliferation and negative regulator of senescence by transcriptional repression of 
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tumour suppressor genes. Finally, it opens up a field of so far undescribed possible 
functions of PRMT6 by validation of novel interaction partners of PRMT6. 
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1.2   Zusammenfassung 
Die aberrante Expression mehrerer PRMTs ist mit der Entstehung von humanem Krebs 
verknüpft. PRMTs katalysieren die Arginin-Methylierung vieler Substrate, die in der 
Krebsentstehung, dessen Verlauf und Aggressivität verwickelt sind. In diesem 
Zusammenhang untersuchten bisher nur wenige Studien PRMT6 und seine mögliche 
Rolle in der Tumorgenese und in der Kontrolle zellulärer Prozesse, die ebenfalls in 
humanem Krebs durch PRMT6 dereguliert sein können. Daher analysierte die 
vorliegende Arbeit die Expression von PRMT6 in murinem Lungenkrebs, versuchte die 
Rolle von PRMT6 in der Zell-Proliferation und Seneszenz aufzudecken und setzte die 
Validierung potentieller PRMT6-Interaktionspartner fort. 
Im ersten Teil dieser Arbeit zeigten immunhistochemische Färbungen, dass die Prmt6 
Proteinspiegel vorwiegend in Lungen-Tumor-Zellen im Vergleich zu gesundem Gewebe 
unter Verwendung der LLC1 und Kras
LA2
 Mausmodelle erhöht sind. Der zweite Teil 
dieser Arbeit bewies, dass PRMT6 die transkriptionelle Expression der 
Tumorsuppressorgene CDKN1A und p16-INK4A negativ regulierte. Beides sind direkte 
Zielgene von PRMT6, wobei das entsprechende Histon-Mark H3R2me2a ausschließlich 
am CDKN1A-Gen angereichert ist. Der Knockdown von PRMT6 resultiert in 
Proliferationsdefekten mehrerer transformierter Zelllinien und induziert einen 
seneszenten Phänotyp in nicht-transformierten humanen diploiden Fibroblasten. 
Darüber hinaus wurde für PRMT6 gefunden, dass es die Entstehung onkogen-
induzierter Seneszenz (OIS) inhibiert, in welcher CDKN1A ein Aktivator des 
seneszenten Phänotyps ist. Im dritten Teil dieser Arbeit wurde gezeigt, dass PRMT6 mit 
PCNA, DDB1 und DDB2 interagiert. Diese Interaktionspartner sind Untereinheiten des 
CUL4A-RING Ubiquitin E3-Ligase Komplexes (CRL4) und deuten auf mögliche neue 
zelluläre Funktionen von PRMT6 in Ubiquitylierungsprozessen entweder nach DNA-
Schaden oder während der Replikation und Transkription hin. 
Zusammenfassend deckt die vorliegende Arbeit eine erhöhte Expression von PRMT6 in 
murinem Lungenkrebs auf. Sie legt neue funktionelle Aspekte von PRMT6 als positiver 
Regulator der Proliferation und als negativer Regulator der Seneszenz durch die 
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transkriptionelle Repression von Tumorsuppressorgenen dar. Abschließend erschließt 
sie aufgrund der Validierung neuer Interaktionspartner von PRMT6 ein Feld bisher 
unbeschriebener, denkbarer Funktionen von PRMT6. 
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2   INTRODUCTION 
2.1   Chromatin structure and post-translational modifications (PTMs) 
The nucleus in eukaryotic cells was first described by the botanist Robert Brown in 
1831. It has a distinct, nonetheless very dynamic structure and contains the DNA as 
carrier of genetic information. Genomic DNA is highly condensed in form of chromatin, 
which is organised in euchromatin and heterochromatin (Lamond and Earnshaw, 
1998). Repeating units of nucleosomes build the platform of chromatin organisation 
and allow a first degree of chromosomal compaction (Rothbart and Strahl, 2014). The 
nucleosome consists of 1.65 superhelical turns of 147 bp DNA wrapped around an 
octamer of core histone proteins, one histone H3/H4 tetramer and two histone 
H2A/H2B dimers (Harshman et al., 2013; Li et al., 2007; Luger et al., 1997). Binding of 
the linker histone H1 to the nucleosome and the linker DNA, which enters and exits the 
core particle, stabilises higher-order chromatin structures (Finch and Klug, 1976; 
Thoma et al., 1979). Various non-histone proteins, such as DNA polymerase, 
transcription factors, co-regulators or chromatin remodelers, can bind to the 
nucleosome and function as structural adapters. For example, the adapter protein HP1 
is the best known heterochromatin protein in higher eukaryotes, which was first 
described in Drosophila (James and Elgin, 1986; Lamond and Earnshaw, 1998). In 
addition, numerous existing histone variants, such as H2AZ or H3.3, increase dynamics 
of chromatin structure and are involved in transcriptional regulation (Mariño-Ramírez 
et al., 2005). 
Histones are small basic proteins rich in lysine and arginine residues, which are 
structured in a flexible, charged histone tail (N-terminal part) and a globular core 
domain associated with DNA (Jenuwein and Allis, 2001). Post-translational 
modifications (PTMs) of histones are not restricted to histone tails. They also occur in 
the core domain of histones (Tropberger and Schneider, 2010). Common types of 
these PTMs are acetylation, phosphorylation, ubiquitylation and methylation (Bhaumik 
et al., 2007; Li et al., 2007). Other, less frequent chromatin modifications are 
SUMOylation, ADP-ribosylation, deimination and proline isomerisation (Kouzarides, 
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2007). PTMs of histones on the same or adjacent histone tails act in an individual or 
combinatorial manner. The interplay of PTMs at the same histone is called cis-
interaction and on adjacent histones trans-interaction (Rothbart and Strahl, 2014). This 
interaction indirectly influences downstream cellular events, such as gene activation or 
repression by binding of "reader"-proteins harbouring for example PHD fingers or 
other regulatory domains, such as Tudor-, MBT-, Bromo- or Chromodomains (Maurer-
Stroh et al., 2003). Alternatively, PTMs on histones can directly regulate chromatin 
characteristics, whereby the interaction between DNA and histone octamer is 
influenced. For example, acetylation of lysine residues generate a recognition site for 
Bromodomain containing proteins that regulate chromatin structure and gene 
expression (Dhalluin et al., 1999; Seet et al., 2006). These processes contribute to the 
shaping of the epigenetic landscape and form the "histone code" (Imhof and Becker, 
2001; Jenuwein and Allis, 2001; Strahl and Allis, 2000). Typical histone modifications, 
which are associated with active transcription, are di- or trimethylation of H3K4 
(H3K4me2, H3K4me3) and acetylation of H3K9 (H3K9ac). Trimethylation of H3K27 
(H3K27me3) is a mark of repressed genes (Li et al., 2007), while trimethylation of H3K9 
and H4K20 (H3K9me3, H4K20me3) occur at pericentric heterochromatin (Muramatsu 
et al., 2013). 
 
2.2   Protein arginine methyltransferases (PRMTs) 
2.2.1   Classification of PRMTs 
Protein methylation is a common form of PTMs. It was first described by Paik and Kim 
(Paik and Kim, 1967, 1968) and typically occurs on substrates with lysine and arginine 
residues (Lee et al., 2005a). For example, almost 2% of all arginines in nuclear protein 
fractions isolated from rat liver were found to be methylated (Boffa et al., 1977). 
Protein methylation on arginine residues is catalysed by the family of protein arginine 
methyltransferases (PRMTs). 
PRMTs are classified into type I, II and III enzymes based on their reaction products as 
depicted in Figure 1 (Baldwin et al., 2014; Yang and Bedford, 2013). In a first step, they 
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promote the covalent addition of a methyl group on one of the terminal (or ω) 
guanidino nitrogen atoms of arginine residues (type III PRMTs). This product is called 
ω-NG-monomethylarginine (MMA) and can be converted into ω-NG,NG-asymmetric 
dimethylarginine (ADMA) by type I enzymes, which add another methyl group to the 
same nitrogen in a second step. Alternatively, a ω-NG,N´G-symmetric dimethylarginine 
(SDMA) can be generated by type II PRMTs, which add another methyl group to a 
different terminal nitrogen atom. The co-substrate S-adenosyl-L-methionine (AdoMet) 
functions as methyl group donor and is metabolised to methylarginine and 
S-adenosylhomocysteine (AdoHcy) (Bedford and Richard, 2005). In yeast, a type IV 
PRMT (Rmt2) has been reported to catalyse the formation of δ-N
G
-
monomethylarginine at an internal guanidine nitrogen atom (Wang and Li, 2012; 
Zobel-Thropp et al., 1998). 
 
Figure 1: Schematic depiction of arginine methylation performed by PRMTs. 
Abbreviations used in the figure are MMA: ω-NG-monomethylarginine, ADMA: ω-NG,NG-asymmetric 
dimethylarginine and SDMA: ω-NG,N´G-symmetric dimethylarginine. Presented from (Yang and Bedford, 
2013). 
Nine PRMTs (PRMT1 - PRMT9) have been described in mammals to date (Yang and 
Bedford, 2013). PRMT1, PRMT2, PRMT3, PRMT4 (CARM1), PRMT6 and PRMT8 belong 
to the class of type I enzymes. PRMT1 possesses the predominant activity (about 85%) 
in mammalian cells (Tang et al., 2000a). The group of type II PRMTs consists of PRMT5 
(JBP1) and potentially PRMT9 (Cook et al., 2006). Recent studies have shown that 
PRMT7 is the only bona fida type III enzyme without type II activity (Feng et al., 2013; 
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Miranda et al., 2004; Zurita-Lopez et al., 2012). A study by Cook and colleagues 
indicated that purified PRMT9 exhibits in vitro methylation activity on several 
substrates by performing SDMA modifications, but an in vivo activity for PRMT9 has 
not been properly clarified (Cook et al., 2006). 
PRMTs are evolutionary conserved enzymes in eukaryotes (Pal and Sif, 2007). For 
example, Saccharomyces cerevisiae possesses four PRMTs with HMT1 (also known as 
Rmt1) being the major type I and HSL7 (also known as Skb1) being a type II enzyme 
(Boisvert et al., 2005). Drosophila melanogaster contains DART1 to DART9 (Boulanger 
et al., 2004). The protozoan parasite Trypanosoma brucei encodes five PRMTs, 
including two type I (TbPRMT1, TbPRMT6), one type II (TbPRMT5), one type III 
(TbPRMT7) enzyme, and one enzyme that still remains uncharacterised (Fisk et al., 
2010; Wang et al., 2014). 
Generally, methylation substrates of PRMTs are not only histones, but also a large 
amount of non-histone proteins. The majority of methylation events occurs on 
substrates, such as RNA-binding proteins (including hnRNPs, fibrillarin and nucleolin), 
enriched in GAR (glycine-arginine-rich) motifs (Liu and Dreyfuss, 1995; Najbauer et al., 
1993). However, PRMT4 is not able to methylate arginines within GAR motifs. PRMTs 
possess various functions in cellular processes, such as transcriptional regulation, 
mRNA splicing, genomic stability, DNA damage repair as well as signal transduction 
(Bedford and Clarke, 2009; Bedford and Richard, 2005; Di Lorenzo and Bedford, 2011; 
Yang and Bedford, 2013). 
 
2.2.2   Structure of PRMTs 
All PRMTs contain an AdoMet binding and a substrate binding (barrel-like) domain, as 
shown in Figure 2. Between the two domains lies the active site pocket that is formed 
by the double-E (glutamic acid-glutamic acid) and THW (threonine-histidine-tryptophan) 
loop and captures the target arginine (Zhang and Cheng, 2003). The substrate binding 
domain is unique for the PRMT family, in contrast to the AdoMet binding domain, 
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which is also found in other AdoMet-dependent methyltransferases (Cheng and 
Roberts, 2001). Additionally, the sequence motifs I, post-I, II, double-E loop and III of 
the AdoMet binding domain are highly conserved between all PRMTs. The same 
applies to the invariant THW loop within the substrate binding domain at the 
respective C-terminus. All PRMTs harbour a dimerisation arm that is necessary for the 
AdoMet binding and enzymatic activity, but it exists a high diversity concerning length 
and composition of this arm (Cheng et al., 2011). In general, homodimerisation is a 
conserved feature of PRMTs (Zhang et al., 2000). However, the type III PRMT7 from 
Caenorhabditis elegans possesses an exceptional character because it was found that 
PRMT7 forms a homodimer-like structure by a single monomer (Hasegawa et al., 
2014). 
 
Figure 2: Schematic depiction of the crystal structure of rat PRMT1. 
The catalytic structure of rat PRMT1 with its substrate arginine and S-adenosylhomocysteine (AdoHcy) is 
depicted. The AdoMet binding (green) and substrate binding (yellow) domains are indicated. 
Additionally, the dimerisation arm (blue), the double-E (EE) and THW loop are shown (see arrows). 
Adapted from (Zhang and Cheng, 2003). 
The N- and C-termini differ between individual PRMTs. For example, PRMT2 contains a 
SH3-domain in the N-terminus, which is essential for its binding to the hnRNP protein 
E1B-AP5 (Kzhyshkowska et al., 2001). PRMT3 harbours a single zinc-finger domain in 
the N-terminal part that recognises RNA-associated substrates (Frankel and Clarke, 
2000). PRMT4 contains an autonomous activation domain in the C-terminus, which is 
required for its co-activator function (Teyssier et al., 2002), while PRMT7 harbours two 
copies of the central catalytic domain caused by gene duplication (Miranda et al., 
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2004). Moreover, PRMT8 possesses an N-terminal myristoylation motif. PRMT8 is 
exclusively expressed in the brain and is anchored to the plasma membrane by 
myristoylation (Kousaka et al., 2009; Lee et al., 2005b). In case of PRMT9, four splice 
variants were identified (Cook et al., 2006). PRMT9 isoform 1 harbours an F-box 
domain in the N-terminal part to associate with Skp1 and the ubiquitin ligase complex. 
PRMT9 also contains a zinc-finger domain in the C-terminus, which mediates substrate 
binding to this complex (Cardozo and Pagano, 2004). Isoform 2 and 3 lack the zinc 
finger motif, whereas isoform 4 lacks both the N- and C-terminal domains. 
To date, the crystal structures of rat PRMT1 and its yeast homologue HMT1, rat 
PRMT3, rat PRMT4, human PRMT5, PRMT7 in Mus musculus and Caenorhabditis 
elegans and AbPRMT10 in Arabidopsis thaliana have been analysed (Antonysamy et 
al., 2012; Cheng et al., 2011; Cura et al., 2014; Ho et al., 2013; Sun et al., 2011; Troffer-
Charlier et al., 2007; Weiss et al., 2000; Yue et al., 2007; Zhang and Cheng, 2003; Zhang 
et al., 2000). Recently, the first crystal structure of PRMT6 from protozoan 
Trypanosoma brucei (apo-TbPRMT6) has been published (Wang et al., 2014). TbPRMT6 
shares only a 31% amino acid sequence identity with its human PRMT6 homologue. 
Although there are numerous unique structural features, the crystal structure of 
TbPRMT6 reveals a high overlap in all conserved structures with other PRMTs, 
including its ability to form a homodimer (Figure 3). 
 
Figure 3: Structural comparison of TbPRMT6 with other type I PRMTs.  
Two views of the superpositions of TbPRMT6 (magenta) with rat PRMT1 (cyan), rat PRMT3 (yellow), rat 
PRMT4 (wheat) and AtPRMT10 (grey), respectively. Adapted from (Wang et al., 2014). 
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In general, each arginine contains five potential hydrogen bond donors, which are 
most frequently bound by a plethora of acceptors (Bedford and Clarke, 2009). Addition 
of a methyl group by PRMTs does not change the overall positive charge of the 
protein. However, blocking of hydrogen bonding, enhanced bulkiness and increase in 
local hydrophobicity have a crucial influence on protein-protein interactions (Lee and 
Stallcup, 2009). 
 
2.2.3   Regulation of arginine methylation 
Analysis of PRMTs as recombinant proteins has demonstrated that most PRMTs exhibit 
an enzymatic activity to methylate different substrates. It is assumed that PRMTs 
possess a constitutive activity in cells, but regulation of PRMTs by PTMs, cross-talk 
between arginine methylation sites and adjacent PTMs or by association of PRMTs 
with other regulatory proteins can influence their activity (Bedford and Clarke, 2009; 
Yang and Bedford, 2013). 
One example of the regulation of PRMTs by PTMs is the automethylation of arginine 
residues in PRMT4, PRMT6 and PRMT8. In case of PRMT4, the automethylation at 
R551 (position in murine PRMT4, isoform 1) has no influence on the substrate 
specificity or enzymatic activity of PRMT4. Nevertheless, its automethylation impairs 
PRMT4-mediated mRNA splicing and has a negative influence on transcription of 
several PRMT4-responsive ERα target genes (Kuhn et al., 2011). PRMT6 was first 
identified by Frankel et al. (2002) to perform automethylation. Later the auto-
methylation site was mapped to arginine residue R35, which is very important for 
PRMT6 stability and inhibition of HIV-1 replication (Singhroy et al., 2013). For PRMT8, 
the biological role of automethylation still remains unknown. However, there is 
evidence that automethylation of PRMT8 has an autoregulatory effect on its ability to 
recognise substrates (Sayegh et al., 2007). Even PRMT1 shows weak automethylation 
as demonstrated by in vitro analyses (Frankel et al., 2002; Sayegh et al., 2007). A 
second example for PRMT regulation by PTMs is the phosphorylation of human PRMT4 
at serine residues S216 and S228. As a result, AdoMet binding is impaired and PRMT4 
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methyltransferase activity is blocked (Feng et al., 2009; Higashimoto et al., 2007). 
Furthermore, S216 phosphorylation of PRMT4 reinforces its translocation to the 
cytoplasm primarily during mitosis (Feng et al., 2009). PRMT4 phosphorylation at S228 
leads to the disruption of its homodimerisation and co-activator complex formation. 
This could not be demonstrated for the S216 phosphorylation. Both, S216 and S228 
phosphorylation of PRMT4, have a negative influence on ER-dependent transcription. 
The kinase responsible for the phosphorylation of PRMT4 still remains unknown. 
PTMs of amino acid residues adjacent to arginine methylation sites can either 
positively or negatively influence the methylation event. For example, the core MLL 
complex (MLL, WDR5, RBBP5, ASH2) mediated H3K4 trimethylation inhibits, but not 
totally blocks the dimethylation of H3R2 by PRMT6 (Guccione et al., 2007; Hyllus et al., 
2007; Iberg et al., 2008). As a consequence, both marks are mutually exclusive in their 
genome-wide location (Guccione et al., 2006). In contrast to this negative cross-talk, 
H3R2me2a positively correlates with the repressive mark H3K27me3, mediated by the 
EZH2 (enhancer of zeste 2) containing PRC2 complex (polycomb repressive complex 2) 
(Cao and Zhang, 2004; Cao et al., 2002). Here, it was demonstrated that H3K27me3 
correlates with the appearance of H3R2me2a (Guccione et al., 2006) and that PRMT6 
activity was enhanced in the presence of H3K27me3 shown by in vitro methylation 
assays (Hyllus et al., 2007). Other examples for PTMs at residues in the proximity of 
arginine methylation sites are H3K9ac and H3K14ac. Both acetylated residues inhibit 
PRMT5-mediated arginine methylation at H3R8 (Pal et al., 2004), which then blocks 
H3K9 methylation mediated by the protein methyltransferase G9a (Rathert et al., 
2008). 
Protein-protein interaction is another mechanism to regulate the enzymatic activity of 
PRMTs. The association of PRMTs with other regulatory proteins can activate, inhibit 
or change their activity. BTG1 and TIS21, also known as BTG2, are two related proteins, 
which bind PRMT1 and positively modulate its catalytic activity (Berthet et al., 2002; 
Lin et al., 1996). A binding partner of BTG1, hCAF1, also interacts with PRMT1 and can 
regulate its activity on several substrates (Robin-Lespinasse et al., 2007). Passeri and 
colleagues have revealed that the interaction between BTG2 and PRMT1 promotes 
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gene-specific methylation of H4R3 by PRMT1 during hematopoietic differentiation of 
myeloid leukemia cells (Passeri et al., 2006). Furthermore, as an integral component of 
the NUMAC complex (nucleosomal methylation activator complex), PRMT4 methylates 
nucleosomal histone H3, whereas recombinant PRMT4 prefers to methylate free core 
histone H3 (Xu et al., 2004). PRMT5 is able to change its substrate specificity from 
H3R8 towards H4R3 when it interacts with CORP5 (Lacroix et al., 2008). Additionally, 
COPR5 is essential for the recruiting of PRMT5 to its target gene CCNE1. PRMT5 also 
associates with BRG1 and BRM, which are the catalytic subunits of the human SWI/SNF 
remodeling complex (Pal et al., 2004). As a result, PRMT5-mediated methylation of 
H3R8 and H4R3 is significantly increased. Interaction between different PRMTs 
influences also their catalytic activity. It was shown that PRMT1 is able to interact with 
PRMT8 and PRMT2. The heterodimerisation of PRMT1 and PRMT8 promotes the 
localisation of PRMT1 to the plasma membrane, which causes a shift of the substrate 
specificity and enzymatic activity of PRMT1 (Lee et al., 2005b). The interaction 
between PRMT1 and PRMT2 leads to an enhanced enzymatic activity of PRMT1 to 
perform ADMA catalysis (Pak et al., 2011). 
Beside the mechanisms mentioned above, arginine methylation might also be 
counteracted by enzymes, which block methylation or remove methyl groups from 
arginine residues (Lee and Stallcup, 2009; Yang and Bedford, 2013). In 2007, JMJD6 
(jumonji domain containing 6) was identified as a putative demethylase of methylated 
arginines. It was shown that JMJD6 demethylates histone H3 at arginine 2 (H3R2me2) 
and histone H4 at arginine 3 (H4R3me2), which are either asymmetrically or 
symmetrically dimethylated (Chang et al., 2007). However, further studies of JMJD6 
demonstrated that this enzyme is a lysine-hydroxylase without demethylation activity 
(Hahn et al., 2010; Webby et al., 2009). These findings were supported by the 
published crystal structure of JMDJ6 in 2010 (Hong et al., 2010; Mantri et al., 2010). 
Therefore, the question still remains whether arginine demethylases exist.  
In 2004, two scientific groups described PADI4 (peptidyl arginine deiminase, type IV) as 
a nuclear enzyme, which counteracts PRMT-mediated methylation at H3 and H4 
histone tails by deimination of MMA and unmodified arginines to citrulline (Cuthbert 
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et al., 2004; Wang et al., 2004). Presumably, PADI4 cannot convert dimethylated 
arginines into citrullin because asymmetrically and symmetrically dimethylated 
arginines can not be accommodated in its substrate-binding site (Holbert and 
Marmorstein, 2005). PADIs block PRMT-mediated methylation, but are not able to 
perform a full reversal, where citrulline residues are converted back to arginines 
(Denman, 2005). 
 
2.2.4   PRMT6, its substrates and functions 
In 2002, sequence analysis of the human genome identified PRMT6 as a novel 
methyltransferase gene on chromosome 1p13.3. PRMT6 is predominantly located in 
the nucleus as identified by immunofluorescence (Frankel et al., 2002). PRMT6 belongs 
to the type I class of PRMTs and prefers ADMA catalysis of already monomethylated 
substrates (Hyllus et al., 2007; Lakowski and Frankel, 2008). Similar to other PRMTs, 
PRMT6 requires homodimerisation for the transfer of a methyl group from AdoMet to 
its substrate (Thomas et al., 2010). 
PRMT6 is capable of catalysing arginine methylation within GAR as well as non-GAR 
motifs. GST-GAR was described as the first substrate of PRMT6 (Frankel et al., 2002). In 
vitro studies reported that the histones H3 at R2 as well as H4 and H2A at R3 are 
further methylation sites for PRMT6 (Hyllus et al., 2007). Additionally, in vivo studies 
have shown that the primary target of PRMT6 is H3R2. The enzyme catalyses the 
asymmetric dimethylation of H3R2 (H3R2me2a) in mammals (Guccione et al., 2007; 
Hyllus et al., 2007; Neault et al., 2012). Interestingly, the analysis of MEFs (mouse 
embryonic fibroblasts) isolated from Prmt6
-/-
 mice revealed that the global 
asymmetrical dimethylation of H3R2 was not fully lost after Prmt6 knockout. This 
oberservation implies that other PRMTs are also able to methylate H3R2 to a certain 
degree (Neault et al., 2012). 
H3R2me2a was demonstrated to inversely correlate with the methylation mark 
H3K4me3 in the promoter regions of MYC-dependent genes (Guccione et al., 2006). 
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H3K4 trimethylation is mediated by the core MLL complex (MLL, WDR5, RBBP5, ASH2) 
and correlates with transcriptional activation of several genes, such as HOX genes and 
MYC-dependent genes (Hughes et al., 2004; Hyllus et al., 2007; Milne et al., 2002). The 
PRMT6-mediated H3R2 dimethylation prevents binding of the MLL complex through 
WDR5 to the N-terminal H3 tail (WDR5 recognises A1, R2 and T3 in histone H3) and 
thereby inhibits H3K4 trimethylation (Couture et al., 2006; Han et al., 2006; Hyllus et 
al., 2007; Iberg et al., 2008; Ruthenburg et al., 2006; Schuetz et al., 2006). As a result, 
H3K4 trimethylation mediated by the core MLL complex is globally reduced and thus 
contributes to gene repression. Apart from an asymmetric dimethylation of H3R2 
(H3R2me2a) mediated by PRMT6, H3R2 can also be symmetrically dimethylated by 
PRMT5 or PRMT7 (H3R2me2s). This enhances WDR5 binding and, as a consequence, 
supports euchromatin maintenance (Migliori et al., 2012). 
In addition to H3R2, PRMT6 is able to catalyse the methylation of H2AR29 
(H2AR29me2). This modification is specifically enriched at genes repressed by PRMT6 
(Waldmann et al., 2011). The methyltransferase does not only methylate arginine 
residues within the histone tail, but also within core histones. A study by Casadio and 
colleagues has shown that PRMT6 and PRMT4 are able to methylate the core histone 
residue H3R42 (Casadio et al., 2013). The thereby created H3R42me2a mark has a 
positive effect on transcription caused by direct disruption of the interaction between 
DNA and the histone octamer. 
PRMT6 is not only capable of methylating histones, but also non-histone proteins. To 
date, several PRMT6-specific non-histone substrates have been described implicating a 
role of PRMT6 in various cellular processes. For example, PRMT6 is involved in base 
excision repair (BER) mediated by the DNA polymerase ß (Pol ß). Here, it was shown 
that Pol ß forms a complex with PRMT6, which methylates Pol ß at positions R83 and 
R152 (El-Andaloussi et al., 2006). As a result, enhanced DNA binding and processivity of 
Pol ß significantly increased the polymerase activity, which lead to more efficient BER. 
Therefore, PRMT6 has a positive effect on BER. Several studies have demonstrated 
that the chromatin-associated factors HMGA1a and HMGA1b (high mobility group AT-
hook 1a/b) are further PRMT6 substrates (Miranda et al., 2005; Sgarra et al., 2006; Zou 
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et al., 2007). PRMT6 methylates these non-histone chromatin proteins mainly at 
arginines in the second AT-hook, which is important for protein-DNA and protein-
protein interactions. Additionally, PRMT6 is a negative regulator of viral transcription 
and replication of the human immunodeficiency virus (HIV) (Boulanger et al., 2005; 
Invernizzi et al., 2006, 2007). For example, PRMT6 is able to directly methylate the 
arginine-rich transactivation motif (ARM) in the transactivator protein (Tat) encoded 
by HIV type I (Boulanger et al., 2005). Upon methylation of Tat by PRMT6, the 
interaction between Tat and the Tat transactivation region (TAR) of viral RNA and 
cyclin T1 is lost (Xie et al., 2007). As a consequence, viral replication activity is 
impaired. Interestingly, PRMT6 automethylation regulates its own stability and is 
indispensable for its antiretroviral activity (Singhroy et al., 2013). 
PRMT6 also functions as a transcriptional co-activator or co-repressor. Synergistically 
with PRMT4, PRMT6 enhances SHR/NR-(steroid hormone receptor/nuclear receptor) 
dependent transcriptional activity in a hormone-dependent manner (Harrison et al., 
2010). As a co-activator PRMT6 supports ERα- and ERβ- (estrogen receptor α and β), 
GR (glucocorticoid receptor) and PR- (progesterone receptor) mediated target gene 
expression (Harrison et al., 2010). Another study showed that PRMT6 specifically 
interacts with ERα via its ligand-binding domain. This interaction leads to methylation 
of ERα and thereby enhanced ERα activity (Sun et al., 2014). Additionally, Herglotz and 
colleagues demonstrated that PRMT6 interacts with the transcription factor RUNX1 
(Herglotz et al., 2013). RUNX1 recruits PRMT6 to a subset of megakaryocytic target 
genes, such as CD41 and miR27a, in human hematopoietic progenitor cells. Here, 
dimethylation of H3R2 by the co-repressor PRMT6 (H3R2me2a) and concomitant 
H3K27 trimethylation (H3K27me3), keep RUNX1 target genes in a repressed state. This 
transcriptional block of RUNX1 target genes is disrupted upon megakaryocytic 
differentiation. 
In order to identify novel interaction partners of PRMT6, which possibly hint to new 
cellular functions of PRMT6 a MS/MS analysis with TAP (tandem affinity purification)-
tagged PRMT6 protein lysates from MCF7 cells was performed in our group. Thereby, 
43 co-purifying proteins were identified, which are putative new interaction partners 
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of PRMT6 (PhD thesis, Claudia Stein). The interaction between PRMT6 and the two 
transcription factors ILF2 (interleukin enhancer binding factor 2) and ILF3, the histone-
binding protein RBBP7 (retinoblastoma binding protein 7) and its homolog RBBP4 
could be confirmed by CoIP/Western blot analyses. PRMT6 also associated with AURKB 
(aurora kinase B), which is implicated in cell cycle regulation (bachelor thesis, Lisa 
Schubert). 
Further interesting putative interaction partners of PRMT6 were DDB1 (damage-
specific DNA binding protein 1) and PCNA (proliferating cell nuclear antigen). DDB1 and 
DDB2 form the damaged DNA binding protein complex (UV-DDB) that detects UV-
induced DNA lesions and recruits the global genome nucleotide excision repair (GG-
NER) machinery to repair the damage (Iovine et al., 2011a; Lee and Zhou, 2007). DDB1 
and PCNA physically associate with the CUL4A-RING ubiquitin E3-ligase complex 
(CRL4). This complex targets various substrates for ubiquitylation and subsequent 
degradation including the cell cycle regulator proteins CDKN1A and E2F1 (Jackson and 
Xiong, 2009). 
 
2.3   PRMTs in lung cancer 
Several publications demonstrated that nearly every PRMT is aberrantly expressed in 
one or more types of human cancer, such as breast, prostate, colorectal or lung cancer 
(Baldwin et al., 2014; Yang and Bedford, 2013). Moreover, PRMTs catalyse the arginine 
methylation of a variety of substrates, which have been linked to cancer development, 
progression and aggressiveness. This relatively novel connection between arginine 
methylation and cancer opens a new field for the development of anti-cancer drugs 
and therapies. Moreover, PRMTs are implicated in cell proliferation and survival or 
resistance of cancer cells to DNA damaging agents. The first part of this thesis focuses 
on the deregulation of PRMTs and especially of PRMT6 in lung cancer to further 
elucidate the role of PRMT6 in this cancer type. Since the method of choice was mainly 
IHC the next chapters will briefly describe the structure and functions of a normal lung 
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(2.3.1) as well as the histology and pathology of a lung tumour (2.3.2). Afterwards, the 
deregulation of PRMTs in lung cancer is described (2.3.3). 
 
2.3.1   Structure and functions of the lung 
The main functions of the respiratory system are air conduction, filtration and 
respiration. The trachea divides into the paired main bronchi and each bronchus enters 
the hilum of the lung and is subdivided into additional bronchial branches, which 
divide into smaller tubes (Figure 4). The segmental bronchi further devide into smaller 
terminal bronchi followed by the respiratory bronchioles. These ducts form the 
beginning of the respiratory passage, in which gas exchange occurs. The wall of a 
bronchiole consists of bundles of smooth muscles and adjacent blood vessels. These 
arteries supply the lung with oxygenated blood and nutrients. Respiratory bronchioles 
divide into alveolar ducts, which terminate in alveolar sacs. Alveolar sacs are enlarged 
spaces surrounded by clusters of alveoli, the primary site of gas exchange. 
Figure 4: Diagram of the divisions of the bronchial tree (left). H&E stainings (75 x) of a bronchiole 
(middle) and an alveolar structure in the human lung (right panel). 
Abbreviations used in the figure are H&E: Hematoxylin and eosin, A: alveolus, AD: alveolar duct, AS: 
alveolar sac, B: bronchiole, BV: blood vessel, SM: smooth muscle. Adapted from "Histology, a text and 
atlas" by Michael H. Ross, Wojciech Pawlina, sixth Edition, Lippincott Williams & Wilkins. 
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2.3.2   Lung cancer, its key features and pathology 
Lung cancer is the leading cause of cancer-related death in humans worldwide. In 85% 
of all lung cancer cases, patients suffer from non-small cell lung carcinoma (NSCLC) 
(Ramalingam et al., 2011). The five-year survival rate of these patients is poor (5 - 15%) 
due to having no symptoms in the early stages and a high metastasis rates in advanced 
stages (Zakrzewicz et al., 2012). Conventional chemotherapy alone cannot sufficiently 
cure the disease in the majority of patients. Novel therapeutic options and targets are 
urgently required for earlier detection of this disease. In this context, PRMTs could be 
attractive targets for the development of drugs (Baldwin et al., 2014). 
In humans, lung cancer is histological divided into two groups, non-small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC) depending on their pathological 
appearance and presumed cellular origin. NSCLC is subclassified into adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma (Zakrzewicz et al., 2012). 
Additionally, the different malignant lung tumour stages are classified into TNM 
(tumour-node-metastasis) subsets to facilitate diagnosis and clinical research 
(Mirsadraee et al., 2012). 
 
2.3.3   Deregulation of PRMTs in lung cancer 
Several PRMTs are deregulated in lung cancer. For example, expression of PRMT5 is 
increased in several human lung cancer cell lines and tissues. Depletion of PRMT5 
causes proliferation defects accompanied by a G1-arrest in A549 cells (Gu et al., 2012). 
Furthermore, the silencing of PRMT5 prevents the growth of A549 lung tumour 
xenografts in mice. In this context it was demonstrated that PRMT5 is involved in FGFR 
signaling, a pathway whose activation is needed for efficient tumour growth. For 
example, PRMT5-depleted A549 cells show a reduced expression of FGFR3, an 
important component of the FGFR pathway (Gu et al., 2012). Further studies 
demonstrated that PRMT5 regulates the HIF-1 signaling pathway. Particularly, it 
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enhanced the expression of several HIF-1 target genes, such as VEGF or PDK1 (Lim et 
al., 2012). 
Moreover, PRMT4 is an important regulator of lung development. In Prmt4 knockout 
mice, pulmonary epithelial cell proliferation and differentiation are impaired. Newborn 
mice, which are deficient for Prmt4, are smaller than their wild type littermates and 
die just after birth (Yadav et al., 2003). These mice have defects in lung unfolding 
accompanied by respiratory problems caused by hyperproliferation of alveolar type II 
cells (O’Brien et al., 2010). Additionally, PRMT4 as well as PRMT1 are deregulated in 
lung tumour tissues from NSCLC patients (Elakoum et al., 2014). 
Besides PRMT1, the expression of PRMT6 was demonstrated to be increased in several 
cancer tissues, such as bladder, lung and prostate cancer (Vieira et al., 2014; 
Yoshimatsu et al., 2011). Both, PRMT6 and PRMT1 are required for proper cell cycle 
progression and proliferation of certain cancer cell lines. For example, siRNA-mediated 
depletion of PRMT6 or PRMT1 impaired growth of several cancer cell lines by affecting 
G1-S cell cycle transition (G0/G1 arrest). This was shown for several lung cancer (such 
as A549) and bladder cancer cell lines (such as SW780) (Yoshimatsu et al., 2011). 
PRMT6 represses the natural inhibitor of angiogenesis and endothelial cell migration 
THBS1 (thrombospondin 1), which supports the idea that PRMT6 can contribute to the 
unimpeded growth of tumour cells (Michaud-Levesque and Richard, 2009). In this 
study, PRMT6 associated with the THBS1 promoter and directly regulated THBS1 
transcription in a repressive manner through dimethylation of H3R2. PRMT6 depletion 
also caused cell migration and invasion defects in U2OS cells (Michaud-Levesque and 
Richard, 2009). Moreover, it was found that THBS1 is deregulated in several human 
and murine cancers, such as invasive cervical cancer or hepatocellular carcinoma 
(Kodama et al., 2001; Poon et al., 2004). Additionally, Harrison and colleagues revealed 
that PRMT6 knockdown inhibits the estrogen-stimulated proliferation of breast cancer 
cells (MCF7) (Harrison et al., 2010). This effect was even enhanced in a double 
knockdown of PRMT6 and PRMT4. These data imply an important role of PRMT6 in 
tumourigenesis. 
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2.4   PRMTs in cellular senescence 
Cellular senescence is a protective mechanism against unlimited cell proliferation and 
therefore presents a barrier to tumourigenesis (Prieur and Peeper, 2008). There is first 
evidence that PRMTs are implicated in the regulation of proliferation and senescence 
in different cell types. The following chapters will first describe key features and causes 
of cellular senescence (2.4.1) and then, the role of PRMTs and especially of PRMT6 in 
this process (2.4.2). 
 
2.4.1   Cellular senescence, its key features and causes 
The process of aging at the cellular level was first described more than five decades 
ago by Hayflick and colleagues (Hayflick, 1965; Hayflick and Moorhead, 1961). They 
observed a spontaneous proliferative arrest of normal untransformed cells (human 
diploid fibroblasts) in the course of serial passaging in in vitro culture. Later, this 
process was termed replicative cellular senescence, in which the lack of endogenous 
telomerase causes telomere attrition and triggers a DNA damage response (DDR) 
(Bodnar et al., 1998; Prieur and Peeper, 2008). Senescent cells undergo a growth arrest 
in G1-phase. They remain viable and metabolically active, but show an enlarged, 
flattened morphology accompanied by enhanced activity of senescence-associated 
ß-galactosidase (SA-ß-gal), resistance to apoptosis (in some cells) and characteristic 
changes in gene expression (Campisi and d’Adda di Fagagna, 2007; Dimri et al., 1995). 
Additionally, cells exhibit an altered chromatin structure through developing SAHF 
(senescence-associated heterochromatin foci) (Narita et al., 2003) and SDF 
(senescence-associated DNA damage foci) (d’Adda di Fagagna et al., 2003; Takai et al., 
2003). Both are also used as cytological markers of senescent cells. 
Independently of replicative cellular senescence caused by telomere shortening 
permanent growth arrest can be induced by other conditions. This process is called 
premature cellular senescence and can be triggered by oxidative stress (ROS - reactive 
oxygen species), DNA damage (such as UV light, γ-irradiation), mitogenic oncogenes 
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(e.g. BRAF), chemotherapeutic drugs or even inadequate culturing conditions 
(Michaloglou et al., 2005; Parrinello et al., 2003; Toussaint et al., 2002). Here, 
oncogene-induced senescence (OIS) provides a link between senescence and cancer. 
At the molecular level, cellular senescence is induced by the tumour suppressor 
proteins p53 (TP53) and pRb (RB1) and the increased expression of the CDK (cyclin-
dependent kinase) inhibitors p21 (p21
CIP/WAF1
, CDKN1A) and p16 (p16-INK4A, CDKN2A). 
Stress as well as oncogenes activate the TP53-CDKN1A-RB1 and/or p16-INK4A-RB1 
cascade dependent on the cell strain and severity of one or even combined stimuli 
(Ben-Porath and Weinberg, 2005; Kuilman et al., 2010). p16-INK4A blocks the 
phosphorylation of RB1 by specifically binding to CDK4 and CDK6 (Serrano et al., 1993; 
Wang et al., 2012a). RB1 is kept in a hypophosphorylated state that binds and 
inactivates the transcription factor E2F. As a result, E2F-target genes, which stimulate 
or support S-phase progression, are repressed in senescent cells (Narita et al., 2003). 
Similarly, the TP53-dependent target gene CDKN1A is increased, particularly binds to 
and inactivates CCNE-CDK2 complexes and thereby causes an arrest in G1-phase in 
these cells (Brugarolas et al., 1995). 
 
2.4.2   Role of PRMTs in cellular senescence 
Evidence has emerged that PRMTs play an important role in cell cycle progression and 
senescence of different cells. Kim and colleagues showed that in synchronised HeLa 
cells PRMT6 protein levels were increased during cell cycle from G0/G1- to G1-phase 
(Kim et al., 2010). Another study demonstrated that protein levels of PRMT6, PRMT1, 
PRMT4 and PRMT5 as well as asymmetric dimethylation of arginines decreased during 
replicative and H2O2-induced premature senescence in human diploid fibroblasts (Lim 
et al., 2008). In contrast, global levels of CDKN1A were reduced in these cells. Another 
example are primary MEFs isolated from Prmt6 knockout mice. These cells showed 
proliferation defects and an elevated senescence phenotype (Neault et al., 2012). 
Similarly, MEFs isolated from Prmt1 knockout mice exhibited a delay in cell cycle 
progression and spontaneous DNA damage (Yu et al., 2009). 
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Moreover, the CDK inhibitor p16-INK4A interacts with and is methylated by PRMT6 at 
arginines R22, R131 and R138 (Wang et al., 2012a). Here, overexpression of PRMT6 
counteracted the cell cycle arrest at G1 phase induced by p16-INK4A in the NSCLC cell 
line A549. Normally, the INK4A-ARF locus is repressed mediated by the binding of 
several Polycomb group (PcG) proteins in pre-senescent fibroblasts (Bracken et al., 
2007; Dietrich et al., 2007; Jacobs et al., 1999). PcG proteins form the two protein 
complexes PRC1 (polycomb repressive complex 1) and PRC2, whose function is to 
maintain transcriptional repression (Dietrich et al., 2007). In senescence cells these 
proteins are displaced. This is accompanied by reduced levels of H3K27me3, while the 
INK4A-ARF locus is actively transcribed (Bracken et al., 2007). Previous studies 
demonstrated that PRMT6 co-purifies and interacts with a subset of PRC core subunits, 
such as CBX8 (chromobox homolog 8) or EZH2, which is the catalytically active subunit 
of PRC2 (PhD thesis, Claudia Stein and personal communication, René Reiner Nötzold). 
These data strengthen the idea that PRMT6 plays an important role in the regulation of 
proliferation and senescence of normal human cells as well as tumour cells. 
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2.5   Objectives 
To date, only a few studies have investigated PRMT6 and its possible role in 
tumourigenesis. Here, cDNA microarray analysis and siRNA-mediated PRMT6 depletion 
experiments gave an inital hint that PRMT6 is overexpressed in bladder and lung 
cancer tissues and that PRMT6 might positively affect the growth of these cancer cells 
(Yoshimatsu et al., 2011). This study aims to further investigate the deregulation of 
PRMT6 in lung cancer. Therefore, it analyses the expression of PRMT6 in the two 
murine lung cancer models LLC1 and Kras
LA2
 by IHC. Moreover, this study investigates 
several human and murine lung cancer cell lines in their PRMT6 expression by RT-qPCR 
and Western blot and analyses whether the clonogenic growth of two human cell lines 
is impaired by depletion of PRMT6. 
Several publications demonstrated that PRMTs are implicated in cell proliferation and 
survival, transformation, invasion of cancer cells and that they contribute to the 
resistance to DNA damaging agents (Baldwin et al., 2014; Yang and Bedford, 2013). 
Furthermore, Lim and colleagues demonstrated that the protein level of PRMT6 is 
strongly reduced in senescent fibroblasts (Lim et al., 2008). These data gave an initial 
hint that PRMT6 plays an important role in the regulation of proliferation and 
senescence in different cell types. To gain a better understanding of PRMT6 and its 
functions in cell proliferation and senescence, this study investigates transformed 
(U2OS) as well as non-transformed cells (TIG3-T) in PRMT6 knockdown experiments. 
Beside the characterisation of phenotypical effects, possible transcriptional 
downstream target genes of PRMT6 should be detected in these cells. Furthermore, 
this study analyses PRMT6 in an oncogene-inducible senescence model (OIS) to 
unravel whether it is implicated in the process of premature cellular senescence 
triggered by the oncogene Braf (TIG3 BRAF-ER cells) (Agger et al., 2009; Woods et al., 
1997). 
Previously, PRMT6 was demonstrated to increase the activity of the DNA polymerase ß 
(Pol ß) in base excision repair (El-Andaloussi et al., 2006). Another study showed that 
PRMT6 stimulates CCDN1 expression upon DNA damage presumably through 
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dimethylation of H3R2 (Iberg et al., 2008). A previous MS/MS analysis of MCF7 cells 
overexpressing TAP-tagged PRMT6 in our group revealed that the two proteins DDB1 
and PCNA are putative interaction partners of PRMT6 (Claudia Stein, PhD thesis). Both 
proteins are implicated in DNA damage repair, where DDB1 forms a complex with 
DDB2 in UV-DDB (Essers et al., 2005; Iovine et al., 2011b) and strengthen the 
hypothesis that PRMT6 possesses additional features in DNA repair. Therefore, this 
study examines the interaction between PRMT6 with PCNA, DDB1 and DDB2 by Co-IP 
studies in MCF7 cells. The validation of putative interaction partners of PRMT6 might 
serve as basis for the future characterisation of PRMT6 and its functional role in 
various cellular processes. 
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3   MATERIALS 
3.1   Material sources 
3.1.1   Enzymes 
Benzonase Nuclease HC, 250 U/µl   Merck 
M-MLV Reverse Transcriptase, 200 U/µl  Life Technologies 
Proteinase K, 20 µg/µl     AppliChem 
Restriction Endonucleases, 10 U/µl    Thermo Scientific 
(BglII, HindIII) 
Ribonuclease A (RNase A) DNase free, 10 µg/µl  AppliChem 
T4 DNA Ligase, 30 U/µl     Thermo Scientific 
. 
3.1.2   Enzyme inhibitors 
Aprotinin, 10 µg/µl in ddH2O    AppliChem 
Leupeptin, 10 µg/µl in ddH2O   AppliChem 
PMSF, 10 µg/µl in ddH2O in isopropanol  Sigma-Aldrich 
Protease Inhibitor Cocktail Tablets (PICs)  Roche 
RiboLock RNase Inhibitor, 40 U/µl    Thermo Scientific 
 
3.1.3   Agarose gel electrophoresis 
Ethidium bromide 1% , 10 mg/ml   Roth  
GeneRuler DNA Ladder Mix     Thermo Scientific 
Orange G       Sigma-Aldrich  
SeaKem LE Agarose     Lonza 
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3.1.4   SDS-PAGE and Western blot 
APS       AppliChem 
BSA (Albumin Fraction V, Protease-free)   AppliChem 
Coomassie Brilliant Blue G 250    Sigma-Aldrich 
p-Coumaric acid       
Roth Hydrogen peroxide 30%   Roth 
Immobilon-P (PVDF membrane)   Millipore 
Luminol       Roth 
Medical X Ray Film Super RX     Fujifilm  
PageRuler Prestained Protein Ladder  Thermo Scientific 
TEMED      AppliChem  
Ultra Pure ProtoGel     Biozym 
(Acrylamide:Bis-Acrylamide 37.5:1) 
Whatman paper      Schleicher and Schuell 
 
3.1.5   Immunohistochemical staining (IHC) 
Antibody diluent      Dako  
Dako Pen      Dako 
Mayer´s hemalum solution    Merck 
Mowiol 4-88      Roth 
Peroxidase solution (30%)    Roth 
Roticlear       Roth 
Streptavidin peroxidase     KPL 
 
Staining boxes and racks (made of lime-soda-glass) Roth 
Staining boxes (made of PMP plastic)  Roth 
Staining chamber (for up to 20 microscope slides) Roth 
Steam cooker      Braun 
Tissue sections from murine lungs   Rajkumar Savai (MPI, Bad Nauheim) 
(HealthyCon #1 - #3, LLC1 #1 - #3, 59s Lung #1, #2, #4) 
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3.1.6   Other chemicals, reagents and consumables 
4-Hydroxytamoxifen (4-OHT)    Sigma-Aldrich 
Polybrene (Hexadimethrine bromide)  Sigma-Aldrich 
Potassium ferricyanide(III) (K3Fe(CN)6)  AppliChem 
Potassium ferrocyanide (K4Fe(CN)6)    AppliChem 
Protein A Sepharose 4 Fast Flow   GE Healthcare 
Salmon Sperm     AppliChem 
X-gal       Roth 
Clear Seal Diamond Heat Sealing Film  Thermo Scientific  
Clear Seal sheets     4titude 
qPCR 96-well plates      Sarstedt 
 
3.1.7   Kits 
Table 1: Kits with corresponding application and supplier. 
Kit Application Supplier 
ABsolute qPCR SYBR Green Mix 
Plus ROX Vial 
RT-qPCR analysis  
(cDNA or ChIP-chromatin) 
Thermo Scientific 
AEC (red) Substrate Kit 
Immunohistochemical staining (IHC) of tissue 
sections 
Life Technologies 
JETQUICK Gel Extraction Spin Kit Agarose gel purification Genomed 
JETSTAR Plasmid Maxiprep Kit Plasmid-DNA isolation from prokaryotic cells Genomed 
RNA Mini Kit RNA isolation from eukaryotic cells Seqlab 
RNeasy Micro Kit 
RNA isolation from eukaryotic cells (from 
very small cell numbers) 
Qiagen 
peqGOLD DNase I Digest Kit DNA digest (RNA isolation) Peqlab 
QIAquick PCR Purification Kit DNA purification (ChIP analysis) Qiagen 
Senescence Cells Histochemical 
Staining Kit 
SA-ß-gal staining of eukaryotic cells Sigma-Aldrich 
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3.2   Standard solutions and buffers 
Standard solutions and buffers were prepared according to standard protocols. 
Additional buffers are listed in the individual subsections of section 4, METHODS. 
PBS 2 mM KH2PO4 - pH 7.4 (NaOH) 
10 mM Na2HPO4 
137 mM NaCl 
2.7 mM KCl 
TBE 89 mM TRIS - pH 7.9 (NaOH) 
2 mM EDTA 
89 mM Boric acid  
TBS 10 mM TRIS - pH 7.9 (HCl) 
150 mM NaCl 
TBS-T (0.05%) TBS - pH 7.9 
0.05% (v/v) Tween 20 
TBS-T (0.5%) TBS - pH 7.9 
0.5% (v/v) Tween 20 
 
3.3   Bacteria strain, culture medium and supplements 
DH5α    E. coli strain  for plasmid-DNA amplification 
LB medium 1% (w/v)  peptone (from casein) 
0.5% (w/v) yeast extract 
1% (w/v) NaCl 
Agar plates   1.5% (w/v)  agar in LB medium 
Ampicillin   100 µg/ml  (final concentration) 
Kanamycin   50 µg/ml  (final concentration) 
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3.4   Cell lines, tissue culture media and antibiotics 
Different eukaryotic cell lines of either human or murine origin were used and are 
listed in Table 2. 
Table 2: Eukaryotic cell lines with corresponding medium and antibiotic. 
Cell line Cell type 
Tissue culture media  
and antibiotics  
[data in (v/v)] 
Source/Reference 
Beas2B 
human transformed bronchial 
epithelial cell line 
DMEM/F-12  
+ 5% FCS + 1% PS 
Rajkumar Savai 
H1299 human lung, carcinoma (NSCLC) 
DMEM 
+ 10% FCS + 1% PS 
Thorsten Stiewe 
H1650 
human lung, bronchoalveolar 
adenocarcinoma (NSCLC) 
RPMI 1640 
(ATCC modification) 
+ 10% FCS + 1% PS 
Rajkumar Savai 
A549 human lung, carcinoma (NSCLC) 
DMEM  
+ 10% FCS + 1% PS 
Thorsten Stiewe 
H358 
human lung, bronchoalveolar 
adenocarcinoma (NSCLC) 
RPMI 1640  
+ 10% FCS + 1% PS 
Sylvie Gazzeri 
MLE12 
murine transformed lung epithelial cell 
line 
DMEM/F-12  
+ 5% FCS + 1% PS 
Rajkumar Savai 
LLC1 mouse Lewis lung carcinoma line 1 
RPMI 1640  
+ 10% FCS + 1% PS 
Rajkumar Savai 
U2OS 
human osteosarcoma cell line 
(epithelial-like) 
DMEM  
+ 10% FCS + 1% PS 
Uta-Maria Bauer 
Phoenix-Eco 
human second-generation retrovirus 
producer cell line for generation of 
ecotropic (Eco) retroviruses 
DMEM  
+ 10% FCS + 1% PS 
(Grignani et al., 
1998) 
TIG3-T 
human diploid embryonic fibroblasts, 
hTERT-immortalised, express ecotropic 
murine receptor (EcoR) 
DMEM  
+ 10% FCS + 1% PS 
Kristian Helin 
(Bracken et al., 
2007; Dietrich et 
al., 2007) 
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TIG3 BRAF-ER 
human diploid embryonic fibroblasts, 
hTERT-immortalised, stably expressing 
a pMSCV-Blast-BRAF-ER plasmid 
(oncogenic Braf kinase domain is fused 
to a mutant form of ligand binding 
domain (LBD) of estrogen receptor 
(ER), which is 4-OHT inducible) 
DMEM  
+ 10% FCS + 1% PS 
Kristian Helin 
(Agger et al., 2009) 
MCF7 
human breast adenocarcinoma  
cell line 
DMEM  
+ 10% FCS + 1% PS 
Uta-Maria Bauer 
 
All tissue culture media and supplements, such as FCS, PS and Trypsin-EDTA (0.05%), 
used in this study were purchased from Life Technologies. The most commonly used 
DMEM contained 4.5 g/l glucose, L-glutamine, phenol red and sodium pyruvate. Cells 
were cultivated at 37°C and 5% CO2. TIG3 BRAF-ER cells were treated every second day 
with 200 nM 4-OHT (Sigma-Aldrich) for the indicated time intervals. Antibiotics 
required for plasmid selection of TIG3-T or TIG3 BRAF-ER cells are listed in Table 3. 
 
 
Table 3: Eukaryotic cell lines with corresponding antibiotics for plasmid selection. 
Cell line Antibiotics Final concentration 
TIG3-T 
Neomycin (G418) - for EcoR 
Hygromycin - for hTERT 
Puromycin - for Puromycin resistence gene 
(infection with pSUPER.retro.puro constructs) 
500 µg/ml 
100 µg/ml 
1 µg/ml 
TIG3 BRAF-ER 
Blasticidin - for BRAF-ER 
Neomycin (G418) - for hTERT 
5 µg/ml 
50 µg/ml 
 
 
 
 
 
MATERIALS 
 
32 
 
3.5   Transfection reagents 
Table 4: Transfection reagents with corresponding application. 
Transfection reagent Application 
Calcium phosphate 
transfection of Phoenix-Eco cells  
(ecotropic retroviruses generation) 
FuGENE HD (Roche) plasmid-DNA transfection of TIG3 BRAF-ER cells 
Lipofectamine RNAiMax (Life Technologies) siRNA transfection of U2OS, H1299 and H358 cells 
Polyethylenimine (PEI), 0.1% (v/v) 
(Sigma-Aldrich) 
siRNA transfection of TIG3 BRAF-ER cells,  
plasmid-DNA transfection of MCF7 cells 
 
3.6   Eukaryotic expression plasmids 
3.6.1   Empty plasmids 
Table 5: Eukaryotic empty plasmids used in this study. 
Plasmid Resistance Comments Source/Reference 
pcDNA3.1 
Ampicillin, 
Neomycin 
control plasmid for pcDNA3.1-hPRMT6, 
myc-his C-terminal (5500 bp) 
Invitrogen 
pSUPER.retro.puro 
Ampicillin, 
Puromycin 
retroviral pSUPER-shRNA plasmid 
(originally from OligoEngine), with RNA 
Polymerase III-dependent H1-RNA 
promoter and Puromycin resistence gene 
(Brummelkamp et 
al., 2002) 
 
3.6.2   Expression plasmids 
Table 6: Eukaryotic expression plasmids used in this study. 
Plasmid Resistance Comments Source/Reference 
p3xFLAG10-HsPCNA  
Ampicillin, 
Neomycin 
interaction analysis of PCNA 
with PRMT6 (IPs) 
Kyungjae Myung 
(Motegi et al., 2006) 
pcDNA3-flag-DDB1 Ampicillin 
interaction analysis of DDB1 
with PRMT6 (IPs) 
Francesca Bernassola 
(Malatesta et al., 2013) 
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pcDNA3.1-hPRMT6 
Ampicillin, 
Neomycin 
hPRMT6-ORF was generated by 
BamHI/EcoRI restriction of 
pGEX-2T-hPRMT6 and cloned 
into pcDNA3.1 (Invitrogen) 
Uta-Maria Bauer 
(Stein et al., 2012) 
 
3.6.3   Retroviral expression plasmids 
Ecotropic retroviral supernatants were produced in Phoenix-Eco cells by transfection 
of pSUPER.retro.puro plasmids encoding several shRNAs. 
Table 7: Retroviral expression plasmids used in this study. 
Plasmid Resistance 
Comments  
(depleted gene) 
Source/Reference 
pSUPER.retro.puro- 
shLuci 
Ampicillin, 
Puromycin 
plasmid for shLuci 
expression 
Uta-Maria Bauer 
(Stein et al., 2012) 
pSUPER.retro.puro- 
shPRMT6_1 
Ampicillin, 
Puromycin 
plasmid for shPRMT6_1 
expression (PRMT6) 
Uta-Maria Bauer 
(Stein et al., 2012) 
pSUPER.retro.puro- 
shPRMT6_2 
Ampicillin, 
Puromycin 
plasmid for shPRMT6_2 
expression (PRMT6) 
Uta-Maria Bauer 
(Stein et al., 2012) 
pSUPER.retro.puro- 
shPRMT6_3 
Ampicillin, 
Puromycin 
plasmid for shPRMT6_3 
expression (PRMT6) 
Uta-Maria Bauer 
(Stein et al., 2012) 
 
3.7   Oligonucleotides 
All oligonucleotides were ordered from Eurofins MWG/Operon and dissolved to a 
concentration of 100 pmol/µl. 
 
3.7.1   Sequencing primers and sequence analysis 
The pSUPER.retro.puro plasmid constructs were sequenced with the sequencing 
primer 5´-pRS GGAAGCTTGGCTTTTG. The DNA sequence analysis was performed by 
LGC Genomics. Other plasmids were sequenced by standard primer pairs available at 
the same company. 
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3.7.2   Reverse transcription (RT) primer  
An oligo(dT)17 primer was used to transcribe 10 ng - 2 µg RNA into cDNA. 
 
3.7.3   Real-time quantitative PCR (RT-qPCR) primers 
RT-qPCR primers were designed with the help of the Universal ProbeLibrary from 
Roche using an intron spanning assay to avoid the amplification of genomic DNA.  
 
3.7.3.1 Human RT-qPCR primers 
Table 8: Human primers for RT-qPCR gene expression analysis. 
Gene 
NCBI number (detected  
transcript variants, TV) 
Sequence (5´→3´) 
forward/reverse 
CCNA2 NM_001237.3 
ATGAGACCCTGCATTTGGCTG 
TTGAGGTAGGTCTGGTGAAGG 
CCND1 NM_053056.2 
GACCTCCTCCTCGCACTTC 
CCCTCGGTGTCCTACTTCAA 
CDKN1A (p21) 
NM_000389.4 (TV1) 
NM_078467.2 (TV2) 
NM_001291549.1 (TV3) 
NM_001220778.1 (TV4) 
NM_001220777.1 (TV5) 
GGCAGACCAGCATGACAGATTTC 
CGGATTAGGGCTTCCTCTTGG 
CDKN1B (p27) NM_004064.4 
CCCTAGAGGGCAAGTACGAGT 
AGTAGAACTCGGGCAAGCTG 
CDKN1C (p57) 
NM_000076.2 (TV1) 
NM_001122630.1 (TV2) 
NM_001122631.1 (TV3) 
CACGATGGAGCGTCTTGTC 
GCTCAGCTCCTCGTGGTC 
EZH2 
NM_004456.4 (TV1) 
NM_152998.2 (TV2) 
NM_001203247.1 (TV3) 
NM_001203248.1 (TV4) 
NM_001203249.1 (TV5) 
TCAAAACCGCTTTCCGGG 
TGTCCCAATGGTCAGCG 
p16-INK4A (CDKN2A) 
NM_000077.4 (TV1) 
NM_001195132.1 (TV5) 
CCCCTTGCCTGGAAAGATAC 
AGCCCCTCCTCTTTCTTCCT 
THBS1 NM_003246.2 AATGCTGTCCTCGCTGTTG 
GCCACAGCTCGTAGAACAGG 
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TP53 (P53) 
NM_000546.5 (TV1) 
NM_001126112.2 (TV2) 
NM_001126114.2 (TV3) 
NM_001126113.2 (TV4) 
NM_001126115.1 (TV5) 
NM_001126116.1 (TV6) 
NM_001126117.1 (TV7) 
NM_001126118.1 (TV8) 
AGGCCTTGGAACTCAAGGAT 
CCCTTTTTGGACTTCAGGTG 
PRMT6 NM_018137.2 
AGACACGGACGTTTCAGGAG 
CCACTTTGTAGCGCAGCAG 
RPLP0 
NM_001002.3 (TV1) 
NM_053275.3 (TV2) 
GTCGGAGGAGTCGGACGAG 
GCCTTTATTTCCTTGTTTTGCAAA 
RPS14 
NM_001025071.1 (TV1) 
NM_001025070.1 (TV2) 
NM_005617.3 (TV3) 
GGCAGACCGAGATGAATCCTCA 
CAGGTCCAGGGGTCTTGGTCC 
UBC NM_021009.6 
CACTTGGTCCTGCGCTTGA 
CAATTGGGAATGCAACAACTTTAT 
 
3.7.3.2 Human/murine RT-qPCR primers 
Primer pairs were designed for detection of both the human and murine transcript 
levels of PRMT6/Prmt6 or the corresponding controls RPLP0/Rplp0 and RPS14/Rps14. 
 
Table 9: Human/murine primers for RT-qPCR gene expression analysis. 
Genes 
NCBI number (detected  
transcript variants, TV) 
Sequence (5´→3´) 
forward/reverse 
PRMT6/Prmt6 
NM_018137.2 
NM_178891.5 
TCGCCTTTTCACCCGGCCAC 
GTCTCCCACTTTGTAGCGCA 
RPLP0/Rplp0 
NM_001002.3 (TV1) 
NM_053275.3 (TV2) 
NM_007475.5 
ACACCATGATGCGCAAGGC 
GTGAGGTCCTCCTTGGTGAAC 
RPS14/Rps14 
NM_001025071.1 (TV1) 
NM_001025070.1 (TV2) 
NM_005617.3 (TV3) 
NM_020600.4 
TGACTGGTGGGATGAAGG 
CAGGTCCAGGGGTCTTGGTC 
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3.7.4   Human ChIP-qPCR primer 
ChIP-qPCR primer pairs were designed using the Primer3 program. 
Table 10: Human primers for ChIP analysis by qPCR. 
Gene (region) 
Sequence (5´→3´) 
forward/reverse 
CDKN1A (-6.8kb) GGAGGGCAAAGTACAGTGGA 
CACATGTGACTTGGGGTGAG 
CDKN1A (-1.0kb) TACGGGCTATGTGGGGAGTA 
AAGGGGAGGATTTGACGAGT 
CDKN1A (TSS) CCGAAGTCAGTTCCTTGTGG 
CGCTCTCTCACCTCCTCTGA 
CDKN1A (+0.5kb) GTGGGGATGAAGTCCGTGTC 
ACTTACTCCACTCCGCTTTC 
CDKN1A (+8.6kb) CTGTAAACCTCTCGAGGGCA 
GCACCTGCTGTATATTCAGC 
p16-INK4A (-1.8kb) CTTTTACCTCCTTGCGCTTG 
TGGGAGACAAGAGCGAAACT 
p16-INK4A (-0.5kb) AGGGGAAGGAGAGAGCAGTC 
CTACCCCCTCAACCCTTGAT 
p16-INK4A (TSS) CCCCTTGCCTGGAAAGATAC 
AGCCCCTCCTCTTTCTTCCT 
p16-INK4A (+0.5kb) TCAGGTAGCGCTTCGATTCT 
GGCTCCTCATTCCTCTTCCT 
p16-INK4A (+1.0kb) CCCTTCACTTTGGGAGATCA 
CCCCCGGCTACTTTTTGTAT 
 
 
 
 
MATERIALS 
 
37 
 
3.7.5   siRNA oligonucleotids 
The depletion of specific or unspecific mRNAs was achieved by transient transfection 
of siRNAs. The siRNA sequences were provided from Dharmacon, Sigma-Aldrich and 
reordered from Eurogentec (20 µM stock solutions). 
Table 11: siRNA oligonucleotides used in this study. 
Name  
(depleted gene) 
NCBI number (detected 
transcript variants, TV) 
Sequence (5´→3´) 
sense/antisense 
Source/Reference 
siGFP -- 
GCAAGCUGACCCUGAAGUU 
AACUUCAGGGUCAGCUUGC 
-- 
siLuci -- 
GAUUAUGUCCGGUUAUGUA 
UACAUAACCGGACAUAAUC 
Dharmacon 
siNon -- 
AUGAACGUGAAUUGCUCAA 
UUGAGCAAUUCACGUUCAU 
Dharmacon 
siScr -- 
CAUAAGCUGAGAUACUUCA 
UGAAGUAUCUCAGCUUAUG 
Martin Eilers 
siPRMT6_1 
(PRMT6) 
NM_018137.2 
GAGCAAGACACGGACGUUU 
AAACGUCCGUGUCUUGCUC 
Dharmacon 
siPRMT6_2 
(PRMT6) 
NM_018137.2 
GCAAGACACGGACGUUUCA 
UGAAACGUCCGUGUCUUGC 
Dharmacon 
siPRMT6_3 
(PRMT6) 
NM_018137.2 
GGAGGGAGAGUGACUUCAU 
AUGAAGUCACUCUCCCUCC 
-- 
siPRMT6_4 
(PRMT6) 
NM_018137.2 
GACGUUUCAGGAGAGAUCA 
UGAUCUCUCCUGAAACGUC 
Sigma-Aldrich 
siPRMT6_5 
(PRMT6) 
NM_018137.2 
CGGAACAGGUGGAUGCCAU 
AUGGCAUCCACCUGUUCCG 
Sigma-Aldrich 
siCDKN1A 
(pool of 
3 sequences) 
(CDKN1A) 
NM_000389.4 (TV1) 
NM_078467.2 (TV2) 
NM_001220778.1 (TV4) 
NM_001220777.1 (TV5) 
CGAUGGAACUUCGACUUUG 
CAAAGUCGAAGUUCCAUCG 
GCGAUGGAACUUCGACUUU 
AAAGUCGAAGUUCCAUCGC 
GAUGGAACUUCGACUUUGU 
ACAAAGUCGAAGUUCCAUC 
Dharmacon 
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3.7.6   shRNA oligonucleotids 
The cloning strategy was based on manufacturer's instructions (OligoEngine) and 
resulted in the production of retroviral expression plasmids (chapter 3.6.3) for the 
selective suppression of one of the displayed human mRNAs listed in Table 12. Each 
oligo pair (sense and antisense) was designed with a BglII restriction site (GATC) at the 
5´-end of the sense oligo and a HindIII restriction site (AGCT) at the 5´-end of the 
antisense oligo. All used shRNAs were identical to siRNA sequences as described above. 
Table 12: Specific and unspecific oligonucleotides used for shRNA production. 
Name  Depleted gene Sequence (5´→3´) 
shLuci (sense) 
-- 
GATCCCCGATTATGTCCGGTTATGTATTCAA  
GAGATACATAACCGGACATAATCTTTTTA 
shLuci (antisense) 
AGCTTAAAAAGATTATGTCCGGTTATGTATC 
TCTTGAATACATAACCGGACATAATCGGG 
shPRMT6_1 (sense) 
PRMT6 
GATCCCCGAGCAAGACACGGACGTTTTTCAA 
GAGAAAACGTCCGTGTCTTGCTCTTTTTA 
shPRMT6_1 (antisense) 
AGCTTAAAAAGAGCAAGACACGGACGTTTTC 
TCTTGAAAAACGTCCGTGTCTTGCTCGGG 
shPRMT6_2 (sense) 
PRMT6 
GATCCCCGCAAGACACGGACGTTTCATTCAA 
GAGATGAAACGTCCGTGTCTTGCTTTTTA 
shPRMT6_2 (antisense) 
AGCTTAAAAAGCAAGACACGGACGTTTCATC 
TCTTGAATGAAACGTCCGTGTCTTGCGGG 
shPRMT6_3 (sense) 
PRMT6 
GATCCCCGGAGGGAGAGTGACTTCATTTCAA 
GAGAATGAAGTCACTCTCCCTCCTTTTTA 
shPRMT6_3 (antisense) 
AGCTTAAAAAGGAGGGAGAGTGACTTCATTC 
TCTTGAAATGAAGTCACTCTCCCTCCGGG 
 
 
 
 
MATERIALS 
 
39 
 
3.8   Antibodies and antisera 
3.8.1   Primary antibodies 
Table 13: Antibodies and antisera used in this study. 
Primary antibody Type of antibody 
Dilution/Amount 
(Application) 
Source/Reference 
α-CDK2 (M2) rabbit, polyclonal IgG 1:5.000 (Wb) Santa Cruz (sc-163) 
α-DDB1 (clone ZD001) mouse, monoclonal IgG1κ  1:500 (Wb) Invitrogen (39-9901) 
α-DDB2 (2246C4a) mouse, monoclonal IgG1 1:800 (Wb) Santa Cruz (sc-81246) 
α-H3 rabbit, polyclonal IgG 
1:1.000 (Wb) 
2 µl (ChIP) 
Abcam (ab1791) 
α-H3R2me2a rabbit, polyclonal IgG 5 µl (ChIP) Millipore (07-585) 
α-IgG rabbit, polyclonal 
6 µg (ChIP) 
45 µg (IP) 
Sigma-Aldrich (I5006) 
α-p16 (JC8) (= p16-INK4A) mouse, monoclonal IgG 1:5 (Wb) Gordon Peters 
α-p21 (N-20) (= CDKN1A) rabbit, polyclonal IgG 1:400 (Wb) Santa Cruz (sc-469) 
α-PCNA (PC10) mouse, monoclonal IgG2a 1:1.000 (Wb) Santa Cruz (sc-56) 
α-PRMT1_milli rabbit, polyclonal IgG 
1:2.000 (Wb) 
1:1.000 (IHC) 
Millipore (07-404) 
α-PRMT1_affi 
rabbit, polyclonal IgG 
(affinity-purified) 
1:50 (IHC) Uta-Maria Bauer 
α-PRMT6_2affi  
(full-length His-tagged 
PRMT6 antigen) 
rabbit, polyclonal IgG 
(affinity-purified) 
1:8.000 (Wb) 
30 µl (ChIP) 
1:100 (IHC) 
affinity-purified from crude 
serum using GST-tagged 
PRMT6 protein, Uta-Maria 
Bauer 
α-PRMT6_3affi 
(full-length GST-tagged 
PRMT6 antigen) 
rabbit, polyclonal IgG 
(affinity-purified) 
1:50 (IHC) 
affinity-purified from crude 
serum using His-tagged 
PRMT6 protein, 
Uta-Maria Bauer 
α-PRMT6_1 (His-tagged) 
α-PRMT6_2 (His-tagged) 
α-PRMT6_3 (GST-tagged) 
α-PRMT6_4 (GST-tagged) 
rabbit, polyclonal IgG 
(crude sera) 
45 µg (IP) Uta-Maria Bauer 
α-PRMT6_1 (His-tagged) 
α-PRMT6_3 (Gst-tagged) 
rabbit, polyclonal IgG 
(preimmune sera) 
45 µg (IP) Uta-Maria Bauer 
α-PRMT6_bethyl rabbit, polyclonal IgG 1:100 (IHC) 
Bethyl Laboratories  
(A300-929A) 
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3.8.2   Secondary antibodies 
Table 14: Secondary antibodies used for Western blot and IHC analysis. 
Secondary antibody Type of antibody 
Dilution 
(Application) 
Source 
α-mouse IgG 
from sheep, polyclonal,  
HRP-conjugated 
1:5.000 (ECL, Wb) GE Healthcare  
α-rabbit IgG 
from donkey, polyclonal,  
HRP-conjugated 
1:5.000 (ECL, Wb) GE Healthcare  
α-mouse  
Lambda light chain 
from goat, polyclonal,  
HRP-conjugated 
1:5.000 (ECL, Wb) Bethyl Laboratories  
α-rabbit IgG 
from goat, polyclonal, 
biotinylated 
1:500 (IHC) Dako  
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4   METHODS 
4.1   Cell biological methods 
4.1.1   Cultivation of eukaryotic cells 
Adherent eukaryotic cell lines were cultivated at a confluence of 70 - 100% in complete 
medium (plus FCS and antibiotics) at 37°C, 5% CO2 and 100% humidity. Cells were 
splitted every two to four days depending on their growth rate. 
In order to split cells the old medium was aspirated from a 145 cm
2
 cell culture dish. 
Cells were washed once with 10 ml PBS and incubated with 2 ml Trypsin-EDTA (0.05%) 
at 37°C for several minutes. Upon detaching of the cells from the plastic surface of the 
vessel trypsin activity was stopped by adding 8 ml complete medium. After 
resuspension of the cells the appropriate amount of splitted cells was transferred into 
a new dish (145 cm
2
) and supplemented with fresh complete medium to a total 
volume of 20 ml. 
 
4.1.2   Freezing and thawing of eukaryotic cells 
A 145 cm
2
 dish was trypsinised as described in chapter 4.1.1 at a cell confluence of 
about 70 - 80%. Cell suspension was transferred into a 50 ml falcon, centrifuged 
(1.200 rpm, 3 minutes, RT) and the cell pellet was quickly resuspended in 1 ml freezing 
medium and transferred into a cryotube. To achieve gentle freezing of the cells, the 
cryotube was wrapped in paper towels and stored in a polystyrene box several days at 
-80°C until long term storage in the liquid nitrogen tank. 
Freezing medium 30% (v/v) FCS  
10% (v/v) DMSO 
60% (v/v) complete medium 
Cells were thawed quickly in a water bath at 37°C and resupended in 10 ml of fresh 
complete medium to avoid possible cell damage by DMSO. After centrifugation 
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(1.200 rpm, 3 minutes, RT), cells were transferred into a new cell culture flask 
depending on the cell pellet size (25 cm
2
 - 175 cm
2
) and cultivated. 
 
4.1.3   Cell counting (Neubauer chamber) 
In every cell culture experiment a defined cell number was needed. For this purpose 
cells were trypsinised (chapter 4.1.1) and diluted in a sufficient quantity of complete 
medium. Cell number was determined by counting at least 4 of 8 big squares of a 
Neubauer chamber and cell concentration was calculated using the following formula.  
concentration	
cells ml⁄  = 	
number	of	cells
number	of	big	squares
× 10 × dilution	factor 
If the cell suspension was diluted before counting for example 1:10, the dilution factor 
of 10 was considered in the calculation of the total cell number. 
 
4.1.4   Transient transfection of eukaryotic cells with plasmid-DNA  
The choice of the best transfection method including transfection reagent was 
dependent on the cell line and highest transfection efficiency with lowest toxicity for 
the cells. The amount of transfection reagent and other supplements in the mix was 
adapted to the size of the dish used in an experiment. 
 
4.1.4.1 FuGENE HD transfection 
A FuGENE HD transfection in a FuGENE HD transfection reagent:DNA ratio of 2:1 was 
the most efficient way to transfect TIG3 BRAF-ER cells with plasmid-DNA. Therefore, 
180.000 cells were seeded in a 6-well plate one day before transfection. On the next 
day 100 µl Opti-MEM/GlutaMAX (Life Technologies) was mixed with 1 µg DNA in a 
tube and 2 µl FuGENE HD was added. After an incubation of 15 minutes at RT the mix 
was added dropwise to a 6-well plate in a total volume of 2 ml complete medium.  
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4.1.4.2 Polyethylenimine (PEI) transfection 
Polyethylenimine (PEI) is a linear cationic polymer. The negative charge of nucleic acids 
associates with PEI whereby plasmid-DNA gets a neutral charge, which is easily 
ingested by eukaryotic cells. 
A 0.1% (v/v) PEI-solution was used to transfect MCF7 cells with plasmid-DNA seeded at 
a density of 3.0 x 10
6
 cells in a 145 cm
2
 dish. Therefore, the medium of the cell dish 
(50% confluent) was replaced by 18 ml fresh complete medium directly before the 
transfection. The DNA and PEI solution were mixed upon separate incubation 
(5 minutes, RT). After another 15 minutes of incubation the transfection mix was 
carefully added to the cell dish and the complete medium was replaced after 4 hours 
with 20 ml fresh complete medium. Cells were harvested 48 hours post-infection for 
co-immunoprecipitation (co-IP) analysis (chapter 4.3.6). 
DNA solution   40 µg DNA in 900 µl PBS 
PEI solution   40 µl PEI in 900 µl PBS 
 
4.1.5   Transfection of eukaryotic cells with siRNA 
For transfection of eukaryotic cells with plasmid-DNA the most efficient siRNA 
transfection method was used for each individual eukaryotic cell line. 
 
4.1.5.1 LipofectamineRNAiMAX (LipoRNAiMAX) transfection 
Cells were seeded 24 hours before transfection in the appropriate complete medium. 
NSCLC cell lines (H1299, H358) were seeded at a density of 1.1 x 10
6
 cells and U2OS 
were seeded at a density of 0.93 x 10
6
 cells in a 56 cm
2
 dish. The transfection mix, 
Opti-MEM/GlutaMAX with siRNA and Opti-MEM/GlutaMAX with LipoRNAiMAX, was 
incubated for 5 minutes at RT and then combined/gently mixed in one tube for 
another incubation of 20 minutes at RT. The DNA-LipoRNAiMAX complexes were 
METHODS 
 
44 
 
added dropwise to the dish and gently mixed. After siRNA-mediated knockdown cells 
were harvested either for RT-qPCR (chapter 4.2.9) and Western blot analysis (chapter 
4.3.5) or were replated for colony formation assay (chapter 4.1.8). All volumina of the 
components used in the LipoRNAiMAX transfection are listed in Table 15. 
 
Table 15: Amounts of siRNA and LipoRNAiMAX for siRNA-mediated depletion in different cell lines. 
56 cm
2
 dish (10 ml): 
H1299, H358 U2OS  
(50 nM siRNA final concentration) (20 nM siRNA final concentration) 
siRNA solution 
1 ml Opti-MEM/GlutaMAX  
+ 25 µl siRNA 
1 ml Opti-MEM/GlutaMAX  
+ 10 µl siRNA 
LipoRNAiMAX solution 
1 ml Opti-MEM/GlutaMAX  
+ 15 µl LipoRNAiMAX 
1 ml Opti-MEM/GlutaMAX  
+ 6 µl LipoRNAiMAX 
 
4.1.5.2 Polyethylenimine (PEI) transfection 
The transfection reagent 0.1% (v/v) PEI was used for transient overexpression of 
plasmid-DNA in eukaryotic cells and siRNA-mediated depletion (20 µM stock solutions) 
in TIG3 BRAF-ER cells. One day before transfection, 180.000 cells were seeded in a 
6-well plate (2 ml final volume) and transfected on the following day. 
Solution A   5 µl siRNA (50 nM final concentration) in 75 µl PBS 
Solution B   4 µl PEI in 75 µl PBS 
Both solutions (A+B) were incubated for 5 minutes at RT, gently mixed, incubated 
another 15 minutes at RT and added dropwise to the cells. In accordance with the 
respective experiment cells were harvested for RT-qPCR analysis (chapter 4.2.9) or 
stained in a SA-ß-gal assay (chapter 4.1.7). 
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4.1.6   Retrovirus production and infection of eukaryotic cells 
Retroviral infection of eukaryotic cells with shRNA constructs is a common method 
that allows stable integration of these shRNA genes into host cell genome. The 
Phoenix-Eco cell line is a second-generation ecotropic retrovirus producer cell line 
based on HEK 293T, which is capable of producing gag, pol and env proteins to 
generate recombinant retroviruses. Thereby, foreign DNA, such as shRNA-encoding 
plasmids (pSUPER.retro.puro), can be easily packaged in their virus particles by 
transfection of these constructs with calcium phosphate (Brummelkamp et al., 2002). 
Human TIG3-T cells that stably express the ecotropic murine receptor allow infection 
by ecotropic retroviruses. 
 
4.1.6.1 Retrovirus production using Phoenix-Eco cells 
The calcium phosphate method was used for efficient transfection of Phoenix-Eco cells 
with pSUPER.retro.puro constructs encoding for shRNAs. The produced precipitates of 
calcium cations and the anionic phosphate groups of the DNA were internalised by 
endocytosis of the Phoenix-Eco cells and production of retroviral supernatants was 
achieved. In the following, a transfection of a 56 cm
2
 dish is described. All used buffers 
were dissolved in ddH2O and sterile-filtered through a 0.2 µm syringe filter. 
Cells were seeded at a density of 5.5 x 10
6
 cells in a 56 cm
2
 dish. On the next day they 
were transfected using 30 µg plasmid-DNA in 1 ml transfection solution. Therefore, 
DNA was filled up to 450 µl with TE (1:10 dilution), vortexed and mixed with 50 µl of 
2.5 mM CaCl2. Then, 500 µl 2 x HBS was added dropwise to the suspension while 
vortexing. This step is very crucial and important for the transfection efficiency 
because of the formation of very fine microcrystalline precipitates. The DNA-calcium-
precipitate mix was incubated for 20 minutes at RT and added dropwise to the dish. 
The dish was carefully swayed. After incubation for 16 - 20 hours cells were washed 
with PBS to remove precipitates and 7 ml of fresh complete medium was added. After 
additional 24 hours the virus supernatant was collected, centrifuged (1.200 rpm, 
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3 minutes, RT), quickly frozen in liquid nitrogen and stored at -80°C. Again 7 ml of fresh 
complete medium was added to the dish. On the next day the second virus 
supernatant was collected as before.  
TE 10 mM TRIS - pH 8.0 
1 mM EDTA 
CaCl2 2.5 mM 
2 x HBS 1.5 mM Na2HPO4 - pH 6.95 
273 mM NaCl 
54 mM HEPES 
 
4.1.6.2 Infection of TIG3-T cells 
At the day of infection the virus was quickly thawed in a water bath at 37°C before 
adding to TIG3-T cells. For a 56 cm
2
 dish, 1.2 x 10
6
 TIG3-T cells were seeded 24 hours 
before infection. 3 ml virus, 2 ml complete medium and 10 µl Polybrene (8 µg/ml final 
concentration) were gently mixed. The medium was aspirated and the virus solution 
was added to the dish. The plate was moved to distribute the virus on the plate and 
cultured. After 14 - 16 hours the procedure was repeated and after additional 8 - 10 
hours, 5 ml of fresh complete medium was added for recovery of the cells. 48 hours 
post-infection with the first virus supernatant TIG3-T cells were selected with 
puromycin (1 µg/ml) for 72 hours. As a control TIG-3 T cells without infection were 
selected with puromycin. After 3 days of puromycin selection the day counting of the 
experiment started and corresponded to day 0. 
Polybrene   4 µg/µl in ddH2O 
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4.1.7   Senescence-associated ß-galactosidase (SA-ß-gal) staining 
Senescent cells have an increased activity of ß-galactosidase (ß-gal), which is 
detectable by histochemical staining at pH 6.0. Enhanced levels of this biomarker are 
associated with aging or other senescence inducing-stimuli (e.g. mitogenic oncogenes, 
oxidative stress), but not detectable in pre-senescent cells (early passage, proliferating 
cells) (Dimri et al., 1995; Storer et al., 2013). 
ß-gal staining was done using the "Senescence Cells Histochemical Staining Kit" from 
Sigma-Aldrich. It contained the chromogenic substrat X-gal (5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside), which was hydrolysed into galactose and 5-bromo-4-
chloro-3-hydroxyindole by ß-galactosidase and later converted into a microscopical 
detectable blue, water-insoluble dye. Based on manufacturer's instructions, 
senescence-induced TIG3 BRAF-ER cells (200 nM 4-OHT at the indicated time points) 
were stained for SA-ß-gal activity. For each condition, 180.000 cells were seeded in 
triplicates using 6-well plates with a grid. SA-ß-gal-positive TIG3 BRAF-ER cells were 
photographed for qualitative analysis and the total number was quantified by counting 
300 cells per condition and calculation of the mean values ± standard deviation. 
After puromycin selection TIG3-T cells were incubated another 6 days in culture for 
efficient shRNA-mediated depletion, replated and stained at day 7 for SA-ß-gal activity 
(Dimri et al., 1995). Therefore, 150.000 cells were seeded in 6-well plates. After 
24 hours cells were washed twice with PBS, fixed with 3% formaldehyde (in PBS) for 
3 - 5 minutes at RT, washed twice in PBS and stained with SA-ß-gal staining solution 
(2 ml per 6-well plate) for 12 - 14 hours at 37°C incubator (without CO2). 
SA-ß-gal staining solution 1 mg/ml X-gal (in DMF) 
    40 mM citric acid/sodium phosphate buffer 
    (C6H8O7 x H2O (0.1 M), Na2HPO4 (0.2 M) - pH 6.0) 
    5 mM potassium ferricyanide(III) (K3Fe(CN)6) 
    5 mM potassium ferrocyanide (K4Fe(CN)6) 
    150 mM NaCl 
    2 mM MgCl2 
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4.1.8   Colony formation assay (CFA) 
A colony formation assay (CFA) or clonogenic assay provides a method to determine 
the ability of cells to form clones without close contact to neighbour cells due to their 
transformational character indicated by unlimited division potential. The examined 
cells were transfected with siRNAs using LipoRNAiMAX as described in chapter 4.1.5.1. 
48 hours post-transfection cells were replated in triplicates using a very high cell 
dilution depending on the cell size. 
 
Table 16: Number of cells seeded per 6-well plate for CFA analysis. 
cell line cell number/6-well plate 
H1299 400 
H358 40.000  
U2OS 400 
After an incubation of 10 or 14 days cells were fixed in 70% (v/v) ethanol at 4°C ON, 
washed twice with PBS and colonies were stained with crystal violet [0.1% (w/v) in 
20% ethanol] for 20 minutes. Cells were thoroughly washed several times with ddH2O, 
dishes were air-dried and photographed. The quantification of crystal-violet stained 
colonies was performed by counting the relative colony number (in %) or by "Colony 
Area", an ImageJ plugin for automatically generated quantification of the colony area 
(in %) of each dish (Guzmán et al., 2014). 
 
4.2   Molecular biological methods 
4.2.1   Hybridisation of oligonucleotides 
The 60-mer complementary oligonucleotides used for shRNA production were 
dissolved in ddH2O (nuclease free) to a final concentration of 100 pmol/µl and 
hybridised in the following annealing reaction. The control of efficient hybridisation 
was achieved by agarose gel electrophoresis. 
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Annealing mix 1 nmol oligo (sense) 
1 nmol oligo (antisense) 
1 µl 100 mM NaCl 
1 µl 20 mM TRIS pH 7.5 
add 50 µl ddH2O 
Annealing reaction 10 minutes 95°C 
5 minutes 80°C  
3 minutes 75°C 
5 minutes, 70°C - slowly cooling-down phase to RT 
 
4.2.2   Restriction digest of plasmid-DNA 
The pSUPER.retro.puro plasmid (7195 bp) possesses amongst others a unique/single 
BglII and HindIII restriction site. The plasmid was restricted with both restriction 
enzyme sites, purified (chapter 4.2.3) and ligated with annealed double stranded oligo 
nucleotides encoding shRNAs (chapter 4.2.4), which were designed with these two 
restriction sites at their termini. According to manufacturer's instructions, restriction 
enzymes were used in their provided restriction buffers with highest enzyme activity.  
Restriction I 20 µg plasmid-DNA (pSUPER.retro.puro)  
4 µl enzyme (HindIII, 10 U/µl)  
5 µl 10 x R restriction buffer  
add 50 µl ddH2O - 2h at 37°C 
Restriction II  Restriction I  
4 µl enzyme (BglII, 10 U/µl) 
3 µl 10 x O restriction buffer 
add 80 µl ddH2O - 2h at 37°C 
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4.2.3   Agarose gel extraction of DNA fragments  
Separation of DNA fragments according to their size was achieved by agarose gel 
electrophoresis (150 V, 1 - 2 hours) using 1 - 3% (w/v) agarose in TBE buffer depending 
on their expected size and 1 - 3 µl ethidium bromide, a fluorescence marker for nucleic 
acids. For quantification, 7 µl of "GeneRuler DNA Ladder Mix" (Thermo Scientific) was 
loaded on the agarose gel. Samples were mixed with 6 x Orange G sample buffer. 
6 x Orange G sample buffer 60 mM TRIS - pH 7.5 
30 mM NaAc 
12 mM EDTA 
60% (v/v) glycerol  
0.36% (w/v) Orange G 
The purification of DNA fragments from agarose gels was performed with the 
"JETQUICK Gel Extraction Spin Kit" (Genomed) according to the manufacturer`s 
instructions. 
 
4.2.4   Ligation of DNA fragments 
The linearised, purified pSUPER.retro.puro plasmid was ligated with the annealed 
60-mer oligonucleotides using T4 DNA ligase. 
Ligation reaction 20 ng plasmid-DNA (pSUPER.retro.puro) 
1 µl insert DNA (annealed oligos) 
1 µl T4 DNA ligase (5 U/µl) 
1 µl 10 x ligation buffer 
add 10 µl ddH2O (nuclease free) - 16°C water bath, ON 
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4.2.5   Transformation of competent bacteria 
Standard bacteria transformation was performed by heat shock. Therefore, chemical 
competent DH5α bacteria were thawed on ice and 100 µl cells were mixed with either 
1 µg recombinant plasmid-DNA or 5 - 10 µl ligation. Cells were incubated for 20 minutes 
on ice. Heat shock was achieved by incubation of the cells at 42°C for 1 - 2 minutes, 
followed by incubation for 2 minutes on ice. In case of kanamycin-resistance plasmids, 
400 µl LB medium (without antibiotic) was mixed with the bacterial cell suspension 
and incubated for 30 minutes up to 1 hour on a 37°C shaker. The transformation was 
plated on a LB dish plus antibiotic or transferred into a LB liquid culture plus antibiotic 
for Mini-/Maxiprep (chapter 4.2.6.1) and was incubated ON at 37°C. 
 
4.2.6   Isolation and purification of nucleic acids  
4.2.6.1 Plasmid-DNA isolation from prokaryotic cells  
Miniprep - analytical scale 
Plasmid-DNA was isolated from a 1.5 ml ON bacteria culture. Cells were pelleted by 
centrifugation (13.000 rpm, 5 minutes, RT) and supernatant was aspirated. The buffers 
E1 (cell resuspension), E2 (cell lysis) and E3 (neutralisation) applied in the Miniprep 
were components of the "JETSTAR Plasmid Maxiprep Kit" (Genomed). Cell pellet was 
dissolved in 300 µl cold E1 buffer. Afterwards 200 µl E2 buffer was added to the cell 
suspension, inverted 5 times and incubated for 5 minutes at RT. In the next step 200 µl 
E3 buffer was mixed with the lysed cells for neutralisation by invertion (10 times) and 
incubation on ice for 5 minutes. Cell debris and denatured/precipitated cell 
components were centrifuged (13.000 rpm, 5 minutes, RT) and the supernatant 
(plasmid-DNA) was mixed with 500 µl 100% ethanol, inverted 5 times and centrifuged 
again. The supernatant was carefully removed. The DNA pellet was dissolved in 200 µl 
ddH2O, vortexed and the solution was treated with 200 µl 9 M LiCl, incubated at -20°C 
for 15 minutes. After centrifugation supernatant was transferred in a new tube, mixed 
with 300 µl isopropanol and incubated at -20°C (15 minutes) for DNA precipitation. The 
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solution was centrifuged, the pellet was dried, washed in 200 µl 70% (v/v) ethanol, 
centrifuged and washed again in 200 µl 100% ethanol. The DNA pellet was completely 
dried and dissolved in 50 µl ddH2O. The DNA concentration was measured using the 
NanoDrop (chapter 4.2.8). 
Maxiprep - preparative scale 
A 300 ml ON culture was centrifuged (5.000 rpm, 15 minutes, 4C). Cell lysis and 
extraction of plasmid-DNA was achieved according to manufacturer's instructions 
using buffers E1 - E6 from the "JETSTAR Plasmid Maxiprep Kit" (Genomed). Afterwards 
10ml isopropanol was added to the eluted DNA for precipitation, mixed by inverting 
(approximately 10 times), incubated for 5 minutes at RT and centrifuged again 
(5.000 rpm, 30 minutes, RT). The supernatant was discarded. After air-drying DNA 
pellet was dissolved in 300 µl ddH2O. DNA was added to 15 µl 5 M NaCl (0.25 M final 
concentration) and mixed. In the next step 900 µl 100% ethanol was carefully added to 
the DNA solution and mixed until a DNA flake appeared. The DNA flake was washed 
twice in 900 µl 75% (v/v) ethanol and was air-dried at RT. According to the size of the 
flake, DNA was dissolved in 100 - 400 µl ddH2O and concentration was measured by 
NanoDrop (chapter 4.2.8). 
 
4.2.6.2 Total RNA isolation from eukaryotic cells 
Adherent cells were scraped in 400 µl RL lysis buffer after aspirating the medium. The 
following isolation and purification of RNA from eukaryotic cells was performed 
according to manufacturer's instructions from the "RNA Mini Kit" (Seqlab). 
Additionally, after RNA binding to the column a DNase digest was performed using 1 µl 
DNase I in 45 µl digest buffer (RNase free) from the "peqGOLD DNase I Digest Kit" 
(Peqlab). After an incubation of 20 minutes at RT the column was washed and RNA was 
eluted in 50 µl ddH2O (RNase free) as described in the kit. After freezing at -20°C the 
RNA concentration was measured by NanoDrop (chapter 4.2.8).  
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RNA from dishes with very small cell numbers, as seeded in the colony formation assay 
(CFA) in U2OS cells, was isolated according to the "RNeasy Micro Kit" (Qiagen). Before 
direct cell lysis buffer RLT was mixed with ß-mercaptoethanol (10 µl per 1 ml buffer). 
Then cell-culture medium was completely aspirated from the 6-well plate, 350 µl 
buffer RLT was added to the cells and cell lysat was collected in a tube. Lysate was 
homogenised by vortexing for 1 minute. Afterwards 1 volume of 70 % ethanol was 
added to the homogenised lysate, mixed and pipetted into an RNeasy spin column. 
After centrifugation (13.000 rpm, 15 seconds, RT) the flow-trough was discarded. As 
described above on-column DNA digestion was performed using the "peqGOLD DNase 
I Digest Kit" (Peqlab). In the next step 700 µl buffer RW1 was added to the RNeasy spin 
column and centrifuged to wash the spin column membrane. Again the flow-through 
was discarded. Two additional washing steps were performed using buffer RPE 
(500 µl). Spin column membrane was dried by centrifugation (13.000 rpm, 2 minutes, 
RT) and RNA was eluted in 11 µl ddH2O (RNase free). 
 
4.2.7   Control digest of DNA fragments 
After ligation of the shRNA-encoding oligonucleotides into the pSUPER.retro.puro 
plasmid (chapter 4.2.4), DH5α bacteria transformation (chapter 4.2.5) and Miniprep 
(chapter 4.2.6.1), a control digest was performed. 
Control digest 0.5 - 1 µg DNA 
0.5 µl enzyme (BglII, 10 U/µl)  
1.5 µl restriction buffer 
add 15 µl ddH2O - 2h at 37°C incubation  
plus 1% (w/v) agarose gel electrophoresis 
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4.2.8   Concentration determination of nucleic acids (NanoDrop) 
RNA and DNA concentration was determined by the NanoDrop ND-1000 spectro-
photometer. The absorption of 1.5 µl of a RNA- or DNA-solution was measured at 
260 nm after adjustment to the solvent ddH2O. The additional measurement of the 
absorbance at 280 nm and thereby the calculation of the absorbance ratio of 260 nm 
and 280 nm provided information about the purity of the DNA or RNA. A ratio of ≥1.8 
for DNA and ≥2.0 for RNA indicated a good purity. 
 
4.2.9   cDNA synthesis (Reverse transcription of mRNA into cDNA) 
Total RNA isolation from eukaryotic cells is explained in chapter 4.2.6.2. Amounts of 
10 ng - 2 µg RNA were applied to reverse transcription after determination of RNA 
concentration using the NanoDrop (chapter 4.2.8). All RNA samples were equalised 
with ddH2O (nuclease free) to a final volume of 10 µl. In a first reaction step, RNA was 
mixed with 5 µl of MasterMix I. Thereby, RNA secondary structures were removed by 
heating the samples to 65°C for 5 minutes followed by a fast cooling-down phase 
(2 minutes, 4°C). In a second step, 10 µl of MasterMix II was added to each sample. 
M-MLV Reverse Transcriptase contained in this mix performed cDNA synthesis using 
the included dNTPs (mix of dATP, dCTP, dGTP and dTTP, each 10 mM). The reaction 
was performed at 37°C for 1 - 2 hours in the thermocycler, stopped at 75°C for 
15 minutes, followed by 4°C and storage at -20°C until RT-qPCR analysis, in which new 
synthesised cDNA served as template (chapter 4.2.10). 
 
Mastermix I 1 µl 10 mM dNTP Mix 
1 µl oligo(dT)17 primer (0.5 µg/µl) 
4 µl ddH2O (nuclease free) 
  
METHODS 
 
55 
 
MasterMix II 2 µl 0.1 M DTT 
0.5 µl RiboLock (RNase inhibitor) 
5 µl 5 x First strand (FS) buffer 
2.5 µl ddH2O (nuclease free) 
0.7 µl M-MLV Reverse Transcriptase  
 
4.2.10  Real time-quantitative PCR (RT-qPCR) 
RT-qPCR analysis was performed with synthesised cDNA (chapter 4.2.9) or DNA from 
ChIP (chapter 4.3.7) using the "ABsolute qPCR SYBR Green Mix Plus ROX Vial" (Thermo 
Scientific) and the Mx3000P qPCR system (Agilent Technologies). DNA polymerase, 
reaction buffer, dNTPs, SYBR Green I (fluorescence dye activated after binding to 
dsDNA) and additionally ROX (passive reference dye for normalisation of data) were 
provided within the kit. 
In a first step, cDNA or chromatin was diluted 1:6 - 1:12 and the primer pair 
(100 pmol/µl, 1:1 mixture of fwd and rev primer) was diluted 1:20 - 1:40 with ddH2O 
(nuclease free) depending on the performed experiment. The cDNA or chromatin 
dilution was pipetted in triplicates, each 6 µl, into the wells of the 96-well qPCR plate. 
The qPCR mix was prepared with 5 - 2.5 pmol/µl of each primer pair as well as 30 nM 
ROX (reference dye) and was added to the cDNA/chromatin dilution in a total volume 
of 25 µl. 
qPCR mix 12.5 µl SYBR Green mix 
8.0 µl ddH2O (nuclease free) 
1 µl primer pair mix (5 - 2.5 pmol/µl) 
30 nM ROX - 19 µl in 96-well 
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The PCR reaction was performed according the following program: 
Initial denaturation  95°C  15 minutes 
Denaturation   95°C  15 seconds 
Annealing   60°C  20 seconds 45 - 55 cycles 
Elongation   72°C  15 seconds 
Denaturation   95°C  1 minute 
Dissociation curve  55°C  30 seconds 
    55°C → 95°C gradually 
    95°C  30 seconds 
The thermal profile included an amplification curve and a dissociation curve. In this 
second phase, the dsDNA product was melted in ssDNA by a stepwise increase in 
temperature from 55°C → 95° to discriminate between specific and non-specific PCR 
products. Additionally, a no template control (NTC), qPCR mix without DNA, was 
included for each primer pair to monitor contaminating template or the presence of 
primer dimers in the reaction. 
The Mx3000P software measured for each sample the Ct value (threshold cycle), a 
defined cycle, in which the fluorescence increase has exceeded a specific threshold, a 
background signal measured in the early rounds of amplification by the software. The 
relative quantification of the gene expression difference between two conditions was 
determined by the ∆∆-method, in which the mRNA expression of a specific target 
gene ( !"#	"#$#) was normalised to the mRNA expression of a constant, non-
regulated housekeeping gene (%&'()*))+,-.	.)-)), such as RPS14, RPLP0 or UBC. In 
the context of a knockdown experiment the ∆∆ value was calculated from the 
∆	value of the specific knockdown and the ∆	value of the control condition.  
∆∆ = ∆/$01/203$ − ∆10$!05 [∆ =  !"#	"#$# − 7089#/##:;$"	"#$#] 
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The relative expression between both conditions was presented in the following 
formula, in which it was presumed that a doubling in cDNA amount has taken place in 
each cycle. 
=>?@AB>	>CD=>EEAFG = 2I∆∆J 
The standard deviation 
E was calculated by the mean value of the triple 
measurement of each sample. The calculation of the relative standard deviation 

E!#5 ;K# according to the law of error propagation was as follows: 
E!#5 ;K# = 2I∆∆J × ?G2 × LE
MGFNMOFPGQ + E
NFG=F?Q  
In ChIP-qPCR analysis immunoprecipitated chromatin was analysed in triplicates, in 
which mean values were relative expressed as % input of chromatin or fold IgG, which 
was equated to 1. The calculation was done as follows (left panel) provided that 1% 
input and same IP dilutions were taken. The calculation of the relative standard 
deviation 
E!#5 ;K# for % input and fold IgG is shown on the right panel. 
%	AGDT = 	
1
2
J	UV	IJ	;$:8
 E!#5 ;K# = %	AGDT	 × ?G2 × LE
WX
Q + E
AGDTQ 
YF?O	WZ[ =
1
2
J	UVIJ	U"\
 E!#5 ;K# = YF?O	WZ[	 × ?G2 × LE
WX
Q + E
WZ[Q 
Histone modifications, such as H3R2me2a, were calculated relative to histone H3 
instead of normalisation to IgG. However, this is identical to the calculation of fold IgG. 
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4.3   Protein biochemical methods 
4.3.1   Preparation of protein whole cell extracts 
4.3.1.1 Protein extraction from eukaryotic cells - FT lysis 
FT (freeze and thaw) lysis is a method for extraction of histones, which are released 
from chromatin using a high salt concentration and Benzonase digest. After removal of 
the medium from a confluent 145 cm
2
 dish cells were washed two times in ice-cold 
PBS and scraped in 3 ml ice-cold PBS. Cells were pelleted (2.000 rpm, 3 minutes, 4°C) 
and resupended in 200 - 400 µl FT lysis buffer plus freshly added protease inhibitors. 
After three freeze and thaw cycles by transferring the tube into liquid nitrogen and 
subsequently thawing in a water bath, the cell lysate was incubated with Benzonase 
(250 nM) in 7 mM MgCl2 for at least 30 - 45 minutes at 4°C on a rotating wheel to 
digest the DNA. The sample was centrifuged (13.000 rpm, 10 - 15 minutes, 4 °C) and a 
Bradford assay of the supernatant was performed (chapter 4.3.2). 
FT lysis buffer 20 mM TRIS - pH 8.0 
600 mM NaCl 
20% (v/v) glycerol  
Protease inhibitors (1:1000) Aprotinin 
Leupeptin 
PMSF (each 10 µg/µl) 
 
4.3.1.2 Protein extraction from eukaryotic cells - IPH lysis 
A confluent cell culture dish (145 cm
2
) was washed twice with ice-cold PBS. Cells were 
collected in 3 ml ice-cold PBS into a falcon, centrifuged (2.000 rpm, 5 minutes, 4°C) and 
cell pellet was stored ON at -20°C. On the next day the cell pellet was resuspended in 
200 µl IPH buffer (400 mM NaCl) with protease inhibitors and incubated at least 
30 minutes at 4°C on a rotating wheel. Protein extracts were diluted with IPH Buffer 
(0 mM NaCl) to a final lysis buffer concentration of 200 nM NaCl. Benzonase (250 U) 
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and 7 mM MgCl2 were added to the suspension and incubated for 1 hour at 4°C on a 
rotating wheel. After centrifugation (13.000 rpm, 15 minutes, 4°C) the supernatant 
was centrifuged again. Protein concentration of the second supernatant was 
determined by Bradford (chapter 4.3.2) for the following Co-IP (chapter 4.3.6) or 
Western blot (chapter 4.3.5) analysis. 
IPH buffer (400 mM NaCl) 50 mM TRIS - pH 8.0 
400 mM NaCl 
5 mM EDTA 
0.5% (v/v) igepal 
Protease inhibitors (1:1000) Aprotinin 
Leupeptin 
PMSF (each 10 µg/µl) 
 
4.3.2   Determination of protein concentration (Bradford)  
Colorimetric protein assay is a spectroscopic method to measure the protein 
concentration in a solution using Coomassie Brilliant Blue G described by Bradford in 
1976 (Bradford, 1976). Each protein sample was measured in duplicates. Therefore, 
100 µl ddH2O was provided in semi-micro cuvettes and the protein sample (1 µl) was 
added. After addition of 900 µl Bradford solution and an incubation of 5 minutes at RT 
the extinction/OD at 595 nm of each sample was measured in the photometer relative 
to a blank solution without protein extract. Quantification of protein concentration 
was realised by an additional calculated standard curve using a BSA standard series 
with a range of 0 - 8 µl BSA (1 µg/µl). 
Bradford solution 0.01% (w/v) Coomassie Brilliant Blue G 250  
in 4.75% (v/v) ethanol,  
10% (v/v) ortho-phosphoric acid (85%) 
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4.3.3   SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) is a technique to separate proteins 
in an electrical field according to their molecular weight. The addition of the detergent 
SDS causes a denaturation of proteins. In detail, SDS interacts with aa side chains and 
removes secondary and tertiary structures. It creates an equal negative charge of the 
unfolded polypeptide chains. Proteins with a smaller size run faster and larger proteins 
run slowier in the polymer grid structure. After SDS-PAGE several other techniques, 
such as Coomassie staining (chapter 4.3.4) or Western blot analysis (chapter 4.3.5), 
were performed. 
The following Table 17 shows the formula of the separation and stacking gel for one 
SDS gel with a size of 1.5 mm. The amount of 30% (w/v) acrylamide/0.8% (w/v) bis-
acrylamide in a separation gel is depending on the percentage of the gel or the size of 
the polymer grid structure, respectively. 
 
Table 17: Composition of the separation and stacking gel used in SDS-PAGE. 
Data for 1 x gel (1.5 mm) Separation gel Stacking gel (4%) 
30% (w/v) acrylamide / 
0.8% (w/v) bis-acrylamide 
 x ml 0.85 ml 
1M TRIS pH 8.8 2.8 ml -- 
1M TRIS pH 6.8 -- 0.625 ml 
20% (w/v) SDS 37.5 µl 25 µl 
ddH2O 4.68 ml - x ml 3.5 ml 
20% (w/v) APS 20 µl 10 µl 
TEMED 10 µl 5 µl 
 
Each protein sample was mixed with an appropriate volume of 4 x SDS sample buffer 
and was incubated for 5 minutes at 95°C to denature the proteins. Proteins were 
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loaded into the pockets of a SDS gel in the running chamber, which was filled up with 
1 x SDS running buffer. The "PageRuler Prestained Protein Ladder" (Thermo Scientific) 
served as molecular weight standard. Proteins were separated for 1 hour 15 minutes 
up to 3 hours at 160 volts depending on the percentage of the separation gel. 
4 x SDS sample buffer 250 mM TRIS - pH 6.8 
2% (w/v) SDS 
40% (v/v) glycerol 
0.1% (w/v) bromophenol blue 
20% (v/v) ß-mercaptoethanol 
1 x SDS running buffer 25 mM TRIS  
192 mM glycine 
0.1% (w/v) SDS 
 
4.3.4   Coomassie staining  
Visualisation of protein bands after separation in a polyacrylamide gel was possible 
using the Coomassie staining method. This staining technique is used to estimate 
protein amounts in the gel in comparison to a (e.g.) BSA standard series. After gel 
electrophoresis the polyacrylamide gel was incubated in staining solution for 
approximately 10 minutes depending on the gel size (RT, shaker). Remains of the dye 
were removed by rinsing the gel in tap water. The gel was bleached by incubation 
three times in the destaining solution (each 10 minutes, RT, shaker) until the desired 
contrast against the background of the gel was received. 
Staining solution 25% (v/v) ethanol 
10% (v/v) acetic acid 
0.25% (w/v) Coomassie Brilliant Blue G 250  
Destaining solution 25% (v/v) ethanol 
10% (v/v) acetic acid 
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4.3.5   Western blot 
4.3.5.1 Transfer of proteins from SDS-PAGE on PVDF membrane 
Western blot is a technique to transfer and immobilise proteins from a polyacrylamide 
gel on a PVDF membrane for later antibody detection. Here, tank blotting was 
performed. 
The hydrophobic surface of the PVDF membrane had to be activated by incubation in 
100% methanol for approximately 10 seconds. The setup of a Western blot from the 
cathode (-) to the anode (+) was as follows: blotting sponge, 2 x Whatman paper 
layers, SDS gel, PVDF membrane, 2 x Whatman paper layers and blotting sponge. All 
components were soaked in transfer buffer. The tank blotting duration differed from 
30 minutes up to 2 hours at 45 volts depending on the size of the proteins. 
Tank blotting buffer 384 nM glycine 
50 nM TRIS 
0.2% (w/v) SDS 
20% (v/v) methanol 
 
4.3.5.2 Immunodetection of proteins immobilsed on PVDF membranes 
Immunodetection is a method to identify proteins from a given sample, which are 
immobilised on a PVDF membrane within and detectable using a primary antibody 
specifically targeting the protein of interest. 
After saturation of the membrane with blocking buffer (1 hour, RT, shaker) to saturate 
unspecific binding sites of PVDF membrane, the blot was incubated with primary 
antibody (chapter 3.8.1) ON at 4°C or at least 2 - 3 hours at RT on a shaker. Then, the 
membrane was washed three times with TBS-T (0.5%), each 10 minutes at RT on a 
shaker to remove excess of antibody. Subsequently the blot was incubated with HRP- 
conjugated secondary antibody (1 hour, RT, shaker) (chapter 3.8.2). After three 
washing steps twice TBS-T (0.5%) and once TBS (each 10 minutes, RT, shaker) to 
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remove unbound secondary antibody antibody bound HRP was detected using ECL 
(enhanced chemi-luminescence). 10 ml of each ECL solution (A and B), were mixed and 
poured on the membrane (5 minutes, RT). Thereby Luminol is oxidised by HRP using 
H2O2 (oxidising reagent) leading to emission of light, which blackens the X-ray film, 
when exposed with the membrane in an X-Ray cassette. 
Blocking buffer  4% (w/v) milk powder in TBS-T (0.5%) 
ECL (solution A) 100 mM TRIS - pH 8.5 
2.5 mM Luminol (in DMSO)  
0.4 mM p-Coumaric acid (in DSMO) in ddH2O  
ECL (solution B) 100 mM TRIS - pH 8.5  
0.036% H2O2 
 
4.3.5.3 Stripping of PVDF membranes 
Stripping of PVDF membranes is a method to remove primary and secondary 
antibodies bound on a membrane either under mild conditions with a pH shift or 
under harsh conditions using ß-mercaptoethanol. 
 
Mild strip 
The membrane was incubated in 50 - 100 ml freshly prepared mild stripping buffer for 
5 - 10 minutes under shaking. The buffer was discarded and the mild strip was 
repeated. The membrane was washed twice with PBS for each 10 minutes, washed 
twice with TBS-T (0.5%) for each 5 minutes and was reblocked with blocking buffer as 
described in chapter 4.3.5.2. 
Mild stripping buffer 1.5% (w/v) glycine 
0.1% (w/v) SDS 
1% (v/v) Tween 20 - pH 2.2 
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Harsh strip 
The blot was incubated in 100 ml harsh stripping buffer for 30 minutes at 65°C in a 
water bath. Afterwards the membrane was rinsed several times in TBS-T (0.5%), 
washed twice in TBS-T (0.5%) for 30 minutes at RT and reblocked for the following 
antibody staining (chapter 4.3.5.2). 
Harsh stripping buffer 50 mM TRIS - pH 6.8 
4% (w/v) SDS 
1% (v/v) ß-mercaptoethanol 
 
4.3.6   Co-Immunoprecipitation (Co-IP) 
Protein-protein-interactions were analysed by semi-endogenous or endogenous Co-IPs 
using whole cell extracts from MCF7 cells. These protein extracts were incubated with 
a specific or control rabbit antibody and were precipitated with protein A sepharose. 
Then, blotting (chapter 4.3.5.1) and immunodetection (chapter 4.3.5.2) were 
performed with the corresponding antibody such as recognising potential interaction 
partners. 
48 hours after PEI transfection (chapter 4.1.4.2) cells were harvested, lysed and 
protein extracts were prepared as described in chapter 4.3.1.2. 1 mg precleared 
extract of each sample with overexpressed or endogenous interaction partners was 
subjected to IP with PRMT6 crude serum (5 µl) in parallel to PRMT6 preimmune serum 
(5 µl) or IgG rabbit (45 µg) as controls (ON, 4°C, on a rotating wheel). All samples were 
adapted to the same sample volume, at least to 500 µl in total. Either 2% or 10% of 
inputs were prepared from the precleared extracts in parallel to the IPs. The required 
amount of protein A sepharose, resuspended in IPH buffer (200 mM NaCl) was blocked 
with BSA (20 µg/ml; ON, 4°C, on a rotating wheel) to minimise unspecific binding to the 
beads. On the next day 20 µl blocked beads were added to the extracts and incubated 
for 2 hours at 4°C on a rotating wheel. After extensive washing (5 x each 1 ml) with IPH 
buffer (200 mM NaCl; plus protease inhibitors) and centrifugation (5.000 rpm, 
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1 minute, RT) precipitates and inputs were analysed by SDS-PAGE (chapter 4.3.3) and 
Western blot (chapter 4.3.5) after solving them in 2 x SDS sample buffer (chapter 4.3.3) 
and incubation for 10 minutes at 95°C. 
IPH buffer (200 mM NaCl) 50 mM TRIS - pH 8.0 
200 mM NaCl 
5 mM EDTA 
0.5% (v/v) igepal 
Protease inhibitors (1:1000) Aprotinin 
Leupeptin 
PMSF (each 10 µg/µl) 
 
4.3.7   Chromatin immunoprecipitation (ChIP)  
Chromatin immunoprecipitation (ChIP) is an efficient tool to examine binding of 
nuclear proteins to specific chromatin regions as well as to analyse the occurence of 
histone modifications. ChIP analysis was performed with U2OS and TIG3-T wild type 
cells, which were seeded at a density of 2.4 x 10
6
 and 2.7 x 10
6
 cells in a 145 cm
2
 dish, 
respectively. 
 
Day 1 (Chromatin crosslink and sonication): 72 hours after seeding confluent dishes 
were treated with 36.5% (v/v) formaldehyde solution (1% final concentration) for 
10 minutes at RT in the fume hood for covalent DNA-protein-crosslink. The reaction 
was stopped by adding 2.5 M glycine (125 mM final concentration) to the medium for 
5 minutes at RT. Cell dishes were washed twice with ice-cold PBS and scraped with 
1 ml ice-cold PBS per dish into a falcon. After centrifugation (1.200 rpm, 5 minutes, 
4°C) the pellet was dissolved in lysis buffer I (1 ml per 145 cm
2
 dish) and incubated for 
20 minutes on ice. Lysed cells were centrifuged again (1.200 rpm, 5 minutes, 4°C) to 
remove cell membranes and organelles. The resulting nuclear pellet was resuspended 
in lysis buffer II (20 x 10
6
 cells/ml) for another 10 minutes on ice and aliquots of 1 ml 
per 15 ml falcon were prepared. In the next step a sonication of the lysats cooled in a 
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water-ice mixture was performed using the microtip from Branson as follows: 
 
 
U2OS cells   80 x 1 second pulse, 3 seconds pause, 15% amplitude 
TIG3-T cells   60 x 1 second pulse, 3 seconds pause, 20% amplitude 
 
Chromatin was centrifuged (13.000 rpm, 15 minutes, 4°C), supernatants were pooled, 
stored on ice ON and a 50 µl aliquot was used for reversion of the crosslink with 
0.4 µg/µl RNase A and 0.4 µg/µl proteinase K in the thermocycler (3 hours at 55°C, ON 
at 65°C). The required amount of protein A sepharose was washed and centrifuged 
twice in lysis buffer II (1.800 rpm, 3 minutes, 4°C). Afterwards the beads were blocked 
with BSA (1 µg/µl) and salmon sperm (400 µg/ml final concentration) ON at 4°C on a 
rotating wheel for minimising unspecific bindings. 
Day 2 (Preclearing and IPs): 50 µl reversed chromatin was purified according to 
manufacturer's instructions ("QIAquick PCR Purification Kit"). Sonication efficiency was 
estimated on a 1% (w/v) agarose gel (110 V, 30 - 50 minutes) with 10 µl of this sample. 
Sheared DNA fragments should have a size between 500 - 1000 bp. Then the reversed 
chromatin was used to measure chromatin concentration by NanoDrop for later IP 
preparation (chapter 4.2.8). 
The blocked beads were washed twice in lysis buffer II and beads were added to 
chromatin (not reversed) for preclearing (2 hours, 4°C, on a rotating wheel) depending 
on the number of IPs (20 µl per IP). Afterwards precleared chromatin was centrifuged 
(1.200 rpm, 5 minutes, 4°C) splitted into the planned IP reactions with equivalent 
amounts of chromatin and minimum of 500 µl volume. Chromatin was incubated with 
the corresponding antibodies (ON, 4°C, on a rotating wheel). Therefore, 80 - 100 µg 
chromatin was used for an IP with the PRMT6 or IgG rabbit antibody and 25 - 40 µg 
chromatin was used for IP with an antibody against H3R2me2a or H3. Triple input (1%) 
of each chromatin sample was transferred in separate tubes. 
Day 3 (Washing and elution of IPs): Each IP was incubated with 28 µl sepharose A for 
2 hours at 4°C on a rotating wheel. Subsequently the beads were centrifuged 
(2.000 rpm, 2 minutes, RT) and washed with 1 ml buffer under centrifugation as follows: 
2 x wash buffer I, 2 x wash buffer II, 4 x wash buffer II, 2 x TE buffer 
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Beads were mixed with 250 µl freshly prepared elution buffer, incubated for 
15 - 30 minutes at RT on a rotating wheel, boiled (4 minutes, 65°C) and centrifuged as 
before. Supernatants were transferred into a new tube and elution was repeated. In 
parallel, 500 µl elution buffer was added to each 1% input sample. Per sample 52 µl 
reversion buffer was added and incubated for 3 hours at 55°C and ON at 65°C in the 
thermocycler. 
Day 4 (Purification and ChIP-qPCR): Based on the manufacturer's instructions of the 
"QIAquick PCR Purification Kit" (Qiagen), chromatin samples were purified and 
dissolved in 50 µl EB elution buffer of the kit and stored at -80°C. ChIP-qPCR analysis 
was performed as described in chapter 4.2.10, in which chromatin and input was 
diluted 1:6 - 1:8 in ddH2O (nuclease free). 
Formaldehyde  36.5% (v/v) in ddH2O (Sigma) 
Glycine   2.5 M (Roth) 
Lysis buffer l 5 mM PIPES - pH 8.0 
85 mM KCl 
0.5% (v/v) igepal  
(plus protease inhibitors: Aprotinin, Leupeptin, PMSF 
1:1000 and PIC tablet) 
Lysis buffer ll 10 mM TRIS - pH 7.5 
150 mM NaCl 
1% (v/v) igepal 
1% (w/v) sodium deoxycholate 
0.1% (w/v) SDS 
1 mM EDTA 
(plus protease inhibitors: Aprotinin, Leupeptin, PMSF 
1:1000 and PIC tablet)  
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Salmon Sperm sonicated, phenol-chloroform extraction 
4-6 µg/µl in ddH2O 
Wash buffer l 20 mM TRIS - pH 8.0 
150 mM NaCl 
2 mM EDTA 
0.1% (w/v) SDS 
1% (v/v) Triton X-100 
Wash buffer ll 20 mM TRIS - pH 8.0 
500 mM NaCl 
2 mM EDTA 
0.1% (w/v) SDS 
1% (v/v) Triton X-100 
Wash buffer lll 10 mM TRIS - pH 8.0 
1 mM EDTA 
250 mM LiCl  
1% (v/v) igepal 
1% (w/v) sodium deoxycholate   
TE buffer 10 mM TRIS - pH 8.0 
1 mM EDTA 
Elution buffer  1% (w/v) SDS 
0.1 M NaHCO3   
Reversion buffer 400 mM TRIS - pH 6.8 
2 M NaCl 
100 mM EDTA 
0.4 µg/µl Proteinase K 
0.2 µg/µl RNase A  
 
METHODS 
 
69 
 
4.3.8   Immunohistochemical staining (IHC) of tissue sections 
Immunohistochemistry allows the detection of antigens in biological tissue sections by 
specific antibody staining directed against the antigen and visualisation with a staining 
dye. Images were taken by NanoZoomer, a digital slide scanner from Hamamatsu using 
the software NDP.view. All used lung tumour sections in this study and usage of the 
NanoZoomer were kindly provided by Rajkumar Savai from the MPI in Bad Nauheim. 
Deparaffinisation (alcohol series), peroxidase block and washing steps of tissue 
sections were performed in staining boxes with racks made of glass and a capacity of 
200 ml. Washing steps in TBS-T (0.05%), TBS or ddH2O were conducted on the 
magnetic stirrer under slow stirring. 
Tissue sections were deparaffined twice for 8 minutes with Roticlear and incubated in 
a descending alcohol series for hydrogenation (3 minutes in each solution). 
alcohol series isopropanol 
96% (v/v) ethanol 
80% (v/v) ethanol 
70% (v/v) ethanol  
In the meantime 1 x TRIS retrieval (200 ml) was filled into a plastic staining box (with 
lid) and preheated in the steam cooker (bottom filled with tap water) for 20 minutes. 
After washing the slides for 3 minutes in ddH2O rack with slides was transferred into 
this staining box. Samples were boiled in TRIS retrieval for 20 minutes in the steam 
cooker to unmask protein epitopes. Subsequently slides were cooled by stepwise 
addition of tap water within the next 15 minutes. Afterwards slides were washed again 
with ddH2O. Tissue sections were blocked with 3% (v/v) peroxidase solution for 
10 minutes at RT (blockage of endogenous peroxidases), washed two times for each 
3 minutes with TBS-T (0.05%) and once in TBS. A staining chamber (Roth) was prepared 
with tap water. Primary antibody (chapter 3.8.1) was diluted in "antibody diluent" 
depending on the total number of sections (100 - 150 µl antibody dilution/slide). 
Excess solution was removed from each slide and each tissue section was circled with a 
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"Dako Pen" for providing a barrier to liquids. Thereby, the sensitive sections should 
never desiccate to avoid tissue damage. Each section was incubated with primary 
antibody in the staining chamber ON at 4°C. On the next day slides were washed twice 
with TBS-T (0.05%), once with TBS and were incubated with biotinylated secondary 
antibody α-rabbit IgG (chapter 3.8.2) in "antibody diluent" (100 - 150 µl/slide) for 
30 minutes at RT. After another washing round 1 - 2 drops of undiluted streptavidin 
peroxidase was added to the slides for the next 30 minutes at RT. Slides were washed 
again and kept in ddH2O until AEC staining using the "AEC (red) Substrate Kit" (Life 
Technologies). Preparation of AEC solution was performed according manufacturer's 
instructions. Subsequently each tissue section was stained with this AEC solution until 
the desired staining grade was reached (1 - 15 minutes) and then, transferred into 
ddH2O to stop the staining reaction. For nuclear counterstaining, slides were incubated 
in "Mayer´s hemalum solution" for 8 - 15 seconds under shaking and rinsed intensively 
in tap water for the next 5 minutes, which was necessary for the pH shift to achieve 
the "blueing" of the slices. Tissue sections were washed another time in ddH2O and 
embedded in Mowiol solution using cover slips for later microscopic analysis. 
10 x TRIS retrieval 100 mM TRIS - pH 9.0 
10 mM EDTA 
(stock and 1 x solution - storage at 4°C) 
Peroxidase block solution 3% (v/v) H2O2 in ddH2O  
(20 ml 30% peroxidase stock solution + 180 ml ddH2O, 
(storage at 4°C) 
Washing buffers  TBS-T (0.05%): TBS - pH 7.9 (HCl), 0.05% (v/v) Tween 20 
TBS: TRIS (10 mM) - pH 7.9 (HCl), NaCl (150 mM)  
Mayer´s hemalum solution 25% (v/v) in ddH2O  
(60 ml hemalum stock solution + 180 ml ddH2O) 
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Mowiol solution 60 g (w/v) glycerol  
24 g (w/v) mowiol 4-88  
add 60 ml ddH2O 
add 120 ml 0.2 M TRIS - pH 8.5, dissolving at 53°C ON 
10 ml aliquots at -20°C, used aliquots at 4°C  
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5   RESULTS 
5.1   PRMT6 is deregulated in lung cancer 
PRMTs are deregulated in a variety of human cancers, such as breast, colorectal and 
lung cancer (Baldwin et al., 2014; Yang and Bedford, 2013). Lung cancer is the single 
largest cause of cancer-related death in humans mostly caused by non-small cell lung 
carcinoma (NSCLC) (Ramalingam et al., 2011). Relatively little is known about the 
deregulation of PRMT6 in lung tumourigenesis. So far, only Yoshimatsu and colleagues 
performed a cDNA microarray expression analysis, in which few tumour tissues were 
compared with corresponding non-neoplastic tissues derived from the same patient 
(Yoshimatsu et al., 2011). Here, gene expression of PRMT6 was shown to be elevated 
in lung cancer (NSCLC, SCLC) and PRMT6 positively influences growth of different lung 
cancer cell lines (e.g. A549) demonstrated by siRNA knockdown of PRMT6. Similar 
results were found for PRMT1. However, since no PRMT6 antibody was available, an 
increase in PRMT6 protein levels could not be validated in cancer tissues by tissue 
microarray analysis. 
 
5.1.1   Prmt6 protein levels are increased in murine lung tumour sections 
In order to get a better insight into the deregulation of PRMT6 in lung cancer 
immunohistochemical (IHC) analysis of Prmt6 was performed in murine lung tumour 
sections. Therefore, Prmt6 protein levels in tissue sections of two murine lung cancer 
models, a LLC1 (Figure 6, LLC1 #1 - #3) and Kras
LA2
 mouse model (Figure 7, 59s Lung #1, 
#2, #4), were compared to healthy C57BL/6 mice (Figure 5, HealthyCon #1 - #3). Both 
tumour models are based on this healthy C57BL/6 mouse strain. In each of these cases 
(C57BL/6, LLC1 or Kras
LA2
 strain), fixed lung tissue sections from three different mice 
were used in each staining procedure with one specific PRMT antibody in this study. All 
murine lung tissue sections were kindly provided by Rajkumar Savai (MPI, Bad 
Nauheim). 
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Lewis lung carcinoma cells were derived from a spontaneous lung carcinoma and used 
for allotransplantation, whereas a suspension of LLC1 cells was intravenously injected 
into the tail of healthy C57BL/6 mice. These treated mice develop lung tumours within 
one month (Henneke et al., 2010). In contrast to LLC1, the Kras
LA2
 mouse harbours a 
targeted, latent Kras G12D allele that is capable of spontaneous somatic activation in 
vivo (Johnson et al., 2001; Mise et al., 2012). These mice form tumours in numerous 
organs within several months, in which especially an early onset of lung cancer is 
detectable. All fixed murine lung tumour sections were stained with an affinity-purified 
PRMT6 antibody, which was raised against human, full-length PRMT6 (PRMT6_2affi) 
(Stein et al., 2012). Thereby, PRMT6_2affi is able to cross-react with murine Prmt6 
because of their 91.5% amino acid sequence identity. Moreover, all sections were 
counterstained with Hematoxylin to achieve blue stained cell nuclei. 
Typical structures of the lung, such as bronchioles (B) adjacent to blood vessels (BV), 
alveolar ducts (AD) and alveolar sacs (AS) with its alveoli (A), were visualised by 
counterstaining in the sections of three healthy C57BL/6 mice (HealthyCon #1 - #3) 
(Figure 5). Similarly, in the tumour tissues, areas of healthy alveolar and bronchiolar 
structures (healthy tissue: HT) were clearly distinguishable from proliferating tumour 
cells (tumour tissue: TT, in Figure 6, 7). The control tissues showed only a few Prmt6-
positive stained lung cells, which were mostly located in the epithelium of the 
bronchioles or in their vicinity. The identity of these positively stained cells is unknown 
and has to be further analysed. In contrast to tissues of healthy C57BL/6 mice, the IHC 
stainings of two LLC1 mice (LLC1 #1 and #2) revealed that Prmt6 levels were elevated 
in the enlarged nuclei and surrounding cytoplasms of cells embedded in the lung 
tumour tissues (Figure 6A, 6B). The same applied to the PRMT6 stainings of three 
Kras
LA2
 mice (59s Lung #1, #2 and #4). Here, cells were positively stained for Prmt6 in 
the tumour mass and the epithelium of bronchioles (Figure 7). However, sections from 
the third LLC1 mouse (LLC1 #3) differed from the two other LLC1 sections (Figure 6C). 
Distinct tumour areas could not be detected in this mouse. Prmt6-positive stainings 
were located everywhere within the bronchiolar and alveolar structures. Presumably, 
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Figure 5: IHC stainings of Prmt6 in lung sections from C57BL/6 mice (PRMT6_2affi). 
(A - C) Paraffin embedded lung tissue sections from healthy C57BL/6 mice (HealthyCon #1 - #3) were 
stained with a PRMT6-specific antibody (PRMT6_2affi) in a 1:100 dilution (AEC, red). Hematoxylin served 
for counterstaining (blue). Shown are representative image parts of three individual murine lungs from 
C57BL/6 mice (HealthyCon #1, #2 and #3) either in a 10 x magnification (left panel, maximal scale bar 
length: 250 µm) and 40 x magnification (right panel, maximal scale bar length: 50 µm). A: alveolus, 
AD: alveolar duct, AS: alveolar sac, B: bronchiole, BV: blood vessel, SM: smooth muscle. 
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Figure 6: IHC stainings of Prmt6 in murine LLC1 lung specimen (PRMT6_2affi). 
(A - C) IHC analysis of Prmt6 protein levels in paraffin embedded lung tissue sections from LLC1 mice 
(LLC1 #1 - #3), in which AEC was used for detection of PRMT6 (PRMT6_2affi, 1:100, red) and 
Hematoxylin for counterstaining (blue). LLC1 #3 was little overstained in the Prmt6 staining. 
Representative images are depicted in a 10 x magnification (left panel, maximal scale bar length: 250 
µm) and 40 x magnification (right panel, maximal scale bar length: 50 µm). B: bronchiole, BV: blood 
vessel, HT: healthy tissue, TT: tumour tissue. 
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Figure 7: IHC stainings of Prmt6 in specific tumour tissues in the lung of Kras
LA2
 mice (PRMT6_2affi). 
(A - C) Paraffin embedded lung tissue sections from Kras
LA2
 mice (59s Lung #1, #2 and #4) were stained 
with a PRMT6 antibody (PRMT6_2affi), which was diluted 1:100 (AEC, red) and counterstained with 
Hematoxylin (blue). A representative result from all Kras
LA2
 mice tissue sections is given using a 10 x 
magnification (left panel, maximal scale bar length: 250 µm) and 40 x magnification (right panel, 
maximal scale bar length: 50 µm). B: bronchiole, HT: healthy tissue, TT: tumour tissue. 
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inflammatory processes were still in process after intravenous injection of LLC1 cells 
into the tail of healthy C57BL/6 mice. As a result, lung tumours were not fully 
developed in LLC1 #3 compared to LLC1 #1 and #2 (personal communication, Rajkumar 
Savai). 
In order to confirm the specificity of all previous observations made in lung tumour 
sections using PRMT6_2affi, IHC stainings of all sections (C57BL/6, LLC1 and Kras
LA2
) 
were repeated with two additional PRMT6 antibodies, a second affinity-purified 
PRMT6 antibody (PRMT6_3affi) from the lab and a commercial PRMT6 antibody 
(PRMT6_bethyl). PRMT6_3affi is able to cross-react with murine Prmt6 identical to 
PRMT6_2affi (91.5% amino acid sequence identity). Equally, PRMT6_bethyl also cross-
reacts with murine Prmt6 as demonstrated in Western blot analysis (Lorenzo et al., 
2014; Neault et al., 2012). Therefore, one of the three analysed and very similar 
stained murine lung sections of the C57BL/6 (HealthyCon #1), LLC1 (LLC1 #1) and 
Kras
LA2
 (59s Lung #1) mice were representatively selected and are depicted in Figure S1 
and S2. 
In general, PRMT6_3affi gave stronger signals in the IHC analysis than the stainings 
using PRMT6_2affi (AEC), while the Hematoxylin staining was less pronounced 
especially in the depicted HealthyCon #1 and LLC1 #1 (Figure 6 and S1). Nevertheless, 
the representative tissue section from the healthy C57BL/6 mouse (HealthyCon #1) 
showed that only a few cells in the alveolar structure are positively stained for Prmt6 
(Figure S1A). These could possibly be macrophages. In contrast, the LLC1 #1 image 
demonstrated elevated Prmt6 levels in the nuclei as well as in the surrounding 
cytoplasms of lung tumour cells (Figure S1B). This result is in agreement with the 
stainings of LLC1 mouse sections using the PRMT6_2affi antibody (Figure 6), in which 
Prmt6 protein levels were elevated in a similar pattern. However, in case of the Kras
LA2
 
mouse, the staining of 59s Lung #1 with PRMT6_3affi differed a little bit from previous 
PRMT6 stainings of Kras
LA2
 mice using PRMT6_2affi (Figure 7 and S1C). Here, the 
representative image of the Kras
LA2
 mouse demonstrated increased Prmt6 levels in 
some cells, which also could possibly be macrophages embedded in the alveolar 
structure (Figure S1C) as in the case of the control staining (Figure S1A). Further 
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investigations are necessary to confirm this hypothesis, such as macrophage-specific 
stainings (Lloyd et al., 2008). 
Finally, IHC-stainings with the PRMT6_bethyl antibody showed a similar staining 
pattern of the healthy C57BL/6 mouse (HealthyCon #1, Figure S2A) compared to the 
PRMT6_3affi antibody. Some stained cells are Prmt6-positive, which could possibly be 
macrophages. The representative LLC1 mouse section (LLC1 #1, Figure S2B) is also 
comparable with previous stained sections using PRMT6_2affi or PRMT6_3affi 
demonstrating increased Prmt6 levels in the nuclei and cytoplasms of lung tumour 
cells (Figure 6A, 6B, S1B). Similar to the PRMT6_3affi staining, the staining pattern of 
the Kras mouse (59s Lung #1, Figure S2C) differed a little bit compared to the previous 
PRMT6_2affi stainings of Kras (Figure 7). 
Taken together, there are differences in the Prmt6 stainings of lung tumour sections 
from the different Kras
LA2
 mice (Figure 7, S1C and S2C) using three different PRMT6 
antibodies (PRMT6_2affi, PRMT6_3affi, PRMT6_bethyl). Nevertheless, Prmt6 protein 
levels seem to be increased in murine tumour cells and may be in some macrophages 
embedded in the alveolar structure of the Kras
LA2
 and healthy C57BL/6 mice. Further 
stainings have to clarify these findings. In the case of the different Prmt6 stainings of 
the LLC1 mice, all sections demonstrated a quite similar staining pattern of healthy and 
lung tumour tissue areas, which confirmed that Prmt6 is overexpressed in the enlarged 
nuclei as well as in the surrounding cytoplasms of these tumour cells (Figure 6, S1B, 
S1C). 
 
5.1.2   Prmt1 protein levels are elevated in murine lung tumour sections 
In parallel to PRMT6, PRMT1 was also analysed in the cDNA microarray by Yoshimatsu 
and colleagues and was demonstrated to be increased in lung cancer tissues 
(Yoshimatsu et al., 2011). Furthermore, IHC stainings of PRMT1 showed that PRMT1 is 
overexpressed in human lung tumour sections (Elakoum et al., 2014). Therefore, IHC 
stainings of Prmt1 served as a positive control in this study. Hence, all murine tumour  
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Figure 8: IHC stainings of Prmt1 in lung tumour sections of LLC1 and Kras
LA2
 mice (PRMT1_milli). 
(A - C) A representative image of lung tissue sections from a (A) healthy C57BL/6 (HealthyCon #1), (B) 
LLC1 (LLC1 #1) and (C) Kras
LA2
 mouse (59s Lung #1) was photographed. A specific antibody directed 
against PRMT1 (PRMT1_milli, 1:1000) was used (AEC, red) and Hematoxylin served for counterstaining 
(blue). For each section a 10 x magnification (left panel, maximal scale bar length: 250 µm) and a 40 x 
magnification (right panel, maximal scale bar length: 50 µm) is shown. AS: alveolar sac, B: bronchiole, 
BV: blood vessel, HT: healthy tissue, TT: tumour tissue. 
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sections were stained for Prmt1 using a commercial (PRMT1_milli) and an affinity-
purified PRMT1 antibody (PRMT1_affi) from the lab. Although raised against human 
PRMT1, both antibodies also cross-react with the murine Prmt1 (see manufacturer´s 
instructions and bachelor thesis, Anna Lena Merkel) (Sakamaki et al., 2011). 
Similar to the PRMT6 stainings, all lung tumour sections of healthy C57BL/6, LLC1 and 
Kras
LA2
 mice (three mice of each strain) were stained with a PRMT1_milli or a 
PRMT1_affi antibody. A representative result for all IHC stainings of each strain 
(HealthyCon #1, LLC1 #1, 59s Lung #1) is depicted in Figure 8 using PRMT1_milli. 
Although PRMT1_affi stained Prmt1 weaker in the lung tumour sections compared to 
PRMT1_milli, staining patterns of Prmt1 using this antibody were quite similar to the 
PRMT1_milli stainings in all sections (data not shown). However, the nuclei and 
surrounding cytoplasms of proliferating LLC1s (Figure 8B) and Kras
LA2
 tumour cells 
(Figure 8C) were Prmt1-positive compared to tissue sections from healthy C57BL/6 
mice (Figure 8A). A few bronchiolar cells were also positively stained for Prmt1 in the 
tumour sections as well as in the sections of healthy C57BL/6 mice. 
In conclusion, Prmt1 protein levels were increased in lung tumour sections using the 
LLC1 and Kras
LA2
 mouse models in comparison to healthy C57BL/6 mice. Although the 
expression pattern of Prmt1 was more prominent in the LLC1 and Kras
LA2
 mice than in 
the Prmt6 stainings, both proteins were found to be overexpressed in murine lung 
cancer cells. This was particularly obvious in the tumour mass of LLC1 mice compared 
to tissue sections from healthy C57BL/6 mice, in which Prmt6 and Prmt1 levels were 
highly expressed in the enlarged nuclei and the surrounding cytoplasms of the tumour 
cells. These IHC results are in accordance with previous observations that gene 
expressions of PRMT6 and PRMT1 are increased in lung cancer (Yoshimatsu et al., 
2011) and support the idea that both proteins might play a role in lung cancer. 
 
 
 
RESULTS 
 
81 
 
5.1.3   PRMT6 is differently expressed in human and murine lung cancer cell lines 
So far, PRMT6 expression was studied in two murine lung cancer models (LLC1 and 
Kras
LA2
) compared to healthy tissue of C57BL/6 mice. Next, the analysis of PRMT6 was 
extended to several human NSCLC cell lines (H1299, H1650, A549 and H358), which are 
common lung cancer cell models. The NSCLC cell lines were compared to Beas2B, a 
transformed human bronchial epithelial cell line. Additionally, LLC1 cells were studied 
compared to MLE12 cells, a murine transformed lung epithelial cell line. Hence, 
RT-qPCR and Western blot analysis of PRMT6 were performed in these cell lines 
(Figure 9). 
The transcript level of PRMT6 was 3.5-fold higher in H358 and 1.2-fold higher in H1650 
compared to Beas2B cells (Figure 9A). No PRMT6 transcript was detected in A549 cells. 
The transcripts of PRMT6 were 0.5 fold lower in H1299 than in Beas2B cells, similar to 
LLC1 compared to MLE12 cells. Western blot analysis revealed that PRMT6 protein 
levels in the different cell lines widely corresponded to their transcripts (Figure 9B). 
Here, PRMT6 was strongest expressed in H358, still highly expressed in H1650, and 
only moderately expressed in H1299 as well as Beas2B. Almost no PRMT6 protein was 
detected in A549 cells. In comparison to the human cell lines, Prmt6 expression was 
relatively low in the two murine cell lines LLC1 and MLE12. H3 was used to 
demonstrate equal loadings of protein samples whereas the housekeeping gene 
RPS14/Rps14 was used for normalisation in the RT-qPCR analysis. A similar result was 
obtained using RPLP0/Rplp0 as housekeeping gene (data not shown). 
 
Figure 9: PRMT6 is differently expressed in human and murine lung cancer cell lines. 
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(A) Several NSCLC cell lines (Beas2B, H1299, H1650, A549 and H358) as well as murine cell lines (MLE12, 
LLC1) were analysed in the expression of PRMT6 or Prmt6 compared to Beas2B (human) or MLE12 cells 
(murine). The PRMT6/Prmt6 primer pair was able to detect both transcript levels (human and murine). 
All values were normalised to RPS14/Rps14 and were relative to their corresponding control (set to 
one). Error bars denote standard deviation of technical triplicates. Depicted is a representative result of 
three independent experiments. 
(B) All human and murine cancer cell lines depicted in Figure (A) were analysed in the PRMT6 protein 
level (FT lysis, 20 µg of each sample) using the PRMT6 antibody (PRMT6_2affi). H3 was used as a loading 
control. 
Taken together, the protein levels of PRMT6 correspond to their mRNA expression 
profile in the analysed human und murine lung cancer cell lines. However, they differ 
from cell line to cell line. 
 
5.1.4   Depletion of PRMT6 negatively affects clonogenic growth of NSCLC cell lines 
The previously demonstrated data showed that PRMT6 was expressed to a different 
extent in several human as well as murine lung cancer cell lines. In order to investigate 
whether PRMT6 influences cell proliferation and survival of these transformed cells, a 
colony formation assay (CFA) was conducted in the two NSCLC cell lines H1299 and 
H358 (Figure 11 and 12). This CFA is a method to determine whether singly plated cells 
are still able to survive and to grow into colonies due to their unlimited division 
potential. Therefore, H1299 or H358 cells were seeded in very low density and colonies 
were detected with crystal violet after 10 and 14 days of siPRMT6 transfection. 
Additionally, it was tested whether the clonogenic growth was differently impaired in 
cells with a higher basal PRMT6 level (H358) than in a cell line with a moderate basal 
PRMT6 level (H1299). 
In a first step, siRNA-experiments were performed to establish an efficient knockdown 
of PRMT6 in both cell lines. This was analysed by RT-qPCR after 3 and 6 days (Figure 
10A and 10C) and by Western blot after 6 days of siRNA transfection against PRMT6 
(Figure 10B and 10D). The RT-qPCR analysis demonstrated that the three specific 
siRNAs (siPRMT6_1, siPRMT6_4 or siPRMT6_5) depleted PRMT6 with an efficiency of 
approximate 90% in comparison to the siControls (siNon, siScr) after three days of 
RESULTS 
 
83 
 
PRMT6 knockdown in both cell lines (Figure 10A and 10C, left panel). After six days of 
knockdown the PRMT6 depletion was partially lost in H1299 (70%), but still 90% 
present in H358 cells (right panel). The Western blots confirmed the almost complete 
depletion of PRMT6 protein levels in H1299 and H358 cells after 6 days of siRNA-
mediated transfection in the three specific siPRMT6 conditions (Figure 10B and 10D). 
 
Figure 10: Establishment of an efficient PRMT6 depletion in H1299 and H358 cells. 
(A - D) H1299 or H358 cells were transfected with three alternative siRNAs directed against PRMT6 
(siPRMT6_1, siPRMT6_4 or siPRMT6_5) compared to the control transfections siNontargeting (siNon) or 
siScramble (siScr) using LipoRNAiMAX. Cells were harvested for RT-qPCR analysis after three and six days 
of siRNA-mediated depletion. Total RNA was prepared and examined for the transcript level of (A and C) 
PRMT6. RPS14 served for normalisation and all values were relative to wild type cells (wt), which were 
set to one. Error bars denote standard deviation of technical triplicates. Similar results were obtained 
compared to the housekeeping gene RPLP0 (data not shown). 
(B and D) In parallel to (A and C), whole cell extracts of H1299 or H358 cells were harvested (FT lysis) 
and 20 µg protein of each sample was loaded on a SDS gel and analysed with a PRMT6-antibody. H3 
detection served as corresponding loading control. The experiment was performed once. 
 
RESULTS 
 
84 
 
Taken together, these data show that PRMT6 depletion was successful in both 
analysed NSCLC cell lines. 
In a second step, CFAs were performed in both cell lines, in which cells were initially 
plated in low density as decribed above. Representative dishes of the CFA in H1299 
cells are depicted after 10 days of PRMT6 knockdown in Figure 11A. The relative 
colony number was determined by counting colonies of PRMT6-depleted H1299 cells 
(Figure 11B). These PRMT6-depleted colonies (siPRMT6_1, siPRMT6_4 or siPRMT6_5) 
were 20 - 40% reduced compared to siNon or siScr after 10 and 14 days. Here, all 
values are relative to siNon (set to one). Another common method to measure the 
clonogenic ability of cells is the application "ColonyArea", an ImageJ plugin (Guzmán et 
al., 2014). This method was used for automatically generated quantification of the 
colony area (in %) of each dish after either 10 or 14 days. siRNA-mediated depletion of 
PRMT6 caused either a reduction in colony area of at least 40% in all conditions after 
10 days (dark grey bars) or 20% in case of siPRMT6_4 and siPRMT6_5 after 14 days 
(light grey bars) compared to siControls (Figure 11C). This effect was not detectable in 
H1299 cells with a PRMT6 knockdown by siPRMT6_1. Further CFA images are depicted 
in Figure S3 (upper panel) of H1299 cell dishes 14 days after siPRMT6 transfection. 
 
 
Figure 11: Depletion of PRMT6 diminishes the clonogenic growth of H1299 cells. 
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(A - C) H1299 cells were treated with siRNAs directed against PRMT6 (siPRMT6_1, siPRMT6_4 or 
siPRMT6_5) or Nontargeting (siNon) and Scramble (siScr) using LipoRNAiMAX as described in Figure 10. 
48 hours post-transfection, 400 cells were replated in triplicates in a 6-well plate for a colony formation 
assay (CFA) and colonies were detected with crystal violet after 10 days of siRNA transfection. The 
experiment was performed once. 
(A) Representative dishes of crystal violet-stained dishes were photographed after 10 days. 
(B and C) The quantification of crystal violet-stained H1299 colonies was performed by (B) counting the 
colony number relative to siNon (in %) after 10 days (dark grey bars) and 14 days (light grey bars). 
Additionally, (C) the automatically generated quantification by "ColonyArea", an ImageJ plugin, was 
used to determine the colony area (in %) of each dish of either 10 days (dark grey bars) or 14 days (light 
grey bars). Depicted is a triple counting / scanning ± standard deviation. 
 
In parallel, a CFA was performed in the NSCLC cell line H358, for which similar results 
were obtained as for H1299 cells. Selected images of the cell dishes are shown in 
Figure 12A after 10 days of siPRMT6 transfection. Two of three siPRMT6 conditions 
(siPRMT6_4, siPRMT6_5) exhibited a clear decrease in cell numbers. The quantification 
by counting the cell number was impossible because of the very small cell size and a 
too high cell number. Nevertheless, the cell growth quantification by "ColonyArea" 
was technically feasible and showed a similar result as judged by eye (Figure 12B). 
Depletion of PRMT6 by siPRMT6_4 and siPRMT6_5 clearly showed a 75% reduced 
colony area compared to both siControls after 10 days (dark grey bars) and a 50% 
reduced colony area after 14 days (light grey bars). This effect was not detected in 
H358 cells depleted of PRMT6 by siPRMT6_1. Additional images of the CFA in H358 
cells after 14 days of siRNA-mediated depletion of PRMT6 are executed in Figure S3 
(lower panel). 
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Figure 12: Depletion of PRMT6 diminishes the clonogenic growth of H358 cells. 
(A and B) H358 cells were treated with siRNAs directed against PRMT6 (siPRMT6_1, siPRMT6_4 or 
siPRMT6_5) or Nontargeting (siNon) and Scramble (siScr) using LipoRNAiMAX as described in Figure 10. 
48 hours post-transfection, 40.000 cells were replated in triplicates in a 6-well plate for a colony 
formation assay (CFA) and colonies were detected with crystal violet after 10 days of siRNA transfection. 
The experiment was performed once. 
(A) Representative dishes of crystal violet-stained dishes were photographed after 10 days. 
(B) The automatically generated quantification of crystal violet-stained H358 colonies was performed by 
"ColonyArea", an ImageJ plugin. The colony area (in %) of each dish was determined after 10 days (dark 
grey bars) and 14 days (light grey bars). Depicted is a triple counting / scanning ± standard deviation.  
 
In summary, these results demonstrate that PRMT6 facilitates the clonogenic growth 
of NSCLC cell lines (H1299 and H358 cells). Two out of three used siRNAs directed 
against PRMT6 (siPRMT6_4 and siPRMT6_5) showed that PRMT6 depletion causes a 
reduction in colony number compared to control siRNA transfected cells. Furthermore, 
these data suggest that defects in the ability to form colonies might be more 
prominent in PRMT6-depleted cells with previously high PRMT6 levels (H358) than in 
cells with previously moderate PRMT6 levels (H1299 cells). However, this CFA 
experiment was executed once in this study. Further experiments have to confirm 
these data. 
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5.2   PRMT6 positively regulates proliferation and blocks senescence 
As explained above, PRMT6 is deregulated in several types of human cancer, such as 
lung cancer (Yoshimatsu et al., 2011). On the one hand, this observation was 
confirmed by IHC stainings in several murine lung tumour tissues in this study (Figure 
6, 7, S1 and S2). On the other hand, PRMT6 depletion caused a reduced proliferation 
capability of tumour cells (CFA in H1299 and H358, Figure 11 and 12), which could 
probably lead to cell cycle arrest. Therefore, further investigations should confirm 
these data whether PRMT6 is also implicated in the proliferation and survival of the 
osteosarcoma cell line U2OS, which is another transformed cell line. In a first 
approach, the CFA was performed after establishment of an efficient PRMT6 
knockdown as it was previously the case for the NSCLC cell lines. 
 
5.2.1   Depletion of PRMT6 reduces the clonogenic growth of U2OS cells 
An efficient depletion of PRMT6 was achieved in U2OS cells using two alternative 
PRMT6 siRNAs (siPRMT6_1, siPRMT6_2) in comparison to siControl (siLuci) (Figure 13). 
The Western blot showed a strong decrease of PRMT6 protein levels after three days 
of siPRMT6 transfection compared to siLuci (Figure 13A). CDK2 was used to 
demonstrate equal sample loadings. The RT-qPCR analysis demonstrated the 
diminished PRMT6 transcript levels in the time interval of 0 to 14 days, which were 
slightly reduced over time and lost after 14 days (Figure 13B). 
 
 
Figure 13: Establishment of an efficient PRMT6 depletion in U2OS cells. 
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(A and B) U2OS cells were transfected with siRNA directed against PRMT6 (siPRMT6_1 or siPRMT6_2) or 
Luciferase (siLuci) using LipoRNAiMAX. 48 hours post-transfection, 400 cells were replated in triplicates 
in a 6-well plate for Western blot or RT-qPCR analysis. A representative result of three independent 
experiments is shown. 
(A) 72 hours after start of siRNA treatment cells were harvested (IPH lysis) and total protein (20 µg) of 
each sample was analysed using a PRMT6 antibody. CDK2 detection served as corresponding loading 
control. 
(B) Every second day of PRMT6 depletion (0 - 14 days knockdown), three dishes with siRNA transfected 
cells were harvested, pooled, total RNA was prepared and analysed by RT-qPCR. Transcript levels of 
PRMT6, normalised to UBC and relative to siLuci (set to one), were determined for siLuci (dark grey 
bars), siPRMT6_1 (light grey bars) and siPRMT6_2 (white bars). Error bars denote standard deviation of 
technical triplicates. 
 
Then, a CFA was performed in order to test whether the clonogenic growth of U2OS 
cells was affected after depletion of PRMT6. Therefore, U2OS cells were seeded at a 
low cell density and forming colonies were detected after 10 and 14 days of siPRMT6 
transfection by crystal violet staining. Images were taken and are depicted in Figure 
14A. The quantification was performed either by triple counting of the colony number 
relative to siLuci (Figure 14B) or by automatical determination of the cell growth using 
"ColonyArea", an ImageJ plugin, after 10 and 14 days of PRMT6 depletion (Figure 14C). 
In both cases, PRMT6 depletion caused a reduction of U2OS colonies of about 60%. 
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Figure 14: Depletion of PRMT6 results in a reduced ability to form colonies of U2OS cells. 
(A - C) In parallel to Western blot and RT-qPCR analysis shown in Figure 13, U2OS cells were transfected 
with siRNA directed against PRMT6 (siPRMT6_1 or siPRMT6_2) or Luciferase (siLuci) using 
LipoRNAiMAX. 48 hours post-transfection, 400 cells were replated in triplicates in a 6-well plate for a 
colony formation assay (CFA) and colonies were detected with crystal violet either after 10 or 14 days of 
siRNA transfection. CFA were performed as biological triplicates and one representative result is shown. 
(A) Representative dishes were photographed after 10 and 14 days. 
(B and C) The evaluation of crystal violet-stained colonies was performed either by (B) counting relative 
to siLuci (in %) or U2OS cell growth was automatically quantified by (C) measuring the colony area (in %) 
using "ColonyArea", an ImageJ plugin. The result shown is the average of a triple counting / scanning ± 
standard deviation of 10 days (dark grey bars) and 14 days (light grey bars) of PRMT6 knockdown.  
 
In conclusion, PRMT6-depleted U2OS cells were also impaired in their clonogenic 
growth as demonstrated for H1299 and H358 cells. 
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5.2.2   Depletion of PRMT6 positively influences CDKN1A gene expression in U2OS 
cells 
Previous experiments have demonstrated that PRMT6 depletion limits the 
proliferation capability of several transformed cell lines, including U2OS cells. 
Therefore, it is assumed that PRMT6 promotes proliferation of cancer cells, while other 
cell cycle regulatory pathways such as senescence might be prohibited by PRMT6. 
Cellular senescence is a protective mechanism against unlimited cell proliferation, 
which is a hallmark of cancer cells. 
In order to answer the question whether key regulators of the cell cycle are involved in 
the PRMT6-mediated proliferation defects, several components of the TP53-cellular 
senescence pathway and further important cell cycle regulators were analysed in 
PRMT6-depleted U2OS cells. Beside the tumour suppressor gene TP53 and its target 
CDKN1A, the expression of the serine/threonine protein kinase CDK2 and the cyclin 
CCND1 were exemplary analysed. CDKN1A functions as a repressor by binding to CDK-
cyclin complexes mostly via CDK2. In addition, CDKN1A is also able to block CDK4/6-
CCND complex formation of the p16-INK4A-RB1 cascade. This prevents an efficient 
kinase activity of these complexes to phosphorylate RB1 (Malumbres and Barbacid, 
2005). As a result, activation of E2F-target genes is prohibited in both pathways, which 
causes then a block in cell cycle progression. However, p16-INK4A itself could not be 
studied in U2OS cells due to the fact that it is silenced by deletion and DNA 
methylation (Miller et al., 1996; Park et al., 2002). 
In addition, the two other CIP/KIP family members, CDKN1B and CDKN1C and the 
cyclin CCNA2 that is an important regulator of G1/S and G2/M transitions in the cell 
cycle and binds to CDK2 during S phase, were studied. The angiogenesis inhibitor 
THBS1, which was previously described as a repressed target gene of PRMT6, was 
thought to be used as a positive control in this experiment (Michaud-Levesque and 
Richard, 2009). 
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The experiment in U2OS cells was performed by using five independent siRNAs 
sequences targeting PRMT6 (siPRMT6_1 - siPRMT6_5) in comparison to several 
controls (wt, Lipo, siNon, siScr). RT-qPCR analysis of PRMT6 in PRMT6-depleted U2OS 
cells demonstrated an efficient PRMT6 knockdown of 70 - 90 % (Figure 15A). 
Interestingly, CDKN1A gene expression was 1.8- to 4.8-fold increased in PRMT6- 
depleted cells compared to the controls (Figure 15B). These findings were confirmed 
by Western blot (Figure 15C). Here, PRMT6 depletion correlated with an increase in 
CDKN1A protein level whereas CDK2 was unaffected. Additionally, the two other 
CIP/KIP family members, CDKN1B and CDKN1C, the cyclins CCNA2 and CCND1, the 
tumour suppressor gene TP53 and THBS1 were analysed by RT-qPCRs as mentioned 
above. 
As a result, TP53 transcript levels were slightly reduced compared to the controls wild 
type (wt) and Lipo in U2OS cells depleted of PRMT6 (Figure 15D). This effect was not 
detected in comparison to siNon or siScr. In case of siPRMT6_3, TP53 trancript was 
even 2-fold increased compared to siNon or siScr. Therefore, no effect of PRMT6 on 
TP53 transcript levels was detected with regard to both controls (siNon, siScr). A 
similar result was detected for CDKN1C transcript level, the third member of the 
CIP/KIP family (Figure 15F). CDKN1C was not uniformly regulated compared to all 
controls in PRMT6-depleted U2OS cells. In case of CDKN1B and CCNA2, these two 
genes were slightly downregulated in U2OS cells depleted of PRMT6 (Figure 15E, 15G). 
This effect was detected compared to wild type (wt) or Lipo transfection, whereas it 
was only weak compared to siNon or siScr in the RT-qPCR analysis. In contrast, CCND1 
transcript level was slighty increased in the PRMT6 knockdown compared to all control 
conditions (Figure 15H). However, THBS1 transcript level was not uniformly affected by 
the different siPRMT6 sequences (Figure 15I). 
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Figure 15: PRMT6 depletion causes an increased CDKN1A gene expression in U2OS cells. 
(A - I) U2OS cells were transfected with several alternative siRNAs targeting PRMT6 (siPRMT6_1 - 
siPRMT6_5) or Nontargeting (siNon) and Scramble (siScr) using LipoRNAiMAX. Wild type cells (wt) and 
cells treated only with Lipofectamine RNAiMAX (Lipo) served as additional controls. After 72 hours cells 
were harvested either for RNA isolation or total protein analysis (IPH lysis). A representative result of 
three independent experiments is given. 
(A and B) and (D - I) Transcript levels of (A) PRMT6, (B) CDKN1A, (D) TP53, (E) CDKN1B and (F) CDKN1C 
or (G) CCNA2 and (H) CCND1 as well as (I) THBS1 were studied in RT-qPCR, in which UBC served for 
normalisation. All values were relative to wild type (wt) cells (set to one). Error bars denote standard 
deviation of technical triplicates. 
(C) Each protein sample (30 µg) was loaded on a SDS gel and analysed by Western blot using antibodies 
directed against PRMT6, CDKN1A and CDK2, serving as loading control. 
 
Taken together, PRMT6 depletion was accompanied by a prominent effect on CDKN1A 
transcript and protein level in U2OS cells. For both analyses, an enhanced gene 
expression and protein synthesis of CDKN1A was detected. In case of all the other 
analysed genes no clear effect was found in PRMT6-depleted U2OS cells. 
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5.2.3   PRMT6 binds to the TSS of the CDKN1A gene locus in U2OS cells 
PRMT6 was demonstrated to regulate CDKN1A gene expression in a negative manner. 
Therefore, it was assumed that PRMT6 directly regulate CDKN1A and binds to its gene 
locus. To test the hypothesis, chromatin immunoprecipitation (ChIP) analysis of PRMT6 
at the CDKN1A gene locus was performed. Primer pairs were used spanning the 
CDKN1A gene locus from -6.8 kb to +8.6 kb using wild type U2OS cells (Figure 16). 
PRMT6 enrichment was analysed by ChIP-qPCR compared to IgG rabbit. Both, the 
graphical presentation of % input of chromatin (Figure 16A, left panel) and the fold IgG 
(right panel) showed similar results. PRMT6 binds at the CDKN1A gene locus with the 
strongest association at the transcriptional start site (TSS, 3- to 4-fold) in comparison to 
IgG rabbit control. As PRMT6 is the major methyltransferase of H3R2me2a (Guccione 
et al., 2007; Hyllus et al., 2007), I analysed whether this methylation mark correlated 
with PRMT6 at the CDKN1A gene locus (Figure 16B). Thus, ChIP analysis using an 
H3R2me2a antibody was conducted. H3R2me2a was specifically enriched 2- to 3-fold 
at the TSS compared to surrounding regions of the CDKN1A gene locus. 
 
Figure 16: PRMT6 binding peaks at the TSS of the CDKN1A gene locus accompanied by an enhanced 
level of H3R2me2a in U2OS cells. 
(A and B) U2OS cells were harvested 72 hours after seeding, chromatin was isolated and subjected to 
ChIP analysis using antibodies against (A) PRMT6 (light grey bars) and IgG rabbit as control (dark grey 
bars) or in (B) H3R2me2a relative to histone H3. Immunoprecipitated DNA was analysed in triplicates 
using primer pairs spanning the indicated regions of the CDKN1A gene locus. Mean values are expressed 
in (A) as % input of chromatin or fold IgG, which was equated to one. Error bars denote standard 
deviation of technical triplicates. A representative result of three independent experiments is given. 
In conclusion, these data show that PRMT6 and H3R2me2a peak at the TSS of the 
CDKN1A gene locus in U2OS cells, whereby this H3R2me2a-associated repressive 
PRMT6 activity seems to be responsible for the pro-proliferative function of PRMT6. 
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5.2.4   PRMT6 is a negative regulator of senescence in TIG3-T cells 
Given that PRMT6 positively affects clonogenic growth of U2OS cells and that PRMT6 
regulates CDKN1A, which is a prominent gene implicated in cell cycle arrest, it was 
questioned whether PRMT6 also contributes to senescence, a permanent arrest in the 
non-transformed cell line TIG3-T. Even though these human diploid fibroblasts are 
immortalised by ectopic hTERT expression (catalytic subunit of the telomerase 
holoenzyme), they are still able to pass stress-induced senescence. This can be 
accomplished by senescence inducers such as non-telomeric DNA damage (Chen et al., 
2001a) and in this case possibly by PRMT6. 
Therefore, TIG3-T cells were infected with retroviral plasmids targeting PRMT6 
(shPRMT6 sequences are identical to corresponding siRNAs) or Luciferase (shLuci) and 
were selected with Puromycin (1 µg/ml). Cells were analysed in a senescence-
associated ß-galactosidase (SA-ß-gal) staining after seven days of shRNA-mediated 
infection (Figure 17). Figure 17A shows an efficient PRMT6 protein depletion in all 
analysed conditions. The number of SA-ß-gal-positive cells was increased using three 
independent shPRMT6 sequences compared to some SA-ß-gal positive cells in the 
shLuci or control condition (Figure 17B). 
 
 
Figure 17: PRMT6 depletion results in an enhanced senescent phenotype in TIG3-T cells. 
(A and B) TIG3-T cells were infected with retroviral plasmids coding for three alternative shRNAs 
targeting PRMT6 (shPRMT6_1, shPRMT6_2, shPRMT6_3) or shLuciferase (shLuci) and the empty plasmid 
(control) as an additional control. 48 hours post-infection, cells were selected with 1 µg/ml Puromycin 
for additional 72 hours. A representative result of three independent experiments is shown. 
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(A) Efficient PRMT6 knockdown was confirmed by Western blot analysis (FT lysis) after seven days of 
shRNA-mediated depletion of PRMT6. CDK2 detection served as corresponding loading control.  
(B) After six days of shRNA-mediated depletion (day 0 corresponds to day 3 of selection) cells were 
replated and detected for SA-ß-gal activity at day 7.  
 
Taken together, these results point towards a role of PRMT6 in promoting proliferation 
and blocking senescence in TIG3-T cells. 
 
5.2.5   Depletion of PRMT6 enhances CDKN1A and p16-INK4A gene expression in 
TIG3-T cells 
To answer the question whether the permanent arrest in TIG3-T cells is caused by a 
similar influence of PRMT6 on the target gene CDKN1A as shown for the transformed 
cell line U2OS, siRNA-mediated experiments were performed in these non-transformed 
cells. Furthermore, the CDK inhibitor p16-INK4A gene locus, which is not mutated in 
these cells, could be studied according to a possible regulation by PRMT6. 
In a first approach it was analysed whether CDKN1A and p16-INK4A gene expression 
were upregulated in PRMT6-depleted TIG3-T cells. Efficient knockdown of PRMT6 (60 - 
90%) using three alternative shRNAs (shPRMT6_1 - shPRMT6_3) in comparison to 
shLuci or control (empty plasmid) was demonstrated by RT-qPCR or Western blot 
analysis (Figure 18A, 18B). CDKN1A and p16-INK4A transcripts were 1.4- to 1.7-fold 
increased compared to control conditions after treatment of the cells with retroviral 
plasmids coding for shPRMT6_2 or shPRMT6_3 (Figure 18C, 18D). In contrast, CDKN1A 
and p16-INK4A transcripts were unaffected by shPRMT6_1. The analysis of CDKN1A 
and p16-INK4A protein levels showed an enhanced CDKN1A level by shPRMT6_1 and 
shPRMT6_2. The p16-INK4A protein level was increased in all shPRMT6 conditions in 
comparison to shLuci and control in TIG3-T cells (Figure 18E). 
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Figure 18: PRMT6 depletion causes an increased CDKN1A and p16-INK4A gene expression in TIG3-T 
cells. 
(A - E) TIG3-T cells were infected with retroviral plasmids coding for shPRMT6 (shPRMT6_1, shPRMT6_2 
or shPRMT6_3) compared to shLuciferase (shLuci) or empty plasmid (control). After 48 hours cells were 
selected with 1 µg/ml Puromycin for the following 72 hours. After additional seven days of shRNA-
mediated depletion of PRMT6 (day 0 corresponds to three days after start of Puromycin selection) cells 
were harvested either for isolation of total RNA (A, C and D) or protein extracts using FT lysis (B and E). 
After the transcription of RNA into cDNA RT-qPCR analysis was performed using primers directed against 
(A) PRMT6, (C) CDKN1A and (D) p16-INK4A transcript levels normalised to RPS14 and relative to control 
(empty plasmid), which was set to one. Error bars denote standard deviation of technical triplicates. 
For Western blot analysis, 30 µg protein of each sample was loaded on a SDS gel for determination of 
(B) PRMT6, (E) CDKN1A, p16-INK4A and (B and E) CDK2 level, which was used to demonstrate equal 
sample loadings. Shown is a representative result of threee independent experiments. 
 
In conclusion, two out of three specific shRNAs directed against PRMT6 caused an 
increased gene expression and protein synthesis of CDKN1A in TIG3-T cells. Gene 
expression of p16-INK4A was also positively affected by two PRMT6-specific shRNAs, 
while its protein level was even affected through all three used retroviral plasmids 
coding for shPRMT6. Both cell cycle inhibitors are repressed by PRMT6 in non-
transformed cells. 
 
RESULTS 
 
97 
 
5.2.6   PRMT6 binds to the CDKN1A and p16-INK4A gene locus in TIG3-T cells 
To elucidate whether PRMT6 directly regulates CDKN1A and p16-INK4A by binding to 
their gene loci in TIG3-T cells, ChIP analysis was performed using TIG3-T wild type cells. 
CDKN1A gene was studied by primer pairs spanning the locus from -6.8 kb to +8.6 kb 
(Figure 19). Here, calculation of % input of chromatin (Figure 19A, left panel) and fold 
IgG (right panel) was conducted. PRMT6 enrichment was detected by a PRMT6 
antibody compared to IgG control. The CDKN1A gene locus was targeted by PRMT6 
with a preferential binding of PRMT6 to the TSS up to 8-fold and with a small portion 
to the +0.5 kb transcribed region (4-fold) compared to surrounding chromatin areas 
and the IgG rabbit controls. The PRMT6 binding was accompanied by a 5-fold 
enhanced H3R2me2 level at the TSS compared to surrounding regions (Figure 19B). 
H3R2me2 level was detected by anti-H3R2me2a. 
 
Figure 19: PRMT6 binding peaks at the TSS of the CDKN1A gene locus accompanied by an enhanced 
H3R2me2a level in TIG3-T cells. 
(A and B) TIG3-T cells were harvested 72 hours after seeding and isolated chromatin was subjected to 
ChIP analysis using specific antibodies directed against (A) PRMT6 (light grey bars) with the 
corresponding IgG rabbit control (dark grey bars) or chromatin was examined with an antibody for (B) 
H3R2me2a in comparison to H3. Immunoprecipitated DNA was analysed in triplicates by qPCR with 
specific primers covering the area around the TSS of CDKN1A gene locus. Mean values are expressed in 
(A) as % input of chromatin or fold IgG, which was equated to one or in (B) mean values are relative to 
histone H3. Error bars denote standard deviation of technical triplicates. A representative result of three 
independent experiments is shown. 
 
In case of the p16-INK4A gene locus, the result was less clear than for the CDKN1A 
gene locus. PRMT6 binding was detected at the 0.5 kb region upstream of the TSS 
(about 3-fold) compared to IgG after calculation of % input of chromatin (Figure 20A, 
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left panel). Using the fold IgG calculation, PRMT6 was even more distributed over the 
whole chromatin area as pictured in the graphic (right panel). The methylation mark 
H3R2me2a was not enriched at the p16-INK4A gene locus (Figure 20B). 
 
Figure 20: PRMT6 binds to the p16-INK4A gene locus in TIG3-T cells. 
(A and B) TIG3-T cells were harvested 72 hours after seeding and isolated chromatin was subjected to 
ChIP analysis using specific antibodies directed against (A) PRMT6 (light grey bars) with the 
corresponding IgG rabbit control (dark grey bars) or chromatin was examined with an antibody for (B) 
H3R2me2a in comparison to H3. Immunoprecipitated DNA was analysed in triplicates by qPCR with 
specific primer pairs covering the area around the TSS of the p16-INK4A gene locus. Mean values are 
expressed in (A) as % input of chromatin or fold IgG, which was equated to one or in (B) mean values are 
relative to histone H3. Error bars denote standard deviation of technical triplicates. A representative 
result of three independent experiments is depicted. 
 
In summary, the binding of PRMT6 overlapped with the presence of H3R2me2a at the 
TSS of the CDKN1A gene locus as demonstrated for U2OS cells. Similarly, PRMT6 also 
binds at the TSS of the p16-INK4A locus. However, H3R2 dimethylation was not 
detected above background level of the control regions suggesting that PRMT6 
possesses no methyltransferase activity towards H3 at this locus and regulates p16-
INK4A independently of its enzymatic activity. Nevertheless, CDKN1A and p16-INK4A 
are both transcriptional downstream targets of PRMT6 in TIG3-T cells that explain its 
function to regulate proliferation in a positive manner, while senescence is blocked by 
PRMT6. 
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5.2.7   Establishment of an efficient oncogene-induced senescence in TIG3 BRAF-ER 
cells 
Premature cellular senescence can be triggered by different stress stimuli, such as 
oxidative stress, DNA or expression of oncogenes. In order to study PRMT6 and its 
relationship to CDKN1A in oncogene-induced senescence (OIS), the TIG3 BRAF-ER cell 
model was used (Figure 21). These fibroblasts possess a protein kinase domain of Braf 
fused to a mutant form of the hormone binding domain of the estrogen receptor (ER), 
referred as ligand binding domain (LBD) (Agger et al., 2009; Woods et al., 1997). LBD is 
responsive to 4-hydroxytamoxifen (4-OHT), but not to ß-estradiol. 
Normally, Braf is constitutively expressed, but the protein remains inactive through 
chaperone binding at the LBD. Its activity can be rapidly induced by treatment of the 
cells with 4-OHT. A conformational change in Braf-LBD results in the dissociation of 
chaperones. Activation of the MAPK signaling cascade induces a G1-arrest in the cell 
cycle and cells undergo oncogene-induced senescence (OIS). The biomarker 
ß-galactosidase is enhanced expressed and detected by SA-ß-gal staining (chapter 
4.1.7). Similar to the former cell model, TIG3-T cells, OIS cannot be bypassed by hTERT 
expression in oncogene overexpressing fibroblasts (Wei and Sedivy, 1999). 
 
Figure 21: Schematic depiction of the oncogene-induced senescence (OIS) model (TIG3 BRAF-ER). 
 
RESULTS 
 
100 
 
To examine whether senescence is inducible in these TIG3 BRAF-ER cells, they were 
treated with 4-OHT treatment (200 nM) over a time period of six days (Figure 22). In 
Figure 22A, representative images of a SA-ß-gal staining are shown. A 40% increase of 
SA-ß-gal-positive stained fibroblasts was detected after four and six days (Figure 22B). 
A decline in EZH2 expression, a subunit of the H3K27 methyltransferase complex PRC2, 
is another indicator that TIG3 BRAF-ER cells undergo rapid OIS after oncogenic stress 
induction (Agger et al., 2009). EZH2 was highly expressed in pre-senescent cells (day 0) 
and prevents cellular senescence. In TIG3 BRAF-ER cells, EZH2 expression was rapidly 
decreased to 10 - 20% after two days of 4-OHT treatment (Figure 22C). 
 
Figure 22: Establishment of an efficient OIS induction in TIG3 BRAF-ER cells. 
(A and B) TIG3 BRAF-ER cells were treated with 200 nM 4-OHT and detected for SA-ß-gal activity at the 
indicated time points. Images were taken with a bright field microscope (A). The number of SA-ß-gal-
positive TIG3 BRAF-ER cells was quantified by counting 300 cells in a triplicate. The average from the 
counting (in %) ± SD is shown in (B). 
(C) TIG3 BRAF-ER cells were treated with 200 nM 4-OHT as in (A). At the indicated time points cells were 
harvested, total RNA was prepared and analysed by RT-qPCR for the transcript level of EZH2. UBC served 
for normalisation and values were relative to day 0 (set to one). Error bars denote standard deviation of 
technical triplicates. A representative result of several independent experiments is given. 
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5.2.8   Oncogene-induced senescence causes an enhanced CDKN1A and p16-INK4A 
expression unlike a reduced PRMT6 expression in TIG3 BRAF-ER cells 
The tumour suppressors’ CDKN1A and p16-INK4A are key regulators in cellular 
senescence (Kuilman et al., 2010). Here, both genes were strongly upregulated in TIG3 
BRAF-ER cells (Figure 23), in which a senescent phenotype was induced by 4-OHT 
treatment (Figure 22). CDKN1A gene expression was 6-fold (Figure 23A) and p16-INK4A 
gene expression was nearly 8-fold increased (Figure 23B) after eight days of 4-OHT 
treatment compared to day 0. To answer the question whether PRMT6 was implicated 
in this process of stress-induced senescence (OIS), RT-qPCR and Western blot analyses 
of PRMT6 were performed under these conditions (Figure 23C, 23D). Transcript levels 
of PRMT6 were slightly increased at day 2 and 4 of 4-OHT treatment compared to day 
0. Interestingly, PRMT6 expression was decreased after eight days of 4-OHT treatment 
(60% reduction) compared to day 0 (Figure 23C). Analysis of PRMT6 protein level 
demonstrated that PRMT6 was reduced even after 2 days of 4-OHT treatment (Figure 
23D). This effect was maintained until day 8. 
 
 
Figure 23: OIS induction causes increased CDKN1A as well as p16-INK4A gene expression accompanied 
by a reduced PRMT6 gene expression in TIG3 BRAF-ER cells. 
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(A - C) TIG3 BRAF-ER cells were treated with 200 nM 4-OHT. At the indicated time points cells were 
harvested, total RNA was prepared and analysed by RT-qPCR for the transcript levels of (A) CDKN1A, (B) 
p16-INK4A and (C) PRMT6. UBC served for normalisation and values were relative to day 0 (set to one). 
Error bars denote standard deviation of technical triplicates. 
(D) TIG3 BRAF-ER cells were treated with 200 nM 4-OHT as in (A - C). Whole cell extracts were harvested 
(IPH lysis) at the indicated time points and 20 µg protein of each sample was analysed by Western blot 
with an antibody directed against PRMT6 (right panel). CDK2 detection served as corresponding loading 
control. Experiments were performed as biological triplicates and one representative experiment is 
shown here. 
 
In conclusion, the increase in CDKN1A and p16-INK4A gene expression correlated with 
a decrease in PRMT6 expression. For this reason, PRMT6 seems to play a distinct role 
in stress-induced senescence (OIS) in TIG BRAF-ER cells, in which a decrease in PRMT6 
expression might cause a transcriptional induction of these two target genes. 
 
5.2.9   Depletion of CDKN1A causes a delayed onset of OIS in TIG3 BRAF-ER cells 
In order to examine whether OIS induction in these cells was dependent on CDKN1A, a 
siRNA-mediated depletion of CDKN1A was established in these cells. CDKN1A gene 
expression was strongly reduced using a pool of three CDKN1A siRNA-sequences 
(siCDKN1A) compared to the control siGFP in a time period of six days of 4-OHT 
treatment in TIG BRAF-ER cells (Figure 24A). PRMT6 expression was unaffected within 
this time course compared to siGFP (Figure 24B). Evaluation of SA-ß-gal staining 
revealed that CDKN1A-depleted TIG3 BRAF-ER cells exhibited a delayed onset of OIS 
compared to the control transfection with siGFP (60% reduction) after six days of 
4-OHT treatment (Figure 24C). 
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Figure 24: Depletion of CDKN1A results in a delayed onset of OIS in TIG3 BRAF-ER cells. 
(A and B) TIG3 BRAF-ER cells were transfected with siCDKN1A (pool of three sequences) or siGFP as a 
control for 48 hours (PEI transfection), then treated with 200 nM 4-OHT. Cells were harvested and 
isolated RNA was examined for transcript levels of (A) CDKN1A and (B) PRMT6 in the siGFP- (dark grey 
bars) or siCDKN1A-depleted cells (light grey bars). All values were normalised to UBC and day 0 of siGFP 
was set to one. Error bars denote standard deviation of technical triplicates. 
(C) TIG3 BRAF-ER cells were treated with siRNA and 200 nM 4-OHT as described in (A and B) and 
detected for SA-ß-gal activity at the indicated time points. Day 0 was the time point of 48 hours after 
siRNA transfection. Quantification of the number of SA-ß-gal-positive TIG3 BRAF-ER cells either for 
siGFP- (dark grey bars) or siCDKN1A-depleted cells (light grey bars) was performed in counting a 
triplicate of each 300 cells per 6-well plate. Average (in %) ± standard deviation of a representative 
counting result of three independent experiments is shown. 
 
A similar result was obtained using the sip21 pool in comparison to three alternative 
control siRNAs (siGFP, siNon, siScr) instead of only one control (siGFP), which confirms 
the available results in an independent larger experimental setup. Here, CDKN1A gene 
expression was also strongly reduced compared to the controls (Figure 25A). The 
corresponding SA-ß gal staining demonstrated a delayed onset of OIS in CDKN1A- 
depleted cells (Figure 25B) as described above (Figure 24C). 
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Figure 25: Depletion of CDKN1A results in a delayed onset of OIS using various siRNA controls in TIG3 
BRAF-ER cells. 
(A and B) TIG3 BRAF-ER cells were subjected to (A) RT-qPCR analysis and (B) SA-ß-gal staining using 
siRNAs (pool of three sequences) directed against the CDKN1A transcript level or GFP (siGFP), 
Nontargeting (siNon) and Scramble (siScr) as siRNAs controls (PEI transfection) and treatment with 200 
nM 4-OHT. All values of the RT-qPCR were normalised to UBC and day 0 of siGFP set to one. Error bars 
denote standard deviation of technical triplicates. The experiment was performed as biological 
triplicates and one representative result is shown here. 
 
In conclusion, knockdown of CDKN1A caused a delayed onset of OIS in TIG3 BRAF-ER 
cells demonstrated by several independent experiments. CDKN1A seems to be 
essential for Braf-induced senescence in these cells. 
 
5.2.10  Overexpression of PRMT6 causes a delayed onset of OIS in TIG3 BRAF-ER cells 
In parallel to the CDKN1A-depleted cell analysis and its effect on the onset of OIS in 
TIG3 BRAF-ER cells (Figure 24, 25), I wanted to examine whether OIS is inhibited in a 
similar manner by overexpression of PRMT6. Therefore, PRMT6 was overexpressed 
compared to a control transfection (pcDNA3.1) in the same cell line. Overexpression of 
PRMT6 was efficient (up to 500 fold at day 3) as demonstrated by RT-qPCR when 
compared to control transfection (Figure 26A). Enhanced PRMT6 expression resulted 
in a slight reduction of senescent cells (up to 25% at day 3) compared to a control 
transfection in TIG3 BRAF-ER cells (Figure 26B). Even after four days a delayed OIS was 
detected in PRMT6 overexpressed cells. 
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Figure 26: Overexpression of PRMT6 leads to a reduced OIS level in TIG3 BRAF-ER cells. 
(A and B) TIG3 BRAF-ER cells were transfected with pcDNA3.1 (empty plasmid) or pcDNA3.1-hPRMT6 
plasmids using FuGENE HD. 48 hours post-transfection, cells were treated with 200 nM 4-OHT for the 
indicated time period. 
(A) Cells were harvested at the indicated time points, total RNA was prepared and analysed by RT-qPCR 
for the transcript levels of PRMT6 comparing pcDNA3.1- (dark grey bars) with pcDNA3.1-hPRMT6 
overexpressing cells (light grey bars). All values were normalised to UBC and were relative to the 
corresponding empty plasmid, which was set to one at each time point (day 0, 1, 2, 3 and 4). Error bars 
denote standard deviation of technical triplicates. 
(B) SA-ß-gal staining and counting of SA-ß-gal-positive TIG3 BRAF-ER cells either of pcDNA3.1- (dark grey 
bars) or pcDNA3.1-hPRMT6 overexpressing cells (light grey bars) was performed at the indicated time 
points as in (A). Day 0 corresponds to two days after start of plasmid overexpression. Data show a 
representative result of the average of a triplicate counting (in %) ± standard deviation of three 
independent experiments. 
 
Taken together, these data showed that PRMT6 is involved in Braf-induced senescence 
of TIG3 BRAF-ER cells. Moreover, they support the idea that OIS onset is dependent on 
PRMT6 because PRMT6 overexpression caused a delayed onset of OIS similar to the 
effect demonstrated by depletion of CDKN1A in these cells. PRMT6 seems to regulate 
senescence in a negative manner through transcriptional repression of the two tumour 
suppressor genes CDKN1A and p16-INK4A. 
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5.3   Validation of novel interaction partners of PRMT6 
The MS/MS anaIysis of MCF7 extracts overexpressing TAP-tagged PRMT6 revealed 43 
putative interaction partners of PRMT6 implying various novel functions of PRMT6 in 
transcription, replication and cell cycle processes or DNA damage response (PhD 
thesis, Claudia Stein). To examine whether PRMT6 interacts with PCNA, DDB1 and 
DDB2, which are proteins of the DNA repair machinery (Essers et al., 2005; Iovine et 
al., 2011b), several co-immunoprecipitations (Co-IPs) were performed using MCF7 cell 
extracts in this study. 
 
5.3.1   PRMT6 interacts with PCNA in MCF7 cells 
MCF7 extracts overexpressing Flag-tagged PCNA were subjected to IP using four 
alternative crude sera directed against endogenous PRMT6 (CS PRMT6_1 - CS PRMT6_4) 
(Figure 27). In parallel, IPs with either IgG rabbit or two PRMT6 preimmune sera (PI 
PRMT6_1 and PI PRMT6_3) served as corresponding controls. Immunostaining of the 
IP reactions with a PCNA antibody revealed a weak interaction between PRMT6 and 
PCNA for all four crude sera. The heavy chain of the IgG antibody was located close to 
the 40 kDa PCNA band, which is detected as an unspecific band at the upper edge of 
the blot. The PCNA-antibody could not detect a signal within the control IPs (IgG 
rabbit, PI PRMT6_1 and PI PRMT6_3). The efficiency of the PRMT6 IP was 
approximately 10% compared to the input band (2%), which was detected in the 
corresponding PRMT6 antibody staining and judged by eye. The Co-IP analysis showed 
a weak, but significant interaction between PRMT6 and PCNA in this study. 
 
 
Figure 27: Endogenous PRMT6 interacts with overexpressed Flag-tagged PCNA in MCF7 cells. 
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MCF7 cells were seeded and after 24 hours transfected with a p3xFLAG10-HsPCNA plasmid using PEI. 
48 hours later, cells were harvested and a cell lysis was performed with IPH buffer (400 mM NaCl). 
Protein extracts were diluted to a final lysis buffer concentration of 200 mM NaCl. 1 mg extract of each 
sample was subjected to IP of overexpressed PCNA with endogenous PRMT6. Several PRMT6 crude sera 
(CS PRMT6_1 - PRMT6_4, each 5 µl) were used in IP in comparison to two PRMT6 preimmune sera (PI 
PRMT6_1, PI PRMT6_3, each 5 µl) or IgG rabbit (45 µg) as controls. The IPs and the input (2%) were 
detected with an anti-PCNA antibody after blotting. PRMT6 detection served as IP control. A 
representative result of three independent experiments is given. 
 
5.3.2   PRMT6 interacts with DDB1 in MCF7 cells 
The interaction between PRMT6 and DDB1 was also analysed by Co-IP studies (Figure 
28). Therefore, PRMT6 was precipitated with each of the four alternative PRMT6 crude 
sera (CS PRMT6_1 - CS PRMT6_4) using whole cell extract from Flag-tagged DDB1 
overexpressing MCF7 cells. The immunostaining of the PRMT6 IPs was performed with 
DDB1 antibody. A very weak DDB1-specific band appeared in the IgG rabbit control, 
whereas the DDB1 signal was clear above background in each of the PRMT6 crude sera 
IPs. An IP efficiency of more than 10% compared to the input was observed in the 
corresponding PRMT6 detection (42 kDa). PRMT6 clearly interacts with DDB1 at a 
height of 130 kDa. 
 
 
Figure 28: Endogenous PRMT6 interacts with overexpressed Flag-tagged DDB1 in MCF7 cells. 
Overexpression of the pcDNA3-flag-DDB1 plasmid in MCF7 cells (PEI transfection), cell lysis and all 
indicated IPs (each 1 mg protein extract) were performed as already described in Figure 27. All samples, 
together with the inputs (2% and 10%), were examined with antibodies directed against DDB1 and 
PRMT6 (IP control) in Western blot. The Western blot shows a representative result of three 
independent experiments. 
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5.3.3   PRMT6 also interacts with DDB2 in MCF7 cells 
The protein DDB1 is often found in the UV-DDB complex together with DDB2, which 
binds to UV-damaged DNA sites (Iovine et al., 2011b; Scrima et al., 2008). Therefore, 
Co-IP analysis was extended to DDB2, although it was not found in the MS/MS analysis. 
Here, cell extracts of wild type MCF7 cells were analysed for the interaction between 
endogenous PRMT6 and endogenous DDB2 (Figure 29). An interaction between 
precipitated PRMT6 using the already described PRMT6 crude sera and DDB2 (45 kDa) 
was detected after immunostaining of the IPs with DDB2 antibody. No band appeared 
in the IgG rabbit control. The PRMT6 IP efficiency was again clearly over input (2%). As 
described above for PRMT6 and DDB1, PRMT6 also interacts with DDB2. 
 
 
Figure 29: Endogenous PRMT6 interacts with endogenous DDB2 in MCF7 cells. 
After 72 hours of seeding MCF7 cells were harvested, lysed in IPH buffer (400 mM NaCl) and equal 
amounts of protein extracts (each 1 mg) were incubated with the indicated PRMT6 crude sera 
(CS PRMT6_1 - PRMT6_4), preimmune sera (PI PRMT6_1, PI PRMT6_3) and IgG control, already 
described in Figure 27. DDB2 detection of all IPs and the input (2%) as well as the PRMT6 detection (IP 
control) is depicted. The scan was cut indicated by the black line, but all stainings depicted are from the 
same Western blot and exposure time. Shown is a representative result of three independent 
experiments. 
 
In conclusion, the interaction between PRMT6 and two putative interaction partners 
found in the MS/MS analysis, PCNA and DDB1, was confirmed within this study. 
Additionally, PRMT6 interacts with DDB2, a component of the UV-DDB complex. 
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6   DISCUSSION 
PRMTs possess manifold biological functions including the transcriptional activation 
and repression of genes, mRNA splicing, signal transduction and DNA damage repair 
(Bedford and Clarke, 2009). The deregulation of PRMTs and PRMT-related processes is 
also linked to the pathogenesis of various diseases such as human cancer (Baldwin et 
al., 2014; Cha and Jho, 2012; Yang and Bedford, 2013). Previously, it was reported that 
PRMT6 is overexpressed in different types of human cancer compared to non-
neoplastic tissues. Therefore, PRMT6 might be an attractive target for therapeutic 
strategies to efficiently treat cancer. Especially in the case of lung cancer, novel 
strategies are urgently required because lung cancer is the leading cause of cancer-
related death in humans worldwide. 
 
6.1   Prmt6 protein levels are increased in murine lung cancer 
A cDNA microarray and several siRNA experiments gave an initial hint that PRMT6 
expression is increased in lung cancer and that PRMT6 might positively affects the 
growth of lung cancer cells (Yoshimatsu et al., 2011). For this reason, PRMT6 levels 
were analysed in different lung tumours in the present work. Immunohistochemical 
(IHC) stainings of tissue sections from the two murine lung cancer models LLC1 and 
Kras
LA2
 demonstrated that the expression of Prmt6 is increased in lung tumours 
compared to healthy tissue. In detail, Prmt6 protein levels were elevated in the 
enlarged nuclei and surrounding cytoplasms of tumour cells within the tumour mass of 
LLC1 mice (Figure 6A, 6B, S1B and S2B). A similar result was obtained for the Kras
LA2
 
model. Here, tumour cells as well as cells embedded in the alveolar and bronchiolar 
structure showed increased Prmt6 levels compared to healthy C57BL/6 mice, although 
there were some differences in the Prmt6 stainings of Kras
LA2
 mice (Figure 7, S1C and 
S2C). These data confirm that Prmt6 protein levels are increased in murine lung cancer. 
Beside PRMT6, PRMT1 was also described to be overexpressed in lung cancer tissues 
(Yoshimatsu et al., 2011). In 2014, another study performed IHC stainings of PRMT1 in 
DISCUSSION 
 
110 
 
human lung tumour tissues and could demonstrate that PRMT1 expression is increased 
in these sections (Elakoum et al., 2014). Therefore, IHC stainings of Prmt1 in the 
murine sections served as a positive control within this study and showed that Prmt1 
expression was indeed elevated in tumour cells from LLC1 and Kras
LA2
 mice (Figure 8). 
Previous immunofluorescence (IF) stainings demonstrated that PRMT6 is predominantly 
located in the nucleus of human HeLa and MCF7 cells (Frankel et al., 2002; Hyllus et al., 
2007). As mentioned above, the analysis of Prmt6 in LLC1 and Kras
LA2
 mice revealed 
that Prmt6 expression was also strongly increased in the nucleus of lung tumour cells 
compared to healthy tissue areas. Moreover, protein levels of Prmt6 were elevated in 
the cytoplasms of these cells. It is unlikely that the increased Prmt6 stainings in the 
cytoplasms of lung tumour cells are unspecific due to the fact that three alternative 
PRMT6 antibodies demonstrated a similar staining pattern of Prmt6 in LLC1 and Kras
LA2
 
lung cancer sections (Figure 6, 7, S1 and S2). It is possible that the nuclear expression 
of Prmt6 is so high that it is also detectable in the cytoplasm of these cells. 
Alternatively, PRMT6 might possess different physiological functions and therefore 
variability in its protein localisation in different cell compartments occurs, which might 
be dependent on the cell type and cell line. For example, several previous publications 
demonstrated that the subcellular localisation of PRMTs varies, e.g. PRMT1 ranges 
from predominantly nuclear to predominantly cytoplasmic dependent on the analysed 
cell line (Côté et al., 2003; Frankel et al., 2002; Herrmann et al., 2005; Tang et al., 
1998). In addition, Goulet and colleagues revealed that PRMT1 N-terminal unique 
sequences affect the intracellular localisation of its different isoforms in HeLa cells 
(Goulet et al., 2007). An example for the regulation of the cellular localisation of 
PRMTs by PTMs is the S216 phosphorylation of PRMT4, which promotes a cytoplasmic 
localisation of this mainly nuclear protein (Feng et al., 2009). For these reasons, it can 
not be excluded that PRMT6 possesses as well different localisations in various cell 
lines or cell types. 
Tumours are composed of proliferating tumour and stromal cells, including surrounding 
blood vessels, endothelial cells, inflammatory and immune cells as well as fibroblasts, 
which form the cellular environment of the tumour, also called as tumour 
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microenvironment (Hao et al., 2012). In order to test whether Prmt6-positive stained 
cells within the tumour mass of LLC1 and Kras
LA2
 mice are those proliferating cells, 
specific double stainings of Prmt6 with Ki-67 could be envisaged using the lung cancer 
sections from this study. Moreover, Ki-67 is a nuclear proliferation marker, which was 
already used to demonstrated a reduced proliferation rate of two different NSCLC cell 
lines (A549, H1299) after depletion of PRMT1 and PRMT4 (Elakoum et al., 2014). 
Furthermore, PRMT5 is essential for the growth of lung cancer cells demonstrated by 
depletion of PRMT5 in A549 cells (Gu et al., 2012). In comparison to these three 
PRMTs, the knockdown of PRMT6 also negatively affected the clonogenic growth of 
the two analysed NSCLC cell line H1299 and H358, which was analysed by colony 
formation assay (CFA) (Figure 11, 12) in this study. This is a common method to 
determine whether singly plated transformed cells are still able to survive and to grow 
into colonies due to their unlimited division potential. Additionally, it seems that this 
inhibitory effect caused by the depletion of PRMT6 might be more prominent in NSCLC 
cells with previously high PRMT6 levels (H358) (Figure 12, S3 lower panel) than in cells 
with previously moderate PRMT6 levels (H1299) (Figure 11, S3 upper panel). In 
conclusion, these data indicate that PRMT6 also possesses a function in the regulation 
of the proliferative capability of transformed cell lines similar to PRMT1, PRMT4 and 
PRMT5. These data are in line with a previous study demonstrating that PRMT6 
promotes the estrogen-stimulated proliferation of breast cancer cells (Harrison et al., 
2010). 
Certain cells embedded in the alveolar structure of the lung tumour sections from 
Kras
LA2
 mice as well as of sections from healthy C57BL/6 mice were positively stained 
for Prmt6 (Figure S1A, S1C, S2A). It is possible that these cells are alveolar 
macrophages. In general, macrophages are widely distributed innate immune cells that 
are also found in the lung (Hao et al., 2012). They can be subdivided into classically 
activated (M1) and alternatively activated (M2) macrophages. Interestingly, 
macrophages are the dominant leukocyte population in tumours, in which especially 
the M2 phenotype provides an immunosuppressive microenvironment for tumour 
growth (Quatromoni and Eruslanov, 2012). These tumour-associated macrophages 
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(TAMs) secrete many cytokines, chemokines and proteases, which promote 
angiogenesis, growth and metastasis of several tumours (Hao et al., 2012). In order to 
clarify whether these cells are macrophages, IHC or IF double stainings of Prmt6 with 
common macrophage-specific markers, such as F4/80, CD68 or CD11b, could be 
performed by using murine tissue sections (Lloyd et al., 2008; Ma et al., 2010; 
Quatromoni and Eruslanov, 2012). In addition, some cells of the Kras
LA2
 and healthy 
C57BL/6 mice were also positively stained for Prmt6 in the epithelium of bronchioles 
(Figure 5A and 7A). It is possible that these cells are Clara cells, which are non-ciliated, 
secretory bronchiolar epithelial cells, and also function as stem/progenitor cells for 
repair in the bronchioles (Wang et al., 2012b). IHC double stainings of Prmt6 with the 
Clara cell marker CCSP (Clara cell secretory protein), which is a crucial secretory 
protein produced by Clara cells, could show whether Prmt6 is expressed in these cells. 
Interestingly, a study by O'Brien and colleagues demonstrated that PRMT4 is already 
linked to lung development because this type I PRMT is expressed in alveolar type II, 
endothelial and also in Clara epithelial cells, which was examined by CCSP staining 
(O’Brien et al., 2010). It would be interesting to analyse whether PRMT6 also plays a 
role in pulmonary epithelial cell proliferation and differentiation as shown for PRMT4. 
As described above, Prmt6 levels were highly increased in lung tumour sections from 
murine LLC1 mice (Figure 6A, 6B, S1B and S2B) compared to healthy tissue areas in the 
same tissue sections. In contrast, protein levels of Prmt6 were relatively low in 
cultured LLC1 compared to MLE12 (murine transformed lung epithelial cells) and 
several other human NSCLC cell lines (Figure 9). So far, the identity of the detected 
Prmt6 levels in these LLC1-derived tissue sections is still unknown. It is possible that 
the elevated PRMT6 levels in LLC1 mice are caused by cells within the tumour 
microenvironment, such as immune cells (e.g. macrophages). However, it is difficult to 
answer this issue because it would be necessary to analyse the influence of this 
surrounding environment on the expression of Prmt6 in comparison to the elevated 
PRMT6 expression in the tumour cells. 
In order to investigate whether the high PRMT6 protein level is essentiell for lung 
tumour formation in LLC1 mice, gene functional knockout of Prmt6 could be achieved 
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using the novel CRISPR/Cas9 system (Fennell et al., 2014; Mali et al., 2013). Then, 
Prmt6 proficient and Prmt6 deficient LLC1 cells could be injected into the tail vein of 
healthy C57BL/6 mice and the comparison of these mice could help to analyse whether 
both mice develop similar or different tumour patterns in the lung after IHC staining of 
Prmt6. It would also be interesting to perform this knockout of Prmt6 by CRISPR/Cas9 
in cultured LLC1, to inject these cells into the flank of healthy C57BL/6 mice in 
comparison to untransfected LLC1 cells and to analyse whether the size of LLC1 
tumours is impaired by depletion of Prmt6 in such an allograft model. In this context, 
the group of Ernesto Guccione demonstrated that depletion of PRMT6 in breast cancer 
cells, followed by orthopic injection into SCID (severe combined immunodeficiency) 
mice caused an inhibition of tumour formation compared to mice injected with control 
cells (Phalke et al., 2012). These data indicate that PRMT6 could also play an important 
role in lung cancer. 
In parallel to the analysis of the importance of PRMT6 in LLC1 mice, it is possible to use 
Prmt6
 
knockout mice from Stéphane Richard´s group for cross-breedings with Kras
LA2
 
mice from Tyler Jacks lab (Johnson et al., 2001; Neault et al., 2012). Here, it is likely 
that Prmt6 knockout reduces Kras-driven tumourigenesis compared to Prmt6 wild type 
Kras
LA2
 mice in a time- and/or growth-dependent manner. 
In this context, Gu and colleagues have already demonstrated that the depletion of 
PRMT5 abolishes the growth of A549 lung tumour xenografts in mice and that PRMT5 
is involved in FGFR (fibroblast growth factor receptor) signaling, a pathway needed for 
tumour growth (Gu et al., 2012). Another study showed that PRMT5 regulates the 
HIF-1 (hypoxia-inducible factor 1) signaling pathway (Lim et al., 2012). HIF-1 is a key 
player in the cellular adaption to hypoxia, which dominates in fast growing tumours. 
These data raise the question whether PRMT6 is also implicated in pathways necessary 
for efficient tumour growth, such as the FGFR or HIF-1 pathway. At least, this study has 
already demonstrated by performing CFAs in NSCLC cell lines that PRMT6 is important 
for the unimpeded growth of tumour cells as described above. 
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6.2   PRMT6 regulates cell proliferation and senescence by transcriptional 
repression of tumour suppressor genes 
In parallel to the CFA in H1299 and H358 cells, siRNA-mediated depletion of PRMT6 
caused also proliferation defects in the transformed cell line U2OS demonstrated by 
another CFA (Figure 14). Moreover, non-transformed human diploid fibroblasts (TIG3-T) 
underwent stress-induced senescence due to a depletion of PRMT6 mediated by 
infection with retroviral plasmids coding for alternative shRNAs against PRMT6 (Figure 
17). This was further supported by measuring population doublings and performing 
FACS analyses. It was demonstrated that depletion of PRMT6 strongly impaired the 
proliferative capacity of TIG3-T cells and resulted in an accumulation of these cells in 
G1-phase, a typical hallmark of senescent cells (PhD thesis, Claudia Stein and Stein et 
al., 2012). These findings are in line with previous publications, which showed that 
PRMT6 positively affects estrogen-stimulated proliferation of breast cancer cells 
(Harrison et al., 2010) and positively impacts the growth of NSCLC cells (Yoshimatsu et 
al., 2011). Moreover, it was found that PRMT6 was downregulated in replicatively and 
oxidatively premature senescent cells compared to young cells similar to PRMT1, 
PRMT4 and PRMT5 (Lim et al., 2008). 
In the search for possible responsible downstream target genes of PRMT6, the CDK 
inhibitor genes CDKN1A of the Cip/Kip family and p16-INK4A of the INK4 family were 
identified to be transcriptionally repressed and bound by PRMT6 (Figure 15, 16, 18, 19 
and 20). Both genes are key regulators of cellular senescence which function via the 
TP53-CDKN1A-RB1 and p16-INK4A-RB1 cascade in inhibition of phosphorylation of RB1 
(retinoblastoma 1) and E2F-target gene expression (Narita et al., 2003). This process 
presents a natural barrier to tumourigenesis by prohibition of unlimited cell 
proliferation (Prieur and Peeper, 2008; Serrano and Blasco, 2007), in which 
derepression of CDKN1A and p16-INK4A causes a growth arrest in G1-phase. Cellular 
senescence can be triggered by telomere shortening (replicative cellular senescence) 
or various types of other stress signals, such as DNA damage, oxidative stress or 
expression of oncogenes (premature cellular senescence). Beside the G1-arrest, 
senescent cells develop further typical senescence-associated features (Campisi and 
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d’Adda di Fagagna, 2007). They exhibit a flat, enlarged cell morphology accompanied 
by increased activity of ß-galactosidase (ß-gal) and changes in gene expression as in 
the case of the analysed human diploid fibroblasts. Especially the SA-ß-gal assay, which 
was performed in this study (Figure 17), is a common method to confirm that these 
cells are able to undergo replicative or premature senescence (Dimri et al., 1995; Lim 
et al., 2008). 
In parallel to our findings (Figure 30A; Stein et al., 2012), Stéphane Richard´s group 
generated a Prmt6 knockout mouse, which is viable, and demonstrated that isolated 
MEFs from these mice had also growth defects (G1-arrest) and underwent rapid 
cellular senescence (Figure 30D; Neault et al., 2012). Here, it was found that PRMT6 
regulated CDKN1A in a TP53-dependent manner. Additionally, Marc Timmers´ 
laboratory showed that depletion of PRMT6 promoted an accumulation of U2OS cells 
in G2-phase due to the fact that CDKN1A induces a growth arrest in G1- as well as G2-
phase (Figure 30B; Kleinschmidt et al., 2012). In this context, Ernesto Guccione´s group 
demonstrated that PRMT6 knockdown caused a diminished proliferation rate, a 
senescent phenotype (SA-ß-gal staining) and a reduced anchorage independent 
growth (soft agar assays) of breast cancer cells by a TP53-independent repression of 
CDKN1A (Figure 30C; Phalke et al., 2012). In conclusion, three further groups also 
revealed that PRMT6 possesses an important cell cycle regulatory function in 
repression of CDKN1A and induction of senescence using different cell systems and 
techniques for knockdown or knockout of PRMT6. 
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Figure 30: PRMT6 is a negative transcriptional regulator - Comparison of four publications. 
CDKN1A was originally identified as a potential mediator of the tumour suppressor 
activity of the transcription factor TP53 (Dulić et al., 1994; el-Deiry et al., 1993; Slebos 
et al., 1994). From the literature it is known that CDKN1A expression can also be 
regulated independently of TP53. For example, the transcription factors SP1, SP3, 
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HOXA10 (homeobox protein Hox-A10), GAX (growth arrest-specific homeobox) or KLF6 
(kruppel-like factor 6) control CDKN1A transcription and upregulate its transcription in 
response to various stimuli and anticancer agents (Abbas and Dutta, 2009). In this 
study, transcript level of TP53 was not significantly altered in PRMT6-depleted U2OS 
(Figure 15D) indicating that the regulation of CDKN1A expression by PRMT6 might be 
independent of TP53. A similar result was detected in the fibroblast cell line TIG3-T 
(PhD thesis, Claudia Stein). These results are in line with the data from Ernesto 
Guccione´s group, who has analysed the two breast cancer cell lines MCF7 (with wild 
type TP53) and MDA-MB-231 (triple negative and mutant TP53) and found that PRMT6 
also regulates CDKN1A in a TP53-independent manner as mentioned above (Figure 
30C; Phalke et al., 2012). Nevertheless, it is still possible that TP53 can recruit PRMT6 
to its target gene CDKN1A in these analysed MCF7 cells similar to our analysed U2OS 
and TIG3-T cells without affecting its expression. In contrast to these data, Neault and 
colleagues demonstrated that the binding of PRMT6 and enrichment in H3R2me2a 
upstream of the Trp53 locus was diminished in Prmt6
-/- 
MEFs indicating that PRMT6 is 
a regulator of TP53 (Figure 30D; Neault et al., 2012). Here, Prmt6
-/-
 MEFs exhibited an 
elevated expression of Trp53 as well as an increased expression of Trp53- target genes, 
such as Cdkn1a and PML. Moreover, deletion of the Trp53 gene (Trp53
-/-
) completely 
rescued the pre-senescent phenotype as shown in Prmt6
-/-
 MEFs. These data indicate 
that PRMT6 regulates senescence in a TP53-dependent manner in these analysed mice 
compared to the results described in this thesis. 
The expression of the two other Cip/Kip family members CDKN1B and CDKN1C was not 
significantly altered in PRMT6-depleted U2OS cells, indicating that PRMT6 does not 
regulate their expression (Figure 15E, 15F). The group of Marc Timmers revealed that 
PRMT6 knockdown caused an upregulation of CDKN1A as well as CDKN1B, but not of 
CDKN1C in U2OS cells (Figure 30B; Kleinschmidt et al., 2012). However, the relatively 
mild effect on the CDKN1B transcript by depletion of PRMT6 was not detectable in the 
present work (Figure 15E). The same applied to the two other genes of the INK4A/B 
tumour suppressor locus. Neither the transcript of p14 (p14-ARF), which represents 
the alternate open reading frame of the INK4A locus, nor the adjacent CDK inhibitor 
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gene p15 (p15-INK4B, CDKN2B) were affected in their transcript levels upon depletion 
of PRMT6 in TIG3-T cells (PhD thesis, Claudia Stein and Stein et al., 2012). In addition, 
the exemplary analysed CCND1, which is a G1/S-specific cyclin, and CCNA2, which 
promotes both cell cycle G1/S- and G2/M-transitions and binds to CDK2 during S phase, 
were not specifically altered in their expression by PRMT6 (Figure 15C, 15G and 15H). 
Moreover, the transcript level of the angiogenesis inhibitor THBS1 was not uniformly 
affected in U2OS cells upon PRMT6 knockdown (Figure 15I), although it was identified 
as a transcriptional repressed target gene of PRMT6 and implied a role of PRMT6 in 
tumourigenesis (Michaud-Levesque and Richard, 2009). However, these data 
strengthen the hypothesis that PRMT6 predominantly targets the two tumour 
suppressor CDKN1A and p16-INK4A. 
CDKN1A and p16-INK4A loci are bound by PRMT6 demonstrated by independent 
chromatin immunoprecipitation (ChIP) analyses in U2OS and TIG3-T cells (Figure 16, 19 
and 20). In case of the CDKN1A gene locus, PRMT6 binding overlapped with 
dimethylated H3R2, which both peaked at the TSS of CDKN1A in comparison to 
surrounding regions of this locus (Figure 16 and 19). Similarly, Kleinschmidt and 
colleagues demonstrated that overexpression of PRMT6 resulted in an increase of the 
H3R2me2a level at the TSS of the CDKN1A gene locus (Kleinschmidt et al., 2012). 
Hence, it is likely that the histone methyltransferase activity of PRMT6 might be 
necessary for repression of the CDKN1A gene locus. Further experiments could confirm 
this hypothesis by using a catalytic inactive PRMT6 mutant in ChIP analysis. 
In contrast to the CDKN1A locus, at the p16-INK4A gene locus PRMT6 binding was 
detected at the TSS as well as neighbouring regions, while H3R2me2a was not 
increased (Figure 20). This finding indicates that PRMT6 does not function as a histone 
arginine methyltransferase towards H3R2 to repress the p16-INK4A locus; rather it 
supports the idea that PRMT6 could here methylate different histone residues. It is 
conceivable that PRMT6 methylates H2AR29 or H3R42 and thereby fulfils its repressive 
function on the p16-INK4A locus (Casadio et al., 2013; Waldmann et al., 2011). 
Alternatively, it is possible that PRMT6 similar to other PRMTs binds to and methylates 
diverse nonhistone protein substrates such as transcriptional coregulators and thereby 
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regulates the derepression of the p16-INK4A locus (Lee and Stallcup, 2009). For 
example, it is known that PRMT1 influences gene expression independently of its 
ability to modify histone residues by functioning as a transcriptional coactivator of the 
transcription factor RUNX1. PRMT1 methylates RUNX1, which impedes the interaction 
between RUNX1 with the corepressor SIN3A and thereby leads to a transcriptional 
activation of RUNX1-target genes (Zhao et al., 2008). Another example is the 
methylation of the histone acetyltransferase and nuclear receptor coactivator SRC-3 
(steroid receptor coactivator 3) by PRMT4, which causes a dissociation of CBP and 
PRMT4 from SRC-3 and then reduces the stability of SRC-3 (Feng et al., 2006; Naeem et 
al., 2007). These findings could also be applicable for PRMT6 to presumably indirectly 
regulate the expression of p16-INK4A by effector proteins. Here, PRMT6 could bind to 
those transcriptional coregulators, influence their stability (e.g. by degradation) and 
capability to interact with other proteins. However, these findings indicate that PRMT6 
seems to act in a different manner at both loci. 
Since PRMT6 does not possess a DNA binding domain and is not able to directly bind 
target genes it remains elusive by which factors PRMT6 is recruited to these gene loci 
to fulfil its repressive function there. In order to unravel this mechanism, the 
transcription factor MYC is a potential candidate, which could lead PRMT6 to the 
CDKN1A gene locus. MYC is known to be recruited to MIZ-1 binding sites at the 
CDKN1A gene promoter by the DNA-binding factor MIZ-1 together with the DNA 
methyltransferase DNMT3a resulting in transcriptional repression of CDKN1A (Brenner 
et al., 2005). Alternatively, it was also demonstrated that MYC interacts with the 
transcription factor SP1, which inhibits the transcriptional activity of SP1 and 
subsequently leads to a transcriptional repression of CDKN1A (Gartel and Shchors, 
2003). In case of the p16-INK4A locus, the recruitment of PRMT6 by one or more 
Polycomb group proteins may also be possible and could be analysed in future 
experiments. In this context, previous studies in our group already demonstrated that 
PRMT6 interacts with several core components of PRC1 (polycomb repressive complex 
1) or PRC2, such as CBX8 or EZH2 (PhD thesis, Claudia Stein and personal 
communication, René Reiner Nötzold). Furthermore, it was shown that the catalytic 
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activity of PRMT6 was enhanced in the presence of H3K27me3 (Hyllus et al., 2007). 
This epigenetic mark is catalysed by EZH2, which promotes the recruitment of the 
PRC1 complex to the p16-INK4A locus and thereby regulates the transcriptional 
expression of this locus in a repressive manner (Lanigan et al., 2011). 
Interestingly, cellular senescence was not only induced by depletion of PRMT6 in 
TIG3-T cells (Figure 17), but PRMT6 is also implicated in stress-induced senescence. 
Here, oncogene-induced senescence (OIS) was analysed in TIG3 BRAF-ER cells by 
activation of the oncogene Braf upon 4-OHT (4-hydroxytamoxifen) treatment (Figure 
22) (Agger et al., 2009; Woods et al., 1997). As a result, OIS caused a reduction of 
PRMT6 on mRNA and protein level, while CDKN1A and p16-INK4A transcript levels 
were strongly increased (Figure 23). In order to unravel the relevance of CDKN1A in 
this OIS model, siRNA-mediated depletion of CDKN1A was performed followed by 
subsequent 4-OHT treatment (Figure 24A). In fact, depletion of CDKN1A impaired the 
onset of OIS as measured by SA-ß-gal staining (Figure 24C). Furthermore, PRMT6 
seems to be important for the onset of OIS because overexpression of PRMT6 has also 
led to a delayed OIS onset similar to CDKN1A (Figure 26). In this context, Phalke and 
colleagues showed that a double knockdown of PRMT6 and CDKN1A rescued the 
detected PRMT6 depletion phenotype as described above (Phalke et al., 2012). 
However, it is still unknown by which transcription factors PRMT6 gene is itself 
regulated in proliferation or cellular senescence and thereby causing an activation or 
repression of PRMT6 transcription. So far, only one study demonstrated that PRMT1 
transcription is controlled by binding of c-Myc to a conserved site in the first intron of 
the PRMT1 gene. Thereby, PRMT1 transcription is upregulated, which plays an 
important role during thyroid hormone-dependent Xenopus metamorphosis (Fujimoto 
et al., 2012). 
The present work showed that PRMT6 promotes cell proliferation and blocks cellular 
senescence in transformed as well as non-transformed cells by transcriptional 
repression of the CDK inhibitors CDKN1A and p16-INK4A. Moreover, PRMT6 seems to 
be overexpressed in lung cancer and seems to promote tumour growth as 
demonstrated by this study and Yoshimatsu et al. (2011). These findings support the 
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idea to develop epigenetic inhibitors targeting PRMT6, which could probably help in 
the treatment of lung cancer and perhaps also with other cancer types by reducing the 
proliferation rate of rapidly dividing tumours. Interestingly, inhibitor screening assays 
were already developed for PRMT1, in which for example allantodapsone was 
identified as a selective PRMT1 inhibitor (Hauser et al., 2012; Spannhoff et al., 2007). 
 
6.3  Identification of novel cellular functions of PRMT6 
A previous gel filtration analysis of nuclear extracts from several human cell lines in our 
group demonstrated that endogenous PRMT6 elutes within a molecular weight range 
of 150 - 440 kDa compared to its monomeric molecular weight of 42 kDa (PhD thesis, 
Claudia Stein). From the literature it is already known that type I PRMTs require 
dimerisation for their enzymatic activity (Weiss et al., 2000; Zhang and Cheng, 2003; 
Zhang et al., 2000). Furthermore, some of the PRMTs, such as PRMT1 and PRMT5, are 
part of higher molecular weight complexes (Friesen et al., 2001, 2002; Lin et al., 1996). 
PRMT1 interacts with BTG1 and TIS21, whereby the enzymatic activity of PRMT1 is 
positively modulated (Lin et al., 1996). PRMT5 associates with MEP50 (methylosome 
protein 50) and both are components of the methylosome, in which MEP50 promotes 
an enhanced enzymatic activity of PRMT5 (Friesen et al., 2002). However, 
homodimerisation of PRMT6 would not explain the presence of PRMT6 in these high 
molecular weight fractions with a molecular weight up to 440 kDa. Rather, it would 
suggest that PRMT6 also interacts with so far unidentified proteins, which possibly 
would link PRMT6 to novel cellular functions. 
In order to uncover novel interaction partners and functions of PRMT6 a MS/MS 
analysis of purified TAP-tagged PRMT6 from MCF7 cells was performed in our group. 
As a result of this unbiased approach, 43 putative interaction partners of PRMT6 were 
identified. Among them were proteins involved in the regulation of transcription, 
proliferation, replication and DNA repair (PhD thesis, Claudia Stein). Especially the two 
identified candidates DDB1 and PCNA together with DDB2 and CUL4A were of interest 
because of their link in DNA damage repair. It is remarkable that DDB1 and PCNA, but 
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not DDB2 and CUL4A, were found in the MS/MS analysis. It is possible that the 
interaction between PRMT6 and these two proteins is rather weak in unstimulated 
MCF7 cells used in this study and hence they were not detected in our unbiased 
approach. For this reason it is likely that an interaction between PRMT6 and DDB2 or 
CUL4A may only be present within the DNA damage response for example caused by 
UV irradiation. 
 
6.3.1   PRMT6 interacts with PCNA, DDB1 and DDB2 
DDB1 is a multifunctional protein that was first identified as a subunit of the damaged 
DNA binding protein complex (UV-DDB). In that complex, DDB1 heterodimerises with 
DDB2, recognises UV-induced photolesions of the DNA and promotes the initial step of 
global genome NER (GG-NER) (Iovine et al., 2011b). DDB1 also plays a role in 
transcriptional regulation of UV-induced genes, such as FMOD (Bevilacqua et al., 2005; 
Iovine et al., 2009). Subsequently, DDB1 was found to function as an adaptor/linker 
protein between CUL4A and the DDB1-CUL4-associated factors (DCAF) in the CUL4A-
RING ubiquitin E3-ligase complex (CRL4) (Iovine et al., 2011b). This DDB1-CUL4A 
complex targets different substrates for ubiquitylation followed by degradation 
through the ubiquitin-proteasome system (UPS). For example, CRL4-mediated 
ubiquitylation of DDB2 causes a rapidly degradation of DDB2 during the early steps of 
GG-NER after UV irradiation (Chen et al., 2001b; El-Mahdy et al., 2006; Nag et al., 
2001; Sugasawa et al., 2005). Further known ubiquitylation targets are the replication 
licensing protein CDT1, the CDK inhibitor CDKN1A or the transcription factor E2F1. All 
these ubiquitylations are dependent on the interaction with the cofactor PCNA (Abbas 
et al., 2008; Nishitani et al., 2008; Senga et al., 2006; Shibutani et al., 2008). PCNA is 
required for the replication-dependent destruction of CDT1 or CDKN1A in S phase and 
thereby couples DNA replication with CUL4-DDB1-dependent proteolysis (Arias and 
Walter, 2006; Kim et al., 2008; Nishitani et al., 2008). Interestingly, PCNA is itself 
monoubiquitinated by CRL4, which is a relevant feature for PCNA-dependent DNA 
repair (Soria et al., 2006; Terai et al., 2010). Furthermore, the complex ubiquitylates 
core histones (H2A, H3 and H4). However, that does not lead to their degradation, but 
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rather weakens the interaction between histones and DNA and thereby facilitates the 
recruitment of repair proteins (e.g. XPC) to damaged DNA sites (Kapetanaki et al., 
2006; Wang et al., 2006). 
Interestingly, it was observed that CUL4A expression is increased in human breast 
cancer and a variety of further tumour cell lines, such as A549 cells (Chen et al., 1998; 
Hori et al., 1999). Additionally, a conditional CUL4A transgenic mouse model confirmed 
that CUL4A is oncogenic in vivo. Here, overexpression of CUL4A has led to an atypical 
epithelial cell growth demonstrated by IHC stainings of lung tissue sections of these 
mice (Yang et al., 2014). The analysis of the expression of several CUL4A-associated 
proteins revealed that for example the expression of Cdkn1a was decreased in these 
lung tumours. In this context, IHC analysis demonstrated that PCNA expression was 
increased in these lung tumours suggesting that PCNA could be involved in Cul4A-
mediated Cdkn1a downregulation. Therefore, it would be interesting to analyse a link 
between CUL4A, PCNA, Cdkn1A, which is a target gene of PRMT6 in the human system, 
and PRMT6 itself in this specific murine lung tumour model. 
Previous data demonstrated that PRMT6 is implicated in base excision repair (BER) as a 
positive regulator of DNA polymerase ß (Pol ß) (El-Andaloussi et al., 2006). Moreover, 
PRMT6 stimulates CCND1 expression upon DNA damage, presumably by PRMT6-
mediated dimethylation of H3R2 (Iberg et al., 2008). The identification of several DNA 
repair-related putative interaction partners of PRMT6 in the MS/MS analysis raised the 
question whether PRMT6 possesses further functions in DNA repair than hitherto 
assumed. Indeed, the conducted CoIPs/Western blots in this study strengthen this 
hypothesis due to the confirmed interactions of PRMT6 with PCNA, DDB1 and DDB2, 
respectively (Figure 27-29). Additionally, the interaction of PRMT6 with CUL4A was 
verified by former CoIP studies (bachelor thesis, Lisa Schubert). 
Future experiments could clarify whether the interaction between PRMT6 and the CRL4 
components is enhanced after UV damage. We will address the question whether 
PRMT6 accumulates at DNA specific damage sites after induction of local UV damage 
by using GFP-tagged PRMT6 overexpressing cells in cooperation with Adriaan 
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Houtsmuller (from the Erasmus MC in Rotterdam). In this context, γ-H2AX is also a 
molecular marker for cellular DNA double-strand breaks (DSBs) caused in telomere-
initiated senescent cells (d’Adda di Fagagna et al., 2003). Therefore, phosphorylated 
histone H2AX (γ-H2AX) stainings could be used to study whether these factors 
co-localise at DNA damage foci together with PRMT6. 
In addition, it has to be further investigated whether PRMT6 influences the activity or 
substrate specificity of the E3 ubiquitin ligase complex CRL4 either in DNA damage 
response or during replication. This can be achieved by comparing the ubiquitylations 
of PRMT6 proficient versus PRMT6 deficient cells. Possibly, PRMT6 is itself a substrate 
of CRL4. This hypothesis could be analysed in the already established OIS model of 
TIG3 BRAF-ER cells. A study from Kotake´s laboratory has created a novel link of DDB1-
CUL4A to cellular senescence (Kotake et al., 2009). They demonstrated that these CRL4 
components are, together with MLL1, required for oncogene-induced p16-INK4A 
activation. Previous results in this study have shown that PRMT6 transcript and protein 
level were decreased in TIG3 BRAF-ER cells after activation of the oncogene Braf by 
4-OHT, while the expression of p16-INK4A transcript increased (Figure 23). It has to be 
analysed, whether at least the reduction of PRMT6 protein level is caused by DDB1-
CUL4A ubiquitylation followed by degradation of PRMT6. 
A previous study demonstrated that CRL4 also interacts and monoubiquitylates the 
transcription factor TP73, which is a structural and functional homolog of the tumour 
suppressor TP53. Thereby, it represses TP73-dependent transcription of target genes, 
such as CDKN1A, GADD45 and PUMA, and apoptosis without affecting its protein 
stability (Malatesta et al., 2013). DDB1 depletion as shown by Malatesta et al. has the 
same effect on CDKN1A expression as PRMT6 depletion in this study (Figure 15, 18). 
Therefore, it would be interesting to analyse whether PRMT6 is linked to this DDB1-
CUL4A-mediated ubiquitylation of TP73 and its subsequent repression of for example 
CDKN1A as a TP73-target gene. 
In this study, IPs were performed by immunoprecipitation of PRMT6 from MCF7 cell 
extracts and subsequent immunostaining of the interaction partner. In order to 
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strengthen these data, further endogenous or inverse CoIPs of PRMT6 and the CRL4 
components could be performed in the future to analyse if the specific interactor also 
immunoprecipitates PRMT6. In addition, further experiments have to clarify whether 
these novel interactors of PRMT6 are substrates of PRMT6 and whether they 
co-regulate the biological function of PRMT6 or vice versa. Therefore, in vitro 
methyltransferase assays and in vivo labelings could answer the question whether 
already confirmed interactors are substrates of PRMT6. It should be clarified whether 
these are direct or indirect interactions by performing GST pulldown assays with 
recombinant proteins expressed in bacteria. If these are direct interactions, the use of 
deletion mutants could help to map the interaction domains in PRMT6 and its 
interaction partners. 
 
6.3.2   Validation of additional PRMT6 interaction partners 
Previous studies in our group already confirmed the interaction between PRMT6 and 
several other putative interaction partners by semi-endogenous and endogenous 
Co-IPs in MCF7 cells found in our MS/MS analysis (bachelor thesis, Lisa Schubert). It 
was possible to verify the interaction between PRMT6 and the transcription factors 
ILF2 and ILF3. The heterodimeric complex of ILF2 and ILF3 was first described to be 
required for transcriptional regulation of the IL-2 (interleukin-2) gene during T-cell 
activation (Corthésy and Kao, 1994; Kao et al., 1994). Interestingly, ILF2 was identified 
as an asymmetrically dimethylated protein in a proteomic screen (Boisvert et al., 2003) 
and ILF3 as an interactor of PRMT1 in mammalian cells (Tang et al., 2000b). It would be 
interesting to analyse whether PRMT6 methylates ILF2 and/or ILF3, presumably in its 
RGG (arginine-glycine-glycine) motif at the C-terminus. Moreover, ILF3 possesses a 
double-stranded RNA binding motif (dsRBM) (Fierro-Monti and Mathews, 2000) and 
thereby controls the mRNA turnover of several genes, such as IL-2 or the PRMT6-target 
gene CDKN1A (Shi et al., 2005; Shim et al., 2002). 
Furthermore, the interaction of PRMT6 with the histone-binding protein RBBP7 
(RbAp46) has previously been confirmed in our group. Similarly, PRMT6 interacts with 
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its homolog RBBP4 (RbAp48). RbAp46/48 (retinoblastoma-associated protein 46/48) 
are components of several chromatin-related complexes, such as the NuRD 
(nucleosome remodeling and deacetylase), PRC2 or the Sin3 complex (Loyola and 
Almouzni, 2004; Philpott et al., 2000). PRMT6 does not possess a DNA binding domain 
and therefore RbAp46/48, as well as the already mentioned transcription factors ILF2 
or ILF3, could recruit PRMT6 to further specific chromatin regions. 
Further CoIP studies demonstrated that PRMT6 also associates with AURKB, which is a 
key regulator of mitosis and participates in microtubule-kinetochore attachment, 
spindle checkpoint and cytokinesis (Fu et al., 2007). Future studies could unravel 
whether AURKB is a substrate of PRMT6 and whether PRMT6 is implicated in the 
regulation of mitosis as another process in the cell cycle. 
 
6.3.3   Further putative interaction partners and functions of PRMT6 
Future experiments should be performed to validate the interaction between PRMT6 
with further putative interaction partners to get a better insight of PRMT6 in the 
regulation of important cell signal pathways and its role in human cancer. For example, 
the nuclear RNA-binding protein TAF15, that is a component of a distinct population of 
TFIID and RNA polymerase II complexes (Jobert et al., 2009), was identified as a 
putative interaction partner of PRMT6 within our MS/MS analysis. TAF15 is already 
linked to arginine methylation and could be a further substrate of PRMT6. A previous 
study demonstrated that TAF15 is arginine methylated at several RGG repeats in its 
C-terminus by PRMT1 (Jobert et al., 2009). This methylation is important for 
subcellular localisation of TAF15 and thereby for the regulation of TAF15 target genes 
in a positive manner. Further experiments have to clarify whether PRMT6 also 
interacts with TAF15, whether it methylates TAF15 and whether methylation of TAF15 
influences its function as demonstrated for PRMT1. 
In addition, the metabolic proteins ATP5B (ATP synthase subunit beta, mitochondrial), 
K6PP (6-phosphofructokinase type C), PGAM5 (phosphoglycerate mutase family 
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member 5) and HK1 (hexokinase 1) were also identified in our unbiased MS/MS 
approach (PhD thesis, Claudia Stein). In this context, a previous MS/MS analysis from 
Han´s laboratory has demonstrated that PRMT6 associates with CRTC2 (CREB-regulated 
transcriptional coactivator 2) in 293T cells, which was then confirmed by CoIP studies. 
Here, PRMT6 is involved in the regulation of hepatic glucose metabolism in a CRTC2-
dependent manner (Han et al., 2014). Therefore, the interaction between PRMT6 and 
the putative interaction candidates from our analysis has to be verified in the future. If 
that is the case, PRMT6 would be linked to further novel functions in metabolic 
processes. 
Interestingly, Lo Sardo and colleagues performed a yeast two-hybrid (Y2H) assay using 
full length PRMT6 as bait with a similar aim to identify novel interaction partners and 
putative substrates of PRMT6 (Lo Sardo et al., 2013). However, the comparison of their 
screen results with our MS/MS data set revealed no overlap in putative interaction 
partners of PRMT6 possibly due to the fact that different cell systems and methods 
were used. Among their 36 new putative interaction partners of PRMT6, they could 
validate the interaction of PRMT6 with hnRNP Q (heterogeneous nuclear 
ribonucleoprotein Q) in a GST-pulldown experiment, but not in a co-affinity 
purification (co-AP) in HEK293T cells. In comparison, we also could identify several 
hnRNPs (HNRNPUL2, HNRNPM, HNRNPG, HNRNPH1, HNRNPC and HNRNPF) as 
putative interaction partners of PRMT6 implying a role of PRMT6 in mRNA processing 
mechanisms. 
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8   APPENDIX 
8.1   Supplementary figures 
 
Figure S1: IHC stainings of Prmt6 in lung sections from C57BL/6, LLC1 and Kras
LA2
 mice (PRMT6_3affi). 
(A - C) A representative image of a lung tissue section from a (A) healthy C57BL/6 (HealthyCon #1), (B) 
LLC1 (LLC #1) and (C) Kras
LA2
 mouse (59s Lung #1) was photographed using an affinity-purified PRMT6 
antibody (PRMT6_3affi, 1:50; AEC, red) and Hematoxylin for counterstaining (blue). For each section a 
10 x magnification (left panel, maximal scale bar length: 250 µm) and a 40 x magnification (right panel, 
maximal scale bar length: 50 µm) is shown. A: alveolus, AS: alveolar sac, B: bronchiole, BV: blood vessel, 
HT: healthy tissue, SM: smooth muscle, TT: tumour tissue. 
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Figure S2: IHC stainings of Prmt6 in murine C57BL/6, LLC1 and Kras
LA2
 lung specimen (PRMT6_bethyl). 
(A - C) A representative image of a lung tissue section from a (A) healthy C57BL/6 (HealthyCon #1), (B) 
LLC1 (LLC #1) and (C) Kras
LA2
 mouse (59s Lung #1) is shown. Stainings were performed using a 
commercial PRMT6 antibody from Bethyl Laboratories (PRMT6_bethyl, 1:100; AEC, red) with 
Hematoxylin for counterstaining. Each staining is depicted in a 10 x magnification (left panel, maximal 
scale bar length: 250 µm) and a 40 x magnification (right panel, maximal scale bar length: 50 µm). 
A: alveolus, AD: alveolar duct, AS: alveolar sac, B: bronchiole, BV: blood vessel, HT: healthy tissue, 
TT: tumour tissue. 
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Figure S3: Clonogenic growth of H358 (high PRMT6 level) and of H1299 cells (moderate PRMT6 level) 
is affected after 14 days of PRMT6 depletion. 
H1299 or H358 cells were transfected with three alternative siRNAs directed against PRMT6 
(siPRMT6_1, siPRMT6_4 or siPRMT6_5) compared to the control transfections siNontargeting (siNon) or 
siScramble (siScr) using LipoRNAiMAX. 48 hours post-transfection either 400 cells (H1299) or 40.000 
cells (H358) were replated in triplicates in a 6-well plate for a colony formation assay (CFA). Colonies 
were stained with crystal violet after 14 days of siRNA transfection. Representative dishes of crystal 
violet-stained dishes were photographed of H1299 (upper panel) and H358 (lower panel) at the 
indicated time point. The experiment was performed once. 
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8.2   List of abbreviations and acronyms 
Amino acids are abbreviated with the common single letter code. The nucleotides 
Adenine, Cytosine, Guanine and Thymine are abbreviated with A, C, G and T, 
respectively. Post-translational modifications of histones are referred to with the 
abbreviation of the corresponding histone (H1, H3, H4, H2A or H2B), the amino acid 
residue in the single letter code including its position within the amino acid sequence 
and the modification state, which could be either symmetrically or asymmetrically 
methylated, in case of the methylation by protein arginine methyltransferases (e.g. 
me2a, me2s, me3, ac). Therefore, histone modifications are abbreviated for instance 
as H3R2me2a or H2AR29me2. 
α anti 
4-OHT 4-hydroxytamoxifen 
ac acetyl/acetylated 
ADMA ω-NG,NG-asymmetric dimethylarginine  
AdoHcy S-adenosylhomocysteine 
AdoMet S-adenosyl-L-methionine 
APS ammonium persulfate 
ASH2 absent, small, or homeotic discs 2 
ATM ataxia telangiectasia mutated 
ATR ataxia telangiectasia and Rad3-related 
AURKB aurora kinase B 
BBC3 (PUMA) BCL2 binding component 3 
BER base excision repair 
bp base pair 
BRAF-ER fusion protein of the LBD of ER with the kinase B-rapidly accelerated 
fibrosarcoma (constitutively expressed) 
BRCA1 breast cancer 1, early onset 
BSA bovine serum albumine 
BTG1 B-cell translocation gene 1 
BTG2 BTG family, member 2 
C- carboxy-/carboxyl- 
C57BL/6 common inbred strain of laboratory mouse 
CARM1 coactivator-associated arginine methyltransferase 1 
CCNA2 cyclin A2 
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CCND1 cyclin D1 
CCNE1 cyclin E1 
CDK cyclin-dependent kinase 
CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, Kip1) 
CDKN1C cyclin-dependent kinase inhibitor 1C (p57, Kip2) 
CDKN2A cyclin-dependent kinase inhibitor 2A 
cDNA complementary DNA 
CDT1 chromatin licensing and DNA replication factor 1 
ChIP chromatin immunoprecipitation 
ChIP-qPCR chromatin immunoprecipitation-quantitiative PCR 
CHK2 checkpoint kinase 2 
chromo chromatin organisation modifier 
chromodomain chromatin organisation modifier domain 
CORP5 cooperator of PRMT5 
CRL4 CUL4A-RING ubiquitin E3-ligase complex 
CRTC2 CREB-regulated transcriptional coactivator 2 
Ct threshold cycle 
CUL4A cullin 4A 
DART Drosophila arginine methyltransferase 
DDB1 damage-specific DNA binding protein 1, 127kDa 
DDB2 damage-specific DNA binding protein 2, 48kDa 
ddH2O bidistilled water 
DHX9 DEAH (Asp-Glu-Ala-His) box helicase 9 
DMEM Dulbecco´s modified Eagle´s medium 
DMF dimethylformamide 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dsDNA double-stranded DNA 
DTT dithiotreithol 
E. coli Escherichia coli 
E2F1 E2F transcription factor 1 
ECL enhanced chemiluminescence 
EDTA ethylenediaminetetraacetic acid 
ER estrogen receptor 
ESC embryonic stem cell 
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit 
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FACS fluorescence-activated cell sorting 
FCS fetal calf serum 
FGFR fibroblast growth factor receptor 
FMOD fibromodulin 
FT freeze and thaw 
fwd forward 
g gravity 
g gram 
G0-phase gap phase 0 
G1-phase gap phase 1 
GADD45 growth arrest and DNA-damage 
GAR glycine-arginine-rich 
GFP green fluorescent protein 
GG-NER global genome nucleotide excision repair 
GR glucocorticoid receptor 
GST glutathione-S-transferase 
hCAF1 CCR4-associated factor 1 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid 
HIF-1 hypoxia-inducible factor 1 
His histidine 
HIV human immunodeficiency virus 
HMGA high mobility group A 
HMT1 hnRNP methyltransferase 1 
hnRNP heterogeneous nuclear ribonucleoprotein 
HOX Homeobox 
HP1 heterochromatin protein 1 
HRP horseradish peroxidase 
HSL7 histone synthetic lethal 7 
IgG immunoglobulin G 
ILF2 interleukin enhancer binding factor 2 
ILF3 interleukin enhancer binding factor 3, 90kDa 
IP immunoprecipitation 
JBP1 Janus kinase-binding protein 1 
JMJD6 Jumonji domain-containing 6 protein 
kb kilobase 
kd knockdown 
kDa kilo dalton 
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LB lysogeny broth 
LBD ligand binding domain 
M molar 
MAPK mitogen-activated protein kinase 
MDM2 mouse double minute 2 homolog (alias proto-oncogene, E3 ubiquitin 
protein ligase) 
me methyl/methylated 
MEF mouse embryonic fibroblast 
MEP50 methylosome protein 50 
miRNA micro-ribonucleic acid 
MLL mixed-lineage leukemia 
MMA ω-NG-monomethylarginine 
mRNA messenger ribonucleic acid 
MS mass spectrometry 
MYC v-myc avian myelocytomatosis viral oncogene homolog 
N- amino- 
NC nucleocapsid 
NCBI National Center for Biotechnology Information 
ncRNA non-coding RNA 
NR nuclear receptor 
NSCLC non-small cell lung cancer 
NUMAC nucleosomal methylation activator complex 
OIS oncogene-induced senescence 
ON over night 
ORF open reading frame 
PADI4 peptidylarginine deiminase 4 
PBS phosphate buffered saline 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PDK1 pyruvate dehydrogenase kinase, isozyme 1 
PEI polyethylenimine 
PHD plant homeodomain 
PMSF phenylmethanesulfonyl fluoride 
Pol polymerase 
PR progesterone receptor 
PRC2 Polycomb repressive complex 2 
PRMT protein arginine methyltransferase 
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PS penicillin/streptomycin 
PTM post-translational modification 
PVDF polyvinylidene difluoride 
qPCR quantitative PCR 
RB1 retinoblastoma 1 
RBBP4 (RbAp48) retinoblastoma binding protein 4 
RBBP5 retinoblastoma binding protein 5 
RBBP7 (RbAp46) retinoblastoma binding protein 7 
rev  reverse 
Rev regulator of viral protein expression 
RHA ATP-dependent RNA helicase A 
Rmt1 type I protein arginine N-methyltransferase Rmt1 
RNA ribonucleic acid 
RNAi RNA interference 
ROS reactive oxygen species 
ROX 6-carboxyl-X-rhodamine 
RPLP0 ribosomal protein, large, P0 
rpm revolutions per minute 
RPS14 ribosomal protein S14 
RT room temperature 
RT-qPCR real-time quantitative PCR 
RUNX1 runt-related transcription factor 1 
SAHF senescence-associated heterochromatin foci 
SA-ß-gal senescence-associated ß-galactosidase 
SCLC small cell lung cancer 
SDF senescence-associated DNA damage foci 
SDMA ω-NG,N´G-symmetric dimethylarginine 
SDS sodium dodecyl sulfate 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SH3 Src homology 3 
SHR steroid hormone receptor 
shRNA short hairpin RNA 
SIN3A SIN3 transcription regulator family member A 
siRNA small interfering RNA 
Skb1 Shk1 kinase-binding protein 1 
Skp1 S-phase-kinase-associated protein-1 
SMARCA2 (BRM) SWI/SNF related, matrix associated, actin dependent regulator of 
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chromatin, subfamily a, member 2 
SMARCA4 (BRG1) SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
S-phase DNA synthesis phase 
ssDNA single-stranded DNA 
SUMO small ubiquitin-like modifier 
SWI/SNF SWItch/Sucrose NonFermentable 
TAP tandem affinity purification 
Tat transactivator 
TBE TRIS-borate-EDTA 
TBS TRIS-buffered saline 
TE TRIS buffered EDTA 
TEMED tetramethylethylenediamine 
TGF-ß transforming growth factor ß 
THBS1 Thrombospondin-1 
THW threonine-histidine-tryptophan 
TP53 tumour protein p53 
TRIS tris(hydroxylmethyl)aminomethane 
TSS transcriptional start site 
TV transcript variant 
UBC ubiquitin C 
v/v volume per volume 
VEGF vascular endothelial growth factor 
w/v weight per volume 
Wb Western blot 
WDR5 WD-repeat domain 5 
wt wild type 
X-gal 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
XPC xeroderma pigmentosum complementation group C 
 
 
 
In order to distinguish between genes, transcripts and proteins the following 
nomenclature was used in this study: 
Genes and transcripts, e.g. PRMT6  (human) 
    Prmt6   (mouse) 
 
Proteins, e.g.   PRMT6  (human) 
    Prmt6  (mouse)  
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